Page last updated: 2024-11-11

indinavir sulfate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Indinavir: A potent and specific HIV protease inhibitor that appears to have good oral bioavailability. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5462355
CHEMBL ID1735
CHEBI ID5899
SCHEMBL ID41040
MeSH IDM0329078
PubMed CID5362440
CHEMBL ID115
CHEBI ID44032
SCHEMBL ID6317
MeSH IDM0329078

Synonyms (172)

Synonym
AC-1935
mk 639
nsc-697197
d-erythro-pentonamide, 2,3,5-trideoxy-n-((1s,2r)-2,3-dihydro-2-hydroxy-1h-inden-1-yl)-5-((2s)-2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-, sulfate (1:1) (salt)
drg-0233
d-erythro-pentonamide, 2,3,5-trideoxy-n-(2,3-dihydro-2-hydroxy-1h-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-, monohydrate, (1(1s,2r),5(s))-, sulfate (1:1)
indinavir sulfate [usan]
d-erythro-pentonamide, 2,3,5-trideoxy-n-(2,3-dihydro-2-hydroxy-1h-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-, (1(1s,2r,5(s))-, sulfate (1:1) (salt)
indinavir sulphate
(alphar,gammas,2s)-alpha-benzyl-2-(tert-butylcarbamoyl)-gamma-hydroxy-n-((1s,2r)-2-hydroxy-1-indanyl)-4-(3-pyridylmethyl)-1-piperazinevaleramide sulfate (1:1) (salt)
hsdb 7158
nsc697197
l-735,524
l 735524
MLS001401425
smr000469161
indinavir sulfate
157810-81-6
C08089
d-erythro-pentonamide,3,5-trideoxy-n-(2,3-dihydro-2- hydroxy-1h-inden-1-yl)-5-[2-[[(1,1-dimethylethyl)amino] carbonyl]-4-(3-pyridinylmethyl)-1-piperazinyl]-2-(phenylmethyl)-, [1(1s,2r),5(s)-, sulfate (1:1) (salt)
indinivar sulphate
indinavir sulfate (usp)
D00897
indinavir, sulfate (1:1)
sulfate, indinavir
HMS2051P19
CHEMBL1735
indinaviri sulfas
chebi:5899 ,
2,3,5-trideoxy-n-[(1s,2r)-2,3-dihydro-2-hydroxy-1h-inden-1-yl]-5-[(2s)-2[[(1,1-dimethylethyl)amino]carbonyl]-4-(3-pyridinylmethyl)-1-piperazinyl]-2-(phenylmethyl)-d-erythro-pentonamide
dtxsid1044221 ,
tox21_302415
NCGC00255764-01
cas-157810-81-6
dtxcid9024221
tox21_111687
AKOS015920149
HMS2231G18
S9567
c36h47n5o4.h2so4
CCG-100982
771h53976q ,
unii-771h53976q
nsc 697197
indinavir sulfate [usan:usp]
indinavir sulfate [orange book]
d-erythro-pentonamide, 2,3,5-trideoxy-n-(2,3-dihydro-2-hydroxy-1h-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-, (1(1s,2r,5(s))-, sulphate (1:1) (salt)
(alphar,gammas,2s)-alpha-benzyl-2-(tert-butylcarbamoyl)-gamma-hydroxy-n-[(1s,2r)-2-hydroxy-1-indanyl]-4-(3-pyridylmethyl)-1-piperazinevaleramide sulfate (1:1) (salt)
indinavir sulfate [hsdb]
(.alpha.r,.gamma.s,2s)-.alpha.-benzyl-2-(tert-butylcarbamoyl)-.gamma.-hydroxy-n-((1s,2r)-2-hydroxy-1-indanyl)-4-(3-pyridylmethyl)-1-piperazinevaleramide sulphate (1:1) (salt)
indinavir sulphate [ema epar]
indinavir sulfate [mart.]
indinavir sulfate [usp monograph]
indinaviri sulfas [who-ip latin]
indinavir sulfate [who-dd]
indinavir sulfate [vandf]
indinavir sulfate [who-ip]
indinavir sulfate [mi]
indinavir (sulfate)
HY-B0689A
MLS006010223
NC00232
SCHEMBL41040
NCGC00159460-04
tox21_111687_1
(s)-1-((2s,4r)-4-benzyl-2-hydroxy-5-(((1s,2r)-2-hydroxy-2,3-dihydro-1h-inden-1-yl)amino)-5-oxopentyl)-n-(tert-butyl)-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide sulfate
mfcd00920346
HMS3715L06
Q27106928
AS-30738
d-erythro-pentonamide, 2,3,5-trideoxy-n-[(1s,2r)-2,3-dihydro-2-hydroxy-1h-inden-1-yl]-5-[(2s)-2-[[(1,1-dimethylethyl)amino]carbonyl]-4-(3-pyridinylmethyl)-1-piperazinyl]-2-(phenylmethyl)-, sulfate (1:1)
indinavir for system suitability
(2s)-1-[(2s,4r)-4-benzyl-2-hydroxy-4-{[(1s,2r)-2-hydroxy-2,3-dihydro-1h-inden-1-yl]carbamoyl}butyl]-n-tert-butyl-4-[(pyridin-3-yl)methyl]piperazine-2-carboxamide; sulfuric acid
EN300-123044
(2s)-1-[(2s,4r)-4-benzyl-2-hydroxy-5-[[(1s,2r)-2-hydroxy-2,3-dihydro-1h-inden-1-yl]amino]-5-oxopentyl]-n-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide sulphate salt
HB7480
Z1546616207
indinavir sulfate (mart.)
indinavir sulfate (usan:usp)
indinavir sulfate (usp monograph)
(alphar,gammas,2s)-alpha-benzyl-2-(tert-butylcarbamoyl)-gamma-hydroxy-n-((1s,2r)-2-hydroxy-1-indanyl)-4-(3-pyridylmethyl)-1-piperazinevaleramide sulphate (1:1) (salt)
AC-20034
BIDD:GT0378
BIDD:PXR0141
indinavir, 19
l-735, 524
bdbm517
mk639
chembl115 ,
(2s)-1-[(2s,4r)-4-benzyl-2-hydroxy-4-{[(1s,2r)-2-hydroxy-2,3-dihydro-1h-inden-1-yl]carbamoyl}butyl]-n-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide
compound j
propolis+indinavir
propolis & 4-hydroxy-n-(2-hydroxy-2,3-dihydro-1h-1-indanyl)-n'-(1,1-dimethylethyl)-2-phenylmethyl-5-[4-(3-pyridylmethyl)-1-piperzinyl]hexanediamide
n-[2(r)-hydroxy-1(s)-indanyl]-5-[(2(s)-tertiary butylaminocarbonyl)-4(3-pyridylmethyl)piperazino]-4(s)-hydroxy-2(r)-phenylmethylpentanamide
l-735524
(2s)-1-[(2s,4r)-4-benzyl-2-hydroxy-5-[[(1s,2r)-2-hydroxyindan-1-yl]amino]-5-oxo-pentyl]-n-tert-butyl-4-(3-pyridylmethyl)piperazine-2-carboxamide
rs-253
crixivan (tm)
indinavir (*1:1 sulfate salt*)
d-erythro-pentonamide, 2,3,5-trideoxy-n-(2,3-dihydro-2-hydroxy-1h-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-, (1(1s,2r),5(s))-
mk-639
150378-17-9
C07051
indinavir
CHEBI:44032 ,
(1(1s,2r),5(s))-2,3,5-trideoxy-n-(2,3-dihydro-2-hydroxy-1h-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-d-erythro-pentonamide
(2s)-1-[(2s,4r)-4-benzyl-2-hydroxy-5-{[(1s,2r)-2-hydroxy-2,3-dihydro-1h-inden-1-yl]amino}-5-oxopentyl]-n-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide
2-benzyl-5-[(2s)-2-(tert-butylcarbamoyl)-4-(pyridin-3-ylmethyl)piperazin-1-yl]-2,3,5-trideoxy-n-[(1s,2r)-2-hydroxy-2,3-dihydro-1h-inden-1-yl]-d-erythro-pentonamide
1SDU
2AVS
2AVV
1K6C
indinavir anhydrous
1C6Y
1HSH
1SGU
1HSG
1SDV
2BPX
2AVO
DB00224
1SDT
crixivan
d-erythro-pentonamide, 2,3,5-trideoxy-n-((1s,2r)-2,3-dihydro-2-hydroxy-1h-inden-1-yl)-5-((2s)-2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-
l735,524
l 735,524
AKOS000280989
indinavir system suitability
(2s)-1-[(2s,4r)-4-benzyl-2-hydroxy-5-[[(1s,2r)-2-hydroxy-2,3-dihydro-1h-inden-1-yl]amino]-5-oxopentyl]-n-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide
bdbm50067593
NCGC00159460-03
indinavir [usan:inn:ban]
9mg78x43zt ,
unii-9mg78x43zt
AM84463
indinavir [inn]
indinavir [who-dd]
indinavir [mi]
(.alpha.r,.gamma.s,2s)-.alpha.-benzyl-2-(tert-butylcarbamoyl)-.gamma.-hydroxy-n-((1s,2r)-2-hydroxy-1-indanyl)-4-(3-pyridylmethyl)-1-piperazinevaleramide
AB00698241-07
HY-B0689
SCHEMBL6317
KS-5060
DTXSID4043802
indinavir & interferon lambda-2
indinavir & il-29
indinavir & il-28b
indinavir & ifnl3
indinavir & il-28a
indinavir & interferon lambda-1
indinavir & interleukin 29
indinavir & ifnl2
indinavir & interleukin 28a
indinavir & interferon lambda-3
indinavir & interleukin 28b
indinavir & ifnl1
AT13874
J-008694
NCGC00159460-01
(s)-1-((2s,4r)-4-benzyl-2-hydroxy-5-((1s,2r)-2-hydroxy-2,3-dihydro-1h-inden-1-ylamino)-5-oxopentyl)-n-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide
butylaminocarbonyl)-4(3-pyridylmethyl)piperazino]-4(s)-hydroxy-2(r)-phenylmethylpentanamide
n-[2(r)-hydroxy-1(s)-indanyl]-5-[(2(s)-tertiary
(2s)-1-[(2s,4r)-4-benzyl-2-hydroxy-5-{[(1s,2r)-2-hydroxy-2,3-dihydro-1h-inden-1-yl]amino}-5-oxopentyl]-n-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide (non-preferred name)
d-erythro-pentonamide,2,3,5-trideoxy-n-[(1s,2r)-2,3-dihydro-2-hydroxy-1h-inden-1-yl]-5-[(2s)-2-[[(1,1-dimethylethyl)amino]carbonyl]-4-(3-pyridinylmethyl)-1-piperazinyl]-2-(phenylmethyl)-
Q425490
gtpl12684
NCGC00159460-13
d-erythro-pentonamide, 2,3,5-trideoxy-n-[(1s,2r)-2,3-dihydro-2-hydroxy-1h-inden-1-yl]-5-[(2s)-2-[[(1,1-dimethylethyl)amino]carbonyl]-4-(3-pyridinylmethyl)-1-piperazinyl]-2-(phenylmethyl)-
NCGC00159460-10
EN300-19767270
(2s)-1-[(2s,4r)-4-benzyl-2-hydroxy-4-{[(1s,2r)-2-hydroxy-2,3-dihydro-1h-inden-1-yl]carbamoyl}butyl]-n-tert-butyl-4-[(pyridin-3-yl)methyl]piperazine-2-carboxamide
2,3,5-trideoxy-n-[(1s,2r)-2,3-dihydro-2-hydroxy-1h-inden-1-yl]-5-[(2s)-2-[[(1,1-dimethylethyl)amino]carbonyl]-4-(3-pyridinylmethyl)-1-piperazinyl]-2-(phenylmethyl)-d-erythro-pentonamide sulfate

Research Excerpts

Overview

Indinavir sulfate is a human immunodeficiency virus type 1 (HIV-1) protease inhibitor indicated for treatment of HIV infection and AIDS in adults. It has been found to be extremely effective in increasing CD4+ cell counts and in decreasing HIV-RNA titers.

ExcerptReferenceRelevance
"Indinavir sulfate is a protease inhibitor used of the treatment of primary HIV infection either as monotherapy or as part of antiretroviral treatment schemes. "( Treatment of indinavir sulfate induced urolithiasis in HIV-positive patients.
Dimitriadis, G; Kalaitzis, C; Kelidis, G; Kuntz, R; Touloupidis, S; Tsatidis, T, 2002
)
2.13
"Indinavir sulfate is an inhibitor of the human immunodeficiency virus (HIV) protease. "( Electrochemical methods for determination of the protease inhibitor indinavir sulfate in pharmaceuticals and human serum.
Canbaz, D; Dogan, B; Ozkan, SA; Uslu, B, 2006
)
2.01
"Indinavir sulfate is a human immunodeficiency virus type 1 (HIV-1) protease inhibitor indicated for treatment of HIV infection and AIDS in adults. "( Single-dose pharmacokinetics of indinavir and the effect of food.
Deutsch, PJ; Haddix, H; Hesney, M; Hoagland, V; Ju, WD; Justice, SJ; Osborne, B; Sterrett, AT; Stone, JA; Waldman, S; Woolf, E; Yeh, KC, 1998
)
1.74
"Indinavir sulfate is a protease inhibitor used in the treatment of the human immunodeficiency virus (HIV). "( Ureteral obstruction secondary to indinavir in the pediatric HIV population.
Berdon, WE; Hensle, TW; Klein, LT; Neu, N; Noble, CB; Staiman, VR, 1998
)
1.74
"Indinavir sulfate is an effective protease inhibitor of the human immunodeficiency virus type 1. "( Imaging characteristics of indinavir calculi.
Armenakas, NA; Schenkman, N; Schwartz, BF; Stoller, ML, 1999
)
1.75
"Indinavir sulfate is a protease inhibitor with poor solubility and significant urinary excretion. "( Imaging characteristics of indinavir calculi.
Armenakas, NA; Schenkman, N; Schwartz, BF; Stoller, ML, 1999
)
1.75
"Indinavir sulfate is a protease inhibitor that has been found to be extremely effective in increasing CD4+ cell counts and in decreasing HIV-RNA titers in patients with HIV and AIDS. "( Indinavir urolithiasis.
Stoller, ML; Wu, DS, 2000
)
1.75

Effects

ExcerptReferenceRelevance
"Indinavir sulfate has been reported to cause asymptomatic crystalluria and nephrolithiasis in patients with human immunodeficiency virus (HIV) infection. "( Acute tubulointerstitial nephritis attributable to indinavir therapy.
Cushing, H; Jaradat, M; Moe, S; Phillips, C; Yum, MN, 2000
)
1.75

Toxicity

ExcerptReferenceRelevance
" The addition of IND to ZDV + 3TC did not result in any significant increase in adverse experiences."( AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients.
, 2000
)
0.31
"7%) patients because of adverse events and three (3."( Efficacy and safety of twice daily first-line ritonavir/indinavir plus double nucleoside combination therapy in HIV-infected individuals. German Ritonavir/Indinavir Study Group.
Bergmann, F; Carls, H; Fätkenheuer, G; Fenske, S; Knechten, H; Nadler, M; Oette, M; Rieke, A; Rockstroh, JK; Thiesen, A; Wiesel, W, 2000
)
0.31
"Our preliminary data suggest that the protease inhibitor combination ritonavir/indinavir plus double nucleoside therapy appears to be effective and safe in short-term treatment (up to 24 weeks)."( Efficacy and safety of twice daily first-line ritonavir/indinavir plus double nucleoside combination therapy in HIV-infected individuals. German Ritonavir/Indinavir Study Group.
Bergmann, F; Carls, H; Fätkenheuer, G; Fenske, S; Knechten, H; Nadler, M; Oette, M; Rieke, A; Rockstroh, JK; Thiesen, A; Wiesel, W, 2000
)
0.31
" The side-effects of this new therapeutic family are quite well known but we wanted to evaluate the attitude of the clinician: can these adverse effects be corrected by symptomatic treatment, do they regress spontaneously or do they lead to an alternative PI therapy? We therefore carried out a retrospective survey in the Infectious Diseases Department of Poitiers Hospital consisting in research on files of patients (n = 70) treated in this department (hospitalization and consultation) for any clinical or biological abnormality attributable to the PI."( [Attitude of the clinican toward adverse effects of protease inhibitors].
Breux, JP; Champagne, X; Nicol, B; Pasdeloup, T; Pérault, MC; Remblier, C; Vandel, B,
)
0.13
"Demographics, dosage regimens, genotype data, viral RNA and CD4+ lymphocyte counts, adverse drug events (ADEs), laboratory tests, and compliance were evaluated over 3 years."( The safety and antiviral effect of protease inhibitors in children.
Koranyi, KI; Nahata, MC; Temple, ME, 2001
)
0.31
"A French study confirms recent reports of hair loss in men as a side effect of the protease inhibitor Crixivan (Indinavir)."( Crixivan side effect update - hair loss and ingrown toenails.
Fornataro, K; Jefferys, R, 1999
)
0.3
"Determination of potential drug toxicity and side effect in early stages of drug development is important in reducing the cost and time of drug discovery."( Prediction of potential toxicity and side effect protein targets of a small molecule by a ligand-protein inverse docking approach.
Chen, YZ; Ung, CY, 2001
)
0.31
" Apart from diarrhoea and nausea, serum lipid abnormalities were identified as the most prominent adverse reaction."( Long-term efficacy and safety of ritonavir/indinavir at 400/400 mg twice a day in combination with two nucleoside reverse transcriptase inhibitors as first line antiretroviral therapy.
Bergmann, F; Carls, H; Fätkenheuer, G; Fenske, S; Knechten, H; Lichterfeld, M; Nadler, M; Nischalke, HD; Oette, M; Rieke, A; Rockstroh, JK; Theisen, A; Wasmuth, JC; Wiesel, W, 2002
)
0.31
"Our results demonstrate that quadruple therapy with RTV/IDV and two NRTIs induces potent, durable and safe HIV suppression and might be particularly beneficial as a first line therapy for patients with a high baseline viral load."( Long-term efficacy and safety of ritonavir/indinavir at 400/400 mg twice a day in combination with two nucleoside reverse transcriptase inhibitors as first line antiretroviral therapy.
Bergmann, F; Carls, H; Fätkenheuer, G; Fenske, S; Knechten, H; Lichterfeld, M; Nadler, M; Nischalke, HD; Oette, M; Rieke, A; Rockstroh, JK; Theisen, A; Wasmuth, JC; Wiesel, W, 2002
)
0.31
" Hyperbilirubinemia (experienced by 31% of subjects), nausea (17%), abdominal pain (14%), and nephrolithiasis (13%) were the most common drug-related adverse events during the extension."( Long-term efficacy, safety, and tolerability of indinavir-based therapy in protease inhibitor-naive adults with advanced HIV infection.
Chen, J; DiNubile, MJ; Fischl, MA; Harvey, CM; Hirsch, MS; Hirschel, B; Leavitt, RY; McMahon, D; Squires, K; Staszewski, S; Steigbigel, RT, 2003
)
0.32
" This is a potent, safe combination for the treatment of HIV-1."( The safety and efficacy of indinavir and ritonavir (400/400 mg BID) in HIV-1-infected individuals from an inner-city minority population: a pilot study.
Asthana, D; Campo, R; Jayaweera, DT; Kolber, MA; Robinson, M; Rode, R; Rodriguez, A; Scerpella, E; Tanner, T, 2003
)
0.32
" Ten patients discontinued the study treatment before W48: adverse events (eight), patient's will (one) and simplification of therapy (one)."( Efficacy and safety of ritonavir/indinavir 100/400 mg twice daily in combination with two nucleoside analogues in antiretroviral treatment-naive HIV-infected individuals.
Agher, R; Ait-Mohand, H; Bricaire, F; Calvez, V; Costagliola, D; Duvivier, C; Ghosn, J; Katlama, C; Marcelin, AG; Myrto, A; Peytavin, G; Schneider, L, 2003
)
0.32
"IDV/RTV 400/100 mg twice daily is an effective and safe first-line antiretroviral therapy."( Efficacy and safety of ritonavir/indinavir 100/400 mg twice daily in combination with two nucleoside analogues in antiretroviral treatment-naive HIV-infected individuals.
Agher, R; Ait-Mohand, H; Bricaire, F; Calvez, V; Costagliola, D; Duvivier, C; Ghosn, J; Katlama, C; Marcelin, AG; Myrto, A; Peytavin, G; Schneider, L, 2003
)
0.32
" In our clinical setting IDV/r showed to be less effective and more toxic than LPV/RTV as first-line HAART."( Lopinavir/ritonavir vs. indinavir/ritonavir in antiretroviral naive HIV-infected patients: immunovirological outcome and side effects.
Adorni, F; Bini, T; Bongiovanni, M; Chiesa, E; Cicconi, P; Monforte d'Arminio, A, 2004
)
0.32
" Treatment was stopped in 18 patients; two from intolerance, two switched therapy, four as a result of serious adverse event-related death, and ten were lost to follow-up."( Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
Anunnatsiri, S; Boonyaprawit, P; Chetchotisakd, P; Mootsikapun, P, 2005
)
0.33
"Our study demonstrates that indinavir/ritonavir 400/100 mg plus stavudine and lamivudine twice daily, the least expensive boosted protease inhibitor, appears to be effective and safe up to 96 weeks despite high baseline viraemia and low CD4+ cell count in antiretroviral-naive patients."( Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
Anunnatsiri, S; Boonyaprawit, P; Chetchotisakd, P; Mootsikapun, P, 2005
)
0.33
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" Decrease in viral load of HIV (VC) has been assessed as primary endpoint and as secondary one, the increase of the numbers of CD4 lymphocytes, percentage of disease progression, adverse reactions and adherence."( [Clinical trial comparing efficacy and safety of four highly active antiretroviral therapy (HAART) in antiretroviral-naive treatment with advanced HIV infection].
Barberá Farré, JR; Beato Pérez, JL; Cuadra García-Tenorio, F; Geijo Martínez, MP; Maciá Martínez, MA; Marcos Sánchez, F; Martínez Alfaro, E; Moreno Mendaña, JM; Rodríguez Zapata, M; Sanz Moreno, J; Sanz Sanz, J; Solera Santos, J, 2006
)
0.33
" Treatment was discontinued due to adverse reactions: 24% in regimen 1, 48% in regimen 2, 26% in regimen 3 and 32% in regimen 4, without significant difference."( [Clinical trial comparing efficacy and safety of four highly active antiretroviral therapy (HAART) in antiretroviral-naive treatment with advanced HIV infection].
Barberá Farré, JR; Beato Pérez, JL; Cuadra García-Tenorio, F; Geijo Martínez, MP; Maciá Martínez, MA; Marcos Sánchez, F; Martínez Alfaro, E; Moreno Mendaña, JM; Rodríguez Zapata, M; Sanz Moreno, J; Sanz Sanz, J; Solera Santos, J, 2006
)
0.33
"In the HIV positive patients with advanced infection, efficacy between the four regimens of HAART is similar, but there is a tendency to require more withdrawal due to adverse effects in the RTV group than in those of IDV, the two used as single PI."( [Clinical trial comparing efficacy and safety of four highly active antiretroviral therapy (HAART) in antiretroviral-naive treatment with advanced HIV infection].
Barberá Farré, JR; Beato Pérez, JL; Cuadra García-Tenorio, F; Geijo Martínez, MP; Maciá Martínez, MA; Marcos Sánchez, F; Martínez Alfaro, E; Moreno Mendaña, JM; Rodríguez Zapata, M; Sanz Moreno, J; Sanz Sanz, J; Solera Santos, J, 2006
)
0.33
"Treatment with indinavir/ritonavir (IDV/RTV) is very effective but hampered by frequent development of IDV-associated adverse events (mainly nephrotoxicity and skin changes)."( Maintenance of indinavir by dose adjustment in HIV-1-infected patients with indinavir-related toxicity.
Burger, D; Hoffmann, C; Lambertz, I; Rockstroh, JK; Vogel, M; Voigt, E; Wasmuth, JC, 2007
)
0.34
"HIV-infected patients with any IDV/RTV regimen who suffer from IDV-related adverse events were included."( Maintenance of indinavir by dose adjustment in HIV-1-infected patients with indinavir-related toxicity.
Burger, D; Hoffmann, C; Lambertz, I; Rockstroh, JK; Vogel, M; Voigt, E; Wasmuth, JC, 2007
)
0.34
" Overall tolerability improved with respect to incidence and severity of adverse events."( Maintenance of indinavir by dose adjustment in HIV-1-infected patients with indinavir-related toxicity.
Burger, D; Hoffmann, C; Lambertz, I; Rockstroh, JK; Vogel, M; Voigt, E; Wasmuth, JC, 2007
)
0.34
" A saquinavir C(min) > 2000 ng/ml was associated with an increased risk of gastrointestinal grade 3 or 4 adverse events and higher total cholesterol."( Pharmacokinetics of two randomized trials evaluating the safety and efficacy of indinavir, saquinavir and lopinavir in combination with low-dose ritonavir: the MaxCmin1 and 2 trials.
Cahn, P; Castagna, A; Clumeck, N; Dragsted, UB; Fox, Z; Gerstoft, J; Justesen, US; Losso, M; Lundgren, JD; Obel, N; Pedersen, C; Peters, B, 2007
)
0.34
" Overall, 142 participants (71%) discontinued the study after a median time of 112 weeks, including 4 (2%) due to unsuppressed viremia and 40 (20%) due to adverse events."( Efficacy, safety, and tolerability of long-term combination antiretroviral therapy in asymptomatic treatment-naïve adults with early HIV infection.
Dinubile, MJ; Marino, DR; McMahon, DK; Meibohm, AR; Robertson, MN,
)
0.13
"Many adverse drug reactions are caused by the cytochrome P450 (CYP)-dependent activation of drugs into reactive metabolites."( Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Jones, LH; Nadanaciva, S; Rana, P; Will, Y, 2016
)
0.43

Pharmacokinetics

ExcerptReferenceRelevance
"To evaluate a potential pharmacokinetic interaction of coadministration of fluconazole, and indinavir, a human immunodeficiency virus (HIV) protease inhibitor, 13 patients were enrolled in a multiple-dose, three-period, placebo-controlled, crossover study."( Effect of fluconazole on indinavir pharmacokinetics in human immunodeficiency virus-infected patients.
Carides, A; Clumeck, N; De Smet, M; De Wit, S; Debier, M; Deutsch, P; Matthews, C; McCrea, J; Stone, J, 1998
)
0.3
"The potential pharmacokinetic drug-drug interaction between delavirdine, a nonnucleoside analogue reverse transcriptase inhibitor, and indinavir, an inhibitor of HIV protease, was evaluated in healthy volunteers."( Pharmacokinetic drug-drug interaction study of delavirdine and indinavir in healthy volunteers.
Batts, DH; Carel, BJ; Carlson, GF; Ferry, JJ; Herman, BD, 1998
)
0.3
"The pharmacokinetic interaction between indinavir and ritonavir was evaluated in five groups of healthy adult volunteers to explore the potential for twice-daily (b."( Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers.
Berg, J; Cao, G; Carothers, L; Dennis, S; El-Shourbagy, T; Erdman, K; Granneman, GR; Hsu, A; Japour, A; Leonard, JM; Sun, E, 1998
)
0.3
"Observational, noncontrolled trial and prospective, open-label, nonrandomized, pharmacokinetic study."( Alteration in indinavir clearance during interleukin-2 infusions in patients infected with the human immunodeficiency virus.
Baseler, M; Falloon, J; Figg, WD; Forrest, A; Metcalf, JA; Piscitelli, SC; Raje, S; Vogel, S,
)
0.13
" Nevirapine significantly reduced median indinavir Cmin (47."( Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1.
Dusek, A; Hall, DB; Lamson, M; Murphy, RL; Myers, M; Sommadossi, JP, 1999
)
0.3
" These results further demonstrate that the concomitant administration technique in combination with the LC/MS/MS method can provide a realistic and reliable means of elucidating important pharmacokinetic properties of drug candidates during product development."( Simultaneous investigation of indinavir nonlinear pharmacokinetics and bioavailability in healthy volunteers using stable isotope labeling technique: study design and model-independent data analysis.
Carides, AD; Ju, WD; Rolan, P; Stone, JA; Woolf, E; Yeh, KC, 1999
)
0.3
" The geometric mean Cmax of theophylline, when coadministered with indinavir, was within 8% of theophylline when administered alone."( Effect of indinavir on the single-dose pharmacokinetics of theophylline in healthy subjects.
Deutsch, PJ; Laurent, A; Mistry, GC; Sterrett, AT, 1999
)
0.3
"hr/ml; 90% CI on the ratio 81%-100%) or Cmax (9."( The effect of azithromycin on the pharmacokinetics of indinavir.
Apseloff, G; Foulds, G; LaBoy-Goral, L; Wei, GC, 1999
)
0.3
"Observational pharmacokinetic study."( The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals.
Beijnen, JH; Hoetelmans, RM; Hsu, A; Lange, JM; Meenhorst, PL; Mulder, JW; Schreij, G; van Heeswijk, RP; Veldkamp, AI, 1999
)
0.3
"028), and for the mean plasma elimination half-life (1."( The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals.
Beijnen, JH; Hoetelmans, RM; Hsu, A; Lange, JM; Meenhorst, PL; Mulder, JW; Schreij, G; van Heeswijk, RP; Veldkamp, AI, 1999
)
0.3
"Combination of indinavir and 100 mg ritonavir in twice daily dosing regimens significantly affects the pharmacokinetic profile of indinavir."( The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals.
Beijnen, JH; Hoetelmans, RM; Hsu, A; Lange, JM; Meenhorst, PL; Mulder, JW; Schreij, G; van Heeswijk, RP; Veldkamp, AI, 1999
)
0.3
" Thus, the potential pharmacokinetic (PK) interaction between these drugs was evaluated."( Altered pharmacokinetics of indinavir by a novel nonnucleoside reverse transcriptase inhibitor (HBY-097): a pharmacokinetic evaluation in HIV-positive patients.
Aweeka, F; Hayashi, S; Jayesekera, D; Jayewardene, A; Shah, A; Thevanayagam, L, 1999
)
0.3
"The indinavir dosage regimen currently used for human immunodeficiency virus (HIV)-infected children is not based on pharmacokinetic data obtained in the target patient population."( Indinavir pharmacokinetics and parmacodynamics in children with human immunodeficiency virus infection.
Bassetti, D; Bassetti, M; Gatti, G; Principi, N; Sala, N; Vella, S; Vigano', A, 2000
)
0.31
"Our data show that there are no significant differences in the pharmacokinetic parameters of daunorubicin in patients receiving DaunoXome in combination with indinavir and ritonavir compared with those in patients not receiving PIs."( The pharmacokinetics of liposomal encapsulated daunorubicin are not modified by HAART in patients with HIV-associated Kaposi's sarcoma.
Careddu, A; D'Incalci, M; Fumagalli, L; Lazzarin, A; Parisi, I; Viganò, MG; Zecca, B; Zucchetti, M, 2000
)
0.31
"Plasma population pharmacokinetic analysis was performed on 805 IDV plasma values from 171 patients, using a non-linear mixed-effects modeling approach."( Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected patients.
Acosta, EP; Collier, AC; Havlir, DV; Hirsch, M; Richman, DD; Sommadossi, JP; Tebas, P; Zhou, XJ, 2000
)
0.31
"Population estimates of pharmacokinetic parameters of IDV and its CSF penetration were in excellent agreement with previously reported data from individual analyses."( Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected patients.
Acosta, EP; Collier, AC; Havlir, DV; Hirsch, M; Richman, DD; Sommadossi, JP; Tebas, P; Zhou, XJ, 2000
)
0.31
" h, a dose increase or a dose reduction was made and pharmacokinetic measurements were repeated 4 weeks later."( Pharmacokinetics of the protease inhibitor indinavir in human immunodeficiency virus type 1-infected children.
Burger, DM; de Groot, R; Geelen, SP; Hartwig, NG; Hoetelmans, RM; Hugen, PW; Scherpbier, HJ; Suur, MH; van Rossum, AM; Vulto, AG, 2001
)
0.31
"Indinavir + ritonavir regimens show improved pharmacokinetic properties, allowing twice-daily dosing with food."( A retrospective, cohort-based survey of patients using twice-daily indinavir + ritonavir combinations: pharmacokinetics, safety, and efficacy.
Aarnoutse, RE; Blok, WL; Burger, DM; Dieleman, JP; Hugen, PW; Lange, JM; Meenhorst, PL; Mulder, JW; Prins, JM; Reiss, P; ten Veen, JH; van der Meer, JT; van der Poll, T, 2001
)
0.31
" Rifampicin pharmacokinetic studies were carried out on day 1 and day 15."( Effect of indinavir on the pharmacokinetics of rifampicin in HIV-infected patients.
Jaruratanasirikul, S; Sriwiriyajan, S, 2001
)
0.31
" Cmax was 16."( Effects of grapefruit juice on pharmacokinetic exposure to indinavir in HIV-positive subjects.
DiFrancesco, R; Hewitt, RG; Shelton, MJ; Wynn, HE, 2001
)
0.31
" In general, this series of heterocyclic inhibitors displayed good activity (in both enzymatic and cellular tests) and low cellular toxicity; furthermore, several analogues exhibited improved pharmacokinetic parameters in animal models."( 4-Hydroxy-5,6-dihydropyrones as inhibitors of HIV protease: the effect of heterocyclic substituents at C-6 on antiviral potency and pharmacokinetic parameters.
Brodfuehrer, J; Domagala, J; Gajda, C; Gracheck, SJ; Hagen, SE; Holler, T; Hupe, D; Lovdahl, M; Lunney, EA; Nouhan, C; Pavlovsky, A; Saunders, J; Tait, BD; Urumov, A; VanderRoest, S; Wise, E; Zeikus, E; Zeikus, G, 2001
)
0.31
"This was a randomized, double-blind, placebo-controlled parallel study in human immunodeficiency virus type 1 (HIV-1)-uninfected healthy subjects to investigate the pharmacokinetic interaction between indinavir (IDV) and ritonavir (RTV)."( Pharmacokinetic profile and tolerability of indinavir-ritonavir combinations in healthy volunteers.
Deutsch, PJ; Nessly, ML; Rhodes, RR; Saah, AJ; Seniuk, MA; Winchell, GA, 2001
)
0.31
"In an open-label, randomized, multicenter, multiple-dose pharmacokinetic study, we determined the steady-state pharmacokinetics of amprenavir with and without coadministration of indinavir, nelfinavir, or saquinavir soft gel formulation in 31 human immunodeficiency virus type 1-infected subjects."( Pharmacokinetic study of human immunodeficiency virus protease inhibitors used in combination with amprenavir.
Eron, JJ; Gillotin, C; Haubrich, R; Lang, W; Lou, Y; Sadler, BM; Stein, DS, 2001
)
0.31
" We present pharmacokinetic data from a randomized placebo-controlled study designed to evaluate the metabolic effects of smoked marijuana and dronabinol in HIV-infected patients receiving indinavir (IDV) or nelfinavir (NFV)."( The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir.
Abrams, DI; Aweeka, FT; Benowitz, NL; Hilton, JF; Kosel, BW; Lizak, PS; Shade, SB, 2002
)
0.31
"Despite a statistically significant decrease in C(max) of IDV in the marijuana arm, the magnitude of changes in IDV and NFV pharmacokinetic parameters in the marijuana arm are likely to have no short-term clinical consequence."( The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir.
Abrams, DI; Aweeka, FT; Benowitz, NL; Hilton, JF; Kosel, BW; Lizak, PS; Shade, SB, 2002
)
0.31
"To examine the use of low-dose ritonavir as a pharmacokinetic enhancer for HIV protease inhibitors."( Low-dose ritonavir for protease inhibitor pharmacokinetic enhancement.
Rathbun, RC; Rossi, DR, 2002
)
0.31
" Pharmacologic data from intensive pharmacokinetic studies and baseline patient characteristics were evaluated as predictors of the increase in CD4 count from baseline to weeks 24, 56, and 80."( CD4 response is correlated with peak plasma concentrations of indinavir in adults with undetectable human immunodeficiency virus ribonucleic acid.
Anderson, PL; Brundage, RC; Fletcher, CV; Kakuda, TN, 2002
)
0.31
" The following pharmacokinetic parameters were determined: highest concentration (Cmax), hour-0 concentration, hour-8 concentration (C8), time to reach Cmax, and area under the plasma concentration-time curve over the 8-hour dosing interval (AUC8)."( Effect of milk thistle on the pharmacokinetics of indinavir in healthy volunteers.
Alfaro, R; Burstein, AH; Falloon, J; Formentini, E; Jagannatha, S; Piscitelli, SC, 2002
)
0.31
"To elucidate the aspects of pharmacokinetic interactions among HIV protease inhibitors (PIs), we investigated the effects of indinavir (IDV) on the hepatic and intestinal first-pass metabolism of other HIV PIs, amprenavir (APV), saquinavir (SQV) and nelfinavir (NFV), in rats."( Hepatic and intestinal contributions to pharmacokinetic interaction of indinavir with amprenavir, nelfinavir and saquinavir in rats.
Gao, W; Kageyama, M; Kimura, K; Kishida, T; Shibata, N; Takada, K; Yoshikawa, Y, 2002
)
0.31
" The goal of this model-based pharmacokinetic analysis was to describe the differences observed in amprenavir pharmacokinetics among treatment arms in the Adult AIDS Clinical Trial Group (AACTG) study protocol 398 and to propose mechanisms to account for them."( Effect of coadministration of nelfinavir, indinavir, and saquinavir on the pharmacokinetics of amprenavir.
Bennett, KK; Hammer, SM; Labbé, L; Lu, JF; Mellors, J; Pfister, M; Rosenkranz, S; Sheiner, LB, 2002
)
0.31
"One hundred seventy-six HIV-positive subjects receiving 1200 mg amprenavir twice daily as part of AACTG protocol 398 were included in the pharmacokinetic study."( Effect of coadministration of nelfinavir, indinavir, and saquinavir on the pharmacokinetics of amprenavir.
Bennett, KK; Hammer, SM; Labbé, L; Lu, JF; Mellors, J; Pfister, M; Rosenkranz, S; Sheiner, LB, 2002
)
0.31
"05) without altering other pharmacokinetic parameter values."( Effect of Seville orange juice and grapefruit juice on indinavir pharmacokinetics.
Acosta, EP; Desai, HD; Edwards, DJ; Hon, YY; Jann, MW; Penzak, SR; Turner, M, 2002
)
0.31
" Based on the pharmacologic characteristics of venlafaxine and indinavir, we hypothesized that significant pharmacokinetic drug-drug interactions would not occur when these drugs where taken concurrently."( A pharmacokinetic drug-drug interaction study of venlafaxine and indinavir.
Carson, SW; DeVane, CL; Eisele, G; Levin, GM; Nelson, LA; Preston, SL, 2001
)
0.31
"Combinations of protease inhibitors (PIs) can have potentially beneficial pharmacokinetic interactions, resulting in higher drug levels and less frequent dose administration."( Coadministration of indinavir and nelfinavir in human immunodeficiency virus type 1-infected adults: safety, pharmacokinetics, and antiretroviral activity.
Deutsch, P; Havlir, D; Kerr, B; Lewis, RH; Peng, Y; Riddler, SA; Saah, A; Squires, KE; Wynne, LH; Yeh, K; Zhong, L, 2002
)
0.31
"Low doses of ritonavir, a strong inhibitor of cytochrome P450 3A4, enhances the pharmacokinetic profile of indinavir with increased serum levels."( Experience of a combination including indinavir 400 mg plus ritonavir 200 mg twice daily in HIV-infected patients: pharmacokinetic data.
Durand, A; Gastaut, JA; Lacarelle, B; Orticoni, M; Petit, N; Solas, C, 2002
)
0.31
"The present population pharmacokinetic (PK) and pharmacodynamic (PD) study modeled the effects of covariates including drug adherence and the coadministration of protease inhibitors (PIs) on the pharmacokinetics of efavirenz (EFV) and the relationship between EFV exposure and virological failure in patients who failed initial PI treatment in Adult AIDS Clinical Trial Group (AACTG) study 398."( Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398.
Bennett, KK; Hammer, SM; Labbé, L; Mellors, J; Pfister, M; Rosenkranz, S; Sheiner, LB, 2003
)
0.32
" Twenty-four-hour pharmacokinetic sampling was performed at the end of each 14-day study period."( Steady-state pharmacokinetic interaction of modified-dose indinavir and rifabutin.
Benson, C; Currier, J; Deutsch, P; Flexner, C; Gerber, J; Hamzeh, FM; Lee, J; McCrea, J; Ruan, P; Wu, H, 2003
)
0.32
" Five HIV-infected patients on steady-state nelfinavir-containing therapy were subject to pharmacokinetic sampling for nelfinavir concentration twice: without sildenafil and with sildenafil 25 mg as a single dose."( Sildenafil does not alter nelfinavir pharmacokinetics.
Bratt, G; Ståhle, L, 2003
)
0.32
"Thirty-six HIV-1-infected patients who participated in HIV-NAT 005 study gave informed consent to record a pharmacokinetic curve 4 weeks after starting a regimen containing either indinavir 800 mg every 8 h (n = 19) or indinavir 800 mg + ritonavir 100 mg every 12 h (n = 17)."( Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients.
Boyd, M; Burger, D; Cooper, D; Duncombe, C; Felderhof, M; Lange, J; Mahanontharit, A; Phanupak, P; Reiss, P; Ruxrungtham, K; Stek, M; Ubolyam, S, 2003
)
0.32
" Median and IQR values for indinavir AUC, Cmax and Cmin were 20."( Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients.
Boyd, M; Burger, D; Cooper, D; Duncombe, C; Felderhof, M; Lange, J; Mahanontharit, A; Phanupak, P; Reiss, P; Ruxrungtham, K; Stek, M; Ubolyam, S, 2003
)
0.32
"The study was retrospective with a prospective pharmacokinetic study at a single centre."( Low-dose indinavir in combination with low-dose ritonavir: steady-state pharmacokinetics and long-term clinical outcome follow-up.
Justesen, US; Levring, AM; Lindberg, JA; Pedersen, C; Tauris, P; Thomsen, A, 2003
)
0.32
" The median IDV morning and evening Cmin were 434 ng/mL and 220 ng/mL, respectively."( Low-dose indinavir in combination with low-dose ritonavir: steady-state pharmacokinetics and long-term clinical outcome follow-up.
Justesen, US; Levring, AM; Lindberg, JA; Pedersen, C; Tauris, P; Thomsen, A, 2003
)
0.32
" However, rather low IDV Cmin suggests that the regimen should be evaluated further before its widespread use and that the regimen probably should be guided by pharmacokinetic evaluation."( Low-dose indinavir in combination with low-dose ritonavir: steady-state pharmacokinetics and long-term clinical outcome follow-up.
Justesen, US; Levring, AM; Lindberg, JA; Pedersen, C; Tauris, P; Thomsen, A, 2003
)
0.32
"A pharmacokinetic study of 10 patients receiving IDV plus dual nucleoside analogue therapy."( Intracellular indinavir pharmacokinetics in HIV-infected patients: comparison with plasma pharmacokinetics.
Back, D; Barry, M; Bergin, C; Clarke, S; Hennessy, M; Hoggard, P; Kelleher, D; Khoo, S; Maher, B; Meadon, E; Mulcahy, F; Spiers, JP; Tjia, J, 2003
)
0.32
" The intracellular elimination half-life and mean residence time of IDV are significantly prolonged compared with plasma."( Intracellular indinavir pharmacokinetics in HIV-infected patients: comparison with plasma pharmacokinetics.
Back, D; Barry, M; Bergin, C; Clarke, S; Hennessy, M; Hoggard, P; Kelleher, D; Khoo, S; Maher, B; Meadon, E; Mulcahy, F; Spiers, JP; Tjia, J, 2003
)
0.32
" High indinavir Cmax values have been associated with indinavir-related nephrotoxicity."( Administration of indinavir and low-dose ritonavir (800/100 mg twice daily) with food reduces nephrotoxic peak plasma levels of indinavir.
Aarnoutse, RE; Burger, DM; de Boo, TM; Fätkenheuer, G; Hekster, YA; Reiss, P; Rockstroh, JK; Schmitz, K; Schneider, K; Wasmuth, JC, 2003
)
0.32
"This was an open-label, randomized, two-treatment, two-period, cross-over pharmacokinetic study performed at steady state."( Administration of indinavir and low-dose ritonavir (800/100 mg twice daily) with food reduces nephrotoxic peak plasma levels of indinavir.
Aarnoutse, RE; Burger, DM; de Boo, TM; Fätkenheuer, G; Hekster, YA; Reiss, P; Rockstroh, JK; Schmitz, K; Schneider, K; Wasmuth, JC, 2003
)
0.32
"Administration of indinavir/ritonavir 800/100 mg on an empty stomach results in a higher indinavir Cmax compared to ingestion with a light meal."( Administration of indinavir and low-dose ritonavir (800/100 mg twice daily) with food reduces nephrotoxic peak plasma levels of indinavir.
Aarnoutse, RE; Burger, DM; de Boo, TM; Fätkenheuer, G; Hekster, YA; Reiss, P; Rockstroh, JK; Schmitz, K; Schneider, K; Wasmuth, JC, 2003
)
0.32
"At week 4 of the study, 12-hour pharmacokinetic profiles for indinavir/ritonavir were obtained for 20 HIV-infected subjects."( Pharmacokinetics of indinavir/ritonavir (800/100 mg) in combination with efavirenz (600 mg) in HIV-1-infected subjects.
Aarnoutse, RE; Boyd, MA; Burger, DM; Cooper, DA; Lange, JM; Phanuphak, P; Ruxrungtham, K; Stek, M; van Heeswijk, RP, 2003
)
0.32
" A >10-fold variation in indinavir Cmin was observed."( Pharmacokinetics of indinavir/ritonavir (800/100 mg) in combination with efavirenz (600 mg) in HIV-1-infected subjects.
Aarnoutse, RE; Boyd, MA; Burger, DM; Cooper, DA; Lange, JM; Phanuphak, P; Ruxrungtham, K; Stek, M; van Heeswijk, RP, 2003
)
0.32
"Despite the known pharmacokinetic interaction between efavirenz and indinavir/ritonavir, the combination of indinavir/ritonavir at 800/100 mg bid and efavirenz at 600 mg qd results in adequate minimum concentrations of both indinavir and efavirenz for treatment-naive patients."( Pharmacokinetics of indinavir/ritonavir (800/100 mg) in combination with efavirenz (600 mg) in HIV-1-infected subjects.
Aarnoutse, RE; Boyd, MA; Burger, DM; Cooper, DA; Lange, JM; Phanuphak, P; Ruxrungtham, K; Stek, M; van Heeswijk, RP, 2003
)
0.32
" No statistically significant differences in peak concentration (11."( Influence of goldenseal root on the pharmacokinetics of indinavir.
Edwards, DJ; Prescilla, RP; Sandhu, RS; Simonelli, TM, 2003
)
0.32
" As these drugs are likely to be coadministered, these studies were performed to assess the pharmacokinetic interactions, safety and toleration of these drugs when taken together."( No clinically significant pharmacokinetic interactions between voriconazole and indinavir in healthy volunteers.
Kleinermans, D; Love, ER; Purkins, L; Wood, N, 2003
)
0.32
"Study A: Seventeen subjects were evaluable for pharmacokinetic analysis (eight voriconazole + indinavir, nine voriconazole + placebo)."( No clinically significant pharmacokinetic interactions between voriconazole and indinavir in healthy volunteers.
Kleinermans, D; Love, ER; Purkins, L; Wood, N, 2003
)
0.32
" Pharmacokinetic evaluations of steady-state concentrations of indinavir and ritonavir were performed before and after administration of rifampin (300 mg every day for 4 days)."( Pharmacokinetic interaction between rifampin and the combination of indinavir and low-dose ritonavir in HIV-infected patients.
Andersen, AB; Brøsen, K; Gerstoft, J; Justesen, US; Klitgaard, NA; Pedersen, C, 2004
)
0.32
" Pharmacokinetic data were derived by using noncompartmental analysis."( Pharmacokinetics of indinavir and nelfinavir in treatment-naive, human immunodeficiency virus-infected subjects.
Collier, A; DiCenzo, R; DiFrancecso, R; Feinberg, J; Fischl, MA; Forrest, A; Morse, GD; Ribaudo, H, 2004
)
0.32
"We evaluated whether the pharmacokinetic parameters of indinavir differ in Koreans and Caucasians."( Pharmacokinetics of indinavir in Koreans and Caucasians.
Chang, KH; Cho, CH; Choi, JY; Kim, JM; Park, YS; Shin, SY; Song, YG, 2004
)
0.32
" This study aimed to assess the pharmacokinetic profile of indinavir in patients infected with human immunodeficiency virus to characterize interpatient and intrapatient variability and to build up a Bayesian approach for dosage adaptation."( Population pharmacokinetics of indinavir in patients infected with human immunodeficiency virus.
Biollaz, J; Buclin, T; Csajka, C; Décosterd, LA; Fattinger, K; Marzolini, C; Telenti, A, 2004
)
0.32
" Plasma samples were then collected for indinavir pharmacokinetic determination."( Effect of high-dose vitamin C on the steady-state pharmacokinetics of the protease inhibitor indinavir in healthy volunteers.
Amsden, JR; Fisher, MA; Hobbs, GR; Khakoo, RA; Lalka, D; Slain, D, 2005
)
0.33
" Indinavir oral clearance and half-life were not significantly different."( Effect of high-dose vitamin C on the steady-state pharmacokinetics of the protease inhibitor indinavir in healthy volunteers.
Amsden, JR; Fisher, MA; Hobbs, GR; Khakoo, RA; Lalka, D; Slain, D, 2005
)
0.33
"This was a steady-state, open-label pharmacokinetic study of 19 patients."( Pharmacokinetics of reduced-dose indinavir/ritonavir 400/100 mg twice daily in HIV-1-infected Thai patients.
Boyd, M; Bunyaprawit, P; Burger, D; Chuenyam, T; Cooper, D; Horsakulchai, M; Lange, J; Mahanontharit, A; Mootsikapun, P; Phanuphak, P; Ruxrungtham, K; Sangkote, J; Ubolyam, S, 2005
)
0.33
" The median (interquartile ranges) for indinavir AUC, Cmax and Cmin were 18."( Pharmacokinetics of reduced-dose indinavir/ritonavir 400/100 mg twice daily in HIV-1-infected Thai patients.
Boyd, M; Bunyaprawit, P; Burger, D; Chuenyam, T; Cooper, D; Horsakulchai, M; Lange, J; Mahanontharit, A; Mootsikapun, P; Phanuphak, P; Ruxrungtham, K; Sangkote, J; Ubolyam, S, 2005
)
0.33
" Therapeutic Cmin levels of indinavir were achieved in >80% of the subjects and short-term virological response was satisfactory in this cohort of patients starting highly active antiretroviral therapy at an advanced disease stage with high baseline viral loads."( Pharmacokinetics of reduced-dose indinavir/ritonavir 400/100 mg twice daily in HIV-1-infected Thai patients.
Boyd, M; Bunyaprawit, P; Burger, D; Chuenyam, T; Cooper, D; Horsakulchai, M; Lange, J; Mahanontharit, A; Mootsikapun, P; Phanuphak, P; Ruxrungtham, K; Sangkote, J; Ubolyam, S, 2005
)
0.33
" Indinavir plasma levels were determined by HPLC and pharmacokinetic parameters by non-compartmental analysis."( Low-doses of indinavir boosted with ritonavir in HIV-infected Thai patients: pharmacokinetics, efficacy and tolerability.
Cressey, TR; Jourdain, G; Kunkeaw, S; Lallemant, M; Leenasirimakul, P; Puttimit, C; Sukrakanchana, PO; Tod, M, 2005
)
0.33
"The objectives of this study were to build a population pharmacokinetic model that describe plasma concentrations of indinavir in human immunodeficiency virus (HIV)-infected patients with sustained virological response under a stable antiretroviral combination, and to characterize the effect of covariates and co-medications on indinavir pharmacokinetics."( Population pharmacokinetic analysis of indinavir in HIV-infected patient treated with a stable antiretroviral therapy.
Baron, G; Brendel, K; Goujard, C; Legrand, M; Mentré, F; Taburet, AM, 2005
)
0.33
" We evaluated potential bidirectional pharmacokinetic interactions between calcium channel blockers and coadministered indinavir and ritonavir."( Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers.
Aberg, JA; Fichtenbaum, CJ; Gerber, JG; Glesby, MJ; Grosskopf, N; Hafner, R; Hall, S; Kendall, MA; Zolopa, AR, 2005
)
0.33
" Twenty-four-hour pharmacokinetic collection was performed on days 7 and 26, with 12-hour collection on day 19."( Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers.
Aberg, JA; Fichtenbaum, CJ; Gerber, JG; Glesby, MJ; Grosskopf, N; Hafner, R; Hall, S; Kendall, MA; Zolopa, AR, 2005
)
0.33
" Full pharmacokinetic curves were available from 45 patients."( Population pharmacokinetics of indinavir alone and in combination with ritonavir in HIV-1-infected patients.
Beijnen, JH; Huitema, AD; Kappelhoff, BS; Meenhorst, PL; Mulder, JW; Prins, JM; Sankatsing, SU; Van Gorp, EC, 2005
)
0.33
"The pharmacokinetic parameters of indinavir were adequately described by our population model."( Population pharmacokinetics of indinavir alone and in combination with ritonavir in HIV-1-infected patients.
Beijnen, JH; Huitema, AD; Kappelhoff, BS; Meenhorst, PL; Mulder, JW; Prins, JM; Sankatsing, SU; Van Gorp, EC, 2005
)
0.33
"The relationship between MDR1 single nucleotide polymorphisms (SNP) and the pharmacokinetic or pharmacodynamic responses to protease inhibitors has been recently challenged."( Absence of association between MDR1 genetic polymorphisms, indinavir pharmacokinetics and response to highly active antiretroviral therapy.
Aboulker, JP; Becquemont, L; Brendel, K; Gérard, L; Launay, O; Marcellin, F; Mentré, F; Morand-Joubert, L; Peytavin, G; Verstuyft, C, 2005
)
0.33
" Mean modelled IDV peak and trough concentrations, as well as clearance modelled from pharmacokinetic model, after 8 weeks of therapy were not significantly different between patients carrying the wild-type haplotype GG-CC (at position 2677 and 3435 respectively) and others."( Absence of association between MDR1 genetic polymorphisms, indinavir pharmacokinetics and response to highly active antiretroviral therapy.
Aboulker, JP; Becquemont, L; Brendel, K; Gérard, L; Launay, O; Marcellin, F; Mentré, F; Morand-Joubert, L; Peytavin, G; Verstuyft, C, 2005
)
0.33
"Six HIV-positive antiretroviral experienced patients initiating therapy with a regimen including lopinavir/ritonavir (400/100 mg twice per day) and indinavir (800 mg twice per day) underwent steady-state pharmacokinetic analysis."( Steady-state pharmacokinetics and tolerability of indinavir-lopinavir/r combination therapy in antiretroviral-experienced patients.
Antoniou, T; Giguere, P; Phillips, EJ; Tseng, AL; van Heeswijk, RP; Walker, SE, 2005
)
0.33
"In this prospective trial, blood samples were drawn during a 6-hour time interval between two doses at enrolment to assess protease inhibitor (PI) pharmacokinetic parameters, and 4 months later to assess plasma trough and peak concentrations."( High variability of indinavir and nelfinavir pharmacokinetics in HIV-infected patients with a sustained virological response on highly active antiretroviral therapy.
Bonnet, B; Diquet, B; Duval, X; Goujard, C; Katlama, C; Legrand, M; Leport, C; Mentré, F; Panhard, X; Peytavin, G; Salmon-Céron, D; Taburet, AM; Vincent, I, 2005
)
0.33
" Ritonavir significantly increased indinavir elimination half-life and plasma exposure."( High variability of indinavir and nelfinavir pharmacokinetics in HIV-infected patients with a sustained virological response on highly active antiretroviral therapy.
Bonnet, B; Diquet, B; Duval, X; Goujard, C; Katlama, C; Legrand, M; Leport, C; Mentré, F; Panhard, X; Peytavin, G; Salmon-Céron, D; Taburet, AM; Vincent, I, 2005
)
0.33
" An intensive pharmacokinetic (PK) evaluation was performed on day 14 and multiple trough concentrations were subsequently collected."( Pharmacodynamics of antiretroviral agents in HIV-1 infected patients: using viral dynamic models that incorporate drug susceptibility and adherence.
Acosta, EP; Eron, JJ; Gerber, JG; Huang, Y; Kuritzkes, DR; Park, JG; Perelson, AS; Rosenkranz, SL; Wu, H; Yu, S, 2006
)
0.33
" At baseline 6/35 (17%) had a serum creatinine concentration within normal limits, but were offered enrolment because of previous nephrotoxicity (nephrolithiasis and/or abnormal serum creatinine), and a screening pharmacokinetic profile associated with increased nephrotoxicity risk."( The use of pharmacokinetically guided indinavir dose reductions in the management of indinavir-associated renal toxicity.
Boyd, MA; Burger, DM; Cooper, DA; Lange, JM; Mahanontharit, A; Phanuphak, P; Reiss, P; Ruxrungtham, K; Siangphoe, U, 2006
)
0.33
" Minimum and maximum concentrations (C subsetmin, C subsetmax), area under the concentration-time curve (AUC subset0-12h), total clearance (CL subsettot) and half-life (t1/2) were calculated."( Pharmacokinetics and tolerability of a combination of indinavir, lopinavir and ritonavir in multiply pretreated HIV-1 infected adults.
Harder, S; Klauke, S; Kurowski, M; Lutz, T; Müller, A; Rottmann, C; Staszewski, S; von Hentig, N, 2006
)
0.33
" 3,467 ng*h/mL; Cmin 220 ng/mL vs."( Pharmacokinetics and tolerability of a combination of indinavir, lopinavir and ritonavir in multiply pretreated HIV-1 infected adults.
Harder, S; Klauke, S; Kurowski, M; Lutz, T; Müller, A; Rottmann, C; Staszewski, S; von Hentig, N, 2006
)
0.33
"Association of IDV to lipid nanoparticles has a favorable half-life and tissue distribution and allows comparable minimum drug concentration in the lymph (where the majority of viral replication occurs) to be achieved with a dosing schedule of every 95."( Feasibility of weekly HIV drug delivery to enhance drug localization in lymphoid tissues based on pharmacokinetic models of lipid-associated indinavir.
Ho, RJ; Snedecor, SJ; Sullivan, SM, 2006
)
0.33
" (Selecting reliable pharmacokinetic data for explanatory analyses of clinical trials in the presence of possible noncompliance."( Improving data reliability using a non-compliance detection method versus using pharmacokinetic criteria.
Acosta, EP; Blaschke, TF; Krygowski, M; Kshirsagar, SA; Sheiner, LB; Verotta, D, 2007
)
0.34
"The protease inhibitor indinavir is characterized by an important interindividual pharmacokinetic variability, which results from the actions of the metabolizing enzymes cytochrome P450 (CYP) 3A and the multidrug efflux pump P-glycoprotein (P-gp), encoded by MDR1."( Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV-infected patients.
Bourgarel-Rey, V; Brunet, C; Drogoul, MP; Durand, A; Frixon-Marin, V; Gastaut, JA; Lacarelle, B; Poizot-Martin, I; Quaranta, S; Simon, N; Solas, C, 2007
)
0.34
"The MDR1 C3435T genotype affects the absorption constant of indinavir suggesting that P-gp may be implicated in its pharmacokinetic variability."( Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV-infected patients.
Bourgarel-Rey, V; Brunet, C; Drogoul, MP; Durand, A; Frixon-Marin, V; Gastaut, JA; Lacarelle, B; Poizot-Martin, I; Quaranta, S; Simon, N; Solas, C, 2007
)
0.34
"This work aimed at building a population pharmacokinetic (PK) model for lamivudine (LMV), stavudine (STV) and zidovudine (ZDV), estimating their inter and intraindividual PK variability and investigating the influence of different covariates."( Population pharmacokinetic analysis of lamivudine, stavudine and zidovudine in controlled HIV-infected patients on HAART.
Diquet, B; Goujard, C; Legrand, M; Mentré, F; Panhard, X; Taburet, AM, 2007
)
0.34
" Data originated from pre-defined pharmacokinetic substudies within two randomized 48-week trials evaluating the safety and efficacy of three protease inhibitor regimens."( Pharmacokinetics of two randomized trials evaluating the safety and efficacy of indinavir, saquinavir and lopinavir in combination with low-dose ritonavir: the MaxCmin1 and 2 trials.
Cahn, P; Castagna, A; Clumeck, N; Dragsted, UB; Fox, Z; Gerstoft, J; Justesen, US; Losso, M; Lundgren, JD; Obel, N; Pedersen, C; Peters, B, 2007
)
0.34
"To evaluate the pharmacokinetic compatibility of a ritonavir-boosted indinavir-fosamprenavir combination among patients with human immunodeficiency virus (HIV)."( Pharmacokinetics of an indinavir-ritonavir-fosamprenavir regimen in patients with human immunodeficiency virus.
Acosta, EP; Easley, KA; Lennox, JL; Ofotokun, I; Pan, Y, 2008
)
0.35
"Single-center, nonrandomized, prospective, multiple-dose, two-phase pharmacokinetic study."( Pharmacokinetics of an indinavir-ritonavir-fosamprenavir regimen in patients with human immunodeficiency virus.
Acosta, EP; Easley, KA; Lennox, JL; Ofotokun, I; Pan, Y, 2008
)
0.35
" After 12-hour pharmacokinetic sampling was performed on all patients (period A), fosamprenavir (a prodrug of amprenavir) 700 mg twice/day was coadministered for 5 days, with a repeat 12-hour pharmacokinetic sampling performed on the fifth day (period B)."( Pharmacokinetics of an indinavir-ritonavir-fosamprenavir regimen in patients with human immunodeficiency virus.
Acosta, EP; Easley, KA; Lennox, JL; Ofotokun, I; Pan, Y, 2008
)
0.35
" With the exception of indinavir C(max), the changes in indinavir and ritonavir pharmacokinetic parameters observed after fosamprenavir coadministration were not statistically significant."( Pharmacokinetics of an indinavir-ritonavir-fosamprenavir regimen in patients with human immunodeficiency virus.
Acosta, EP; Easley, KA; Lennox, JL; Ofotokun, I; Pan, Y, 2008
)
0.35
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" We evaluated potential pharmacokinetic interactions between IDV and AG, and assessed whether AG improves IDV-induced insulin resistance."( Pharmacokinetic and metabolic effects of American ginseng (Panax quinquefolius) in healthy volunteers receiving the HIV protease inhibitor indinavir.
Andrade, AS; Brown, TT; Caballero, B; Dobs, AS; Flexner, CW; Hendrix, C; Parsons, TL; Yuan, CS, 2008
)
0.35
"Pharmacokinetic studies in mice traditionally require one animal per time point, resulting in dosing and euthanizing a large number of animals and producing suboptimal quality of pharmacokinetic data due to inter-animal variability and dosing error."( Improved pharmacokinetic and bioavailability support of drug discovery using serial blood sampling in mice.
Hageman, W; Huebert, ND; Peng, SX; Rockafellow, BA; Skedzielewski, TM, 2009
)
0.35
"We evaluate by simulation three model-based methods to test the influence of a single nucleotide polymorphism on a pharmacokinetic parameter of a drug: analysis of variance (ANOVA) on the empirical Bayes estimates of the individual parameters, likelihood ratio test between models with and without genetic covariate, and Wald tests on the parameters of the model with covariate."( Comparison of model-based tests and selection strategies to detect genetic polymorphisms influencing pharmacokinetic parameters.
Bertrand, J; Comets, E; Mentre, F, 2008
)
0.35
" Pharmacokinetic analysis showed higher volume of distribution median values related to the C/C genotype in comparison with C/T or T/T genotypes for exon 26 (4."( Pharmacokinetic study of the variability of indinavir drug levels when boosted with ritonavir in HIV-infected children.
Bellusci, C; Bologna, R; Bramuglia, GF; Cáceres Guido, P; Curras, V; Hocht, C; Mangano, A; Mariño Hernández, E; Mecikovsky, D; Niselman, V; Rubio, MC; Sen, L, 2009
)
0.35
"The in vivo pharmacokinetic study and in situ single-pass intestinal perfusion model were employed in the research."( Effects of St. John's wort extract on indinavir pharmacokinetics in rats: differentiation of intestinal and hepatic impacts.
Ho, YF; Hsueh, WC; Huang, DK; Lai, MY; Tsai, TH; Yu, HY, 2009
)
0.35
"Oral administration of either 150 or 300 mg/day SJW for 15 days significantly reduced indinavir plasma levels with certain pharmacokinetic parameter changes."( Effects of St. John's wort extract on indinavir pharmacokinetics in rats: differentiation of intestinal and hepatic impacts.
Ho, YF; Hsueh, WC; Huang, DK; Lai, MY; Tsai, TH; Yu, HY, 2009
)
0.35
"Herb-drug pharmacokinetic interactions between SJW and indinavir can be clearly observed in the Wistar rat model."( Effects of St. John's wort extract on indinavir pharmacokinetics in rats: differentiation of intestinal and hepatic impacts.
Ho, YF; Hsueh, WC; Huang, DK; Lai, MY; Tsai, TH; Yu, HY, 2009
)
0.35
"Compartmental as well as noncompartmental analyses are used routinely in pharmacokinetic analysis."( Pharmacokinetic properties of indinavir in rat: some limitations of noncompartmental analysis.
Hamidi, M, 2010
)
0.36
"To investigate the potential for a pharmacokinetic interaction between darunavir (DRV, TMC114, Prezista), indinavir (IDV, Crixivan) and low-dose ritonavir (RTV, Norvir)."( Pharmacokinetic interaction between indinavir and darunavir with low-dose ritonavir in healthy volunteers.
De Marez, T; De Paepe, E; De Pauw, M; Hoetelmans, RM; Lefebvre, E; Sekar, V; Vangeneugden, T, 2010
)
0.36
" On day 7, full pharmacokinetic profiles of DRV, IDV and RTV were determined."( Pharmacokinetic interaction between indinavir and darunavir with low-dose ritonavir in healthy volunteers.
De Marez, T; De Paepe, E; De Pauw, M; Hoetelmans, RM; Lefebvre, E; Sekar, V; Vangeneugden, T, 2010
)
0.36
" Our motivation arises from problems where the response is a continuously measured quantity, typically some pharmacokinetic parameter."( Dynamic calibration of pharmacokinetic parameters in dose-finding studies.
Fenton, T; Hughes, MD; O'Quigley, J; Pei, L, 2010
)
0.36
" During pharmacokinetic studies in male Wistar rats there was no significant difference in the serum levels of indinavir for SLE, SLE-A3 and SLE-G3 formulations at all time points."( Development of indinavir submicron lipid emulsions loaded with lipoamino acids-in vivo pharmacokinetics and brain-specific delivery.
Apte, SS; Bollam, S; Kandadi, P; Veerabrahma, K, 2011
)
0.37
" The in vivo pharmacokinetic and tissue distribution were conducted in mice."( Brain delivery of transferrin coupled indinavir submicron lipid emulsions--pharmacokinetics and tissue distribution.
Afzal, SM; Kishan, V; Kumar, PU; Prabhakar, K; Rajanna, A, 2011
)
0.37
"To assess the effects of venlafaxine extended-release (XR) capsules and desvenlafaxine extended-release (XR) tablets upon indinavir pharmacokinetic properties when co-administrated to healthy volunteers."( Lack of a pharmacokinetic drug-drug interaction with venlafaxine extended-release/indinavir and desvenlafaxine extended-release/indinavir.
Jann, MW; Momary, K; Penzak, SR; Spratlin, V; Turner, D; VanDenBerg, C; Wright, A; Zhang, H, 2012
)
0.38
" Indinavir pharmacokinetic parameters were calculated by noncompartmental analysis using validated computer software."( Lack of a pharmacokinetic drug-drug interaction with venlafaxine extended-release/indinavir and desvenlafaxine extended-release/indinavir.
Jann, MW; Momary, K; Penzak, SR; Spratlin, V; Turner, D; VanDenBerg, C; Wright, A; Zhang, H, 2012
)
0.38
"No pharmacokinetic drug-drug interaction was demonstrated between venlafaxine XR and indinavir or between desvenlafaxine XR and indinvair."( Lack of a pharmacokinetic drug-drug interaction with venlafaxine extended-release/indinavir and desvenlafaxine extended-release/indinavir.
Jann, MW; Momary, K; Penzak, SR; Spratlin, V; Turner, D; VanDenBerg, C; Wright, A; Zhang, H, 2012
)
0.38
" The present work explored the feasibility of using Ctrough or Cmax in the area under the concentration-time curve (AUC) prediction of indinavir."( Differences in the Prediction of Area Under the Curve for a Protease Inhibitor Using Trough Versus Peak Concentration: Assessment Using Published Pharmacokinetic Data for Indinavir.
Srinivas, NR,
)
0.13
" These indinavir pharmacokinetic modulation effects were not dependent on the presence of aloverose and also not on the average molecular weight of the isolated fractions."( Evaluation of Isolated Fractions of Aloe vera Gel Materials on Indinavir Pharmacokinetics: In vitro and in vivo Studies.
Abay, E; Ellis, S; Gouws, C; Hamman, J; Malan, M; Otto, DP; Steyn, D; Wallis, L; Wiesner, L, 2016
)
0.43
"Patients receiving anti-retroviral drug treatment are sometimes simultaneously taking herbal remedies, which may result in pharmacokinetic herb-drug interactions."( Herb-Drug Pharmacokinetic Interactions: Transport and Metabolism of Indinavir in the Presence of Selected Herbal Products.
Abay, E; Calitz, C; Gouws, C; Hamman, J; Steenekamp, J; Viljoen, J; Wiesner, L, 2015
)
0.42
" Indinavir significantly increased the pharmacokinetic exposure of lamivudine in mice; however, the effect by indinavir was significantly less pronounced in Mate1 (-/-) mice as compared to Mate1(+/+) mice."( Indinavir Alters the Pharmacokinetics of Lamivudine Partially via Inhibition of Multidrug and Toxin Extrusion Protein 1 (MATE1).
Guo, D; Huang, J; Li, Q; Polli, JE; Shu, Y; Yang, H; Ye, Z; Zhang, W; Zhu, P, 2018
)
0.48

Compound-Compound Interactions

ExcerptReferenceRelevance
"The potential pharmacokinetic drug-drug interaction between delavirdine, a nonnucleoside analogue reverse transcriptase inhibitor, and indinavir, an inhibitor of HIV protease, was evaluated in healthy volunteers."( Pharmacokinetic drug-drug interaction study of delavirdine and indinavir in healthy volunteers.
Batts, DH; Carel, BJ; Carlson, GF; Ferry, JJ; Herman, BD, 1998
)
0.3
" Many of the drugs commonly taken by patients with HIV have a strong potential to interact with the protease inhibitors."( Drug interactions of HIV protease inhibitors.
Kuper, JJ; Malaty, LI, 1999
)
0.3
"Due to changes in hepatic metabolism, protease inhibitors may interact with concurrent treatment."( [HIV protease inhibitors: drug interactions].
Dubreuil, L; Gérard, Y; Maulin, L; Mouton, Y, 1999
)
0.3
"To compare the safety and efficacy of stavudine (d4T) + lamivudine (3TC) with zidovudine (ZDV) + 3TC, each in combination with indinavir (IDV)."( A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I).
Clark, R; Cohen, C; Cooley, T; Grosso, R; Gulick, R; Marlowe, SI; Mauney, J; Mulanovich, V; Santana, J; Schoellkopf, N; Squires, KE; Stevens, M; Tebas, P; Uffelman, K; Wright, D; Yangco, B, 2000
)
0.31
"These results support the choice of d4T + 3TC as a nucleoside analog pair in combination with a protease inhibitor in an initial HIV treatment regimen."( A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I).
Clark, R; Cohen, C; Cooley, T; Grosso, R; Gulick, R; Marlowe, SI; Mauney, J; Mulanovich, V; Santana, J; Schoellkopf, N; Squires, KE; Stevens, M; Tebas, P; Uffelman, K; Wright, D; Yangco, B, 2000
)
0.31
"To compare the efficacy and safety of two-times-daily versus three-times-daily indinavir in combination with zidovudine and lamivudine."( Comparative studies of two-times-daily versus three-times-daily indinavir in combination with zidovudine and lamivudine.
Arathoon, E; Benetucci, L; Cahn, P; Chodakewitz, J; Chung, MO; Collier, AC; Currier, J; de Jesus Pedro, R; Gallant, JE; Haas, DW; Harvey, C; Lewi, DS; Mehrotra, D; Nguyen, BY; Noriega, LM; Paar, D; Ramirez-Ronda, CH; Thompson, MA; Uip, DE; Uribe, P; White, AC, 2000
)
0.31
"Three-times-daily indinavir appears more efficacious than two-times-daily dosing when administered with zidovudine and lamivudine."( Comparative studies of two-times-daily versus three-times-daily indinavir in combination with zidovudine and lamivudine.
Arathoon, E; Benetucci, L; Cahn, P; Chodakewitz, J; Chung, MO; Collier, AC; Currier, J; de Jesus Pedro, R; Gallant, JE; Haas, DW; Harvey, C; Lewi, DS; Mehrotra, D; Nguyen, BY; Noriega, LM; Paar, D; Ramirez-Ronda, CH; Thompson, MA; Uip, DE; Uribe, P; White, AC, 2000
)
0.31
" In addition, the effects on viral load, CD4 counts, and opportunistic infections were examined with the use of combination chemotherapy combined with HAART."( Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy.
Ambinder, R; Flexner, C; Grochow, L; Hamzeh, F; Harrington, W; Herndier, B; Kaplan, L; Lee, J; Levine, A; Ratner, L; Redden, D; Scadden, D; Straus, D; Tan, B; Tang, S, 2001
)
0.31
" The first 40 patients entered onto the study received reduced doses of cyclophosphamide and doxorubicin, combined with vincristine and prednisone (modified CHOP [mCHOP]), whereas the subsequent 25 patients entered onto the study received full doses of CHOP combined with granulocyte colony-stimulating factor (G-CSF)."( Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy.
Ambinder, R; Flexner, C; Grochow, L; Hamzeh, F; Harrington, W; Herndier, B; Kaplan, L; Lee, J; Levine, A; Ratner, L; Redden, D; Scadden, D; Straus, D; Tan, B; Tang, S, 2001
)
0.31
"The complete response rates were 30% and 48% among patients who received mCHOP and full-dose CHOP combined with HAART, respectively."( Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy.
Ambinder, R; Flexner, C; Grochow, L; Hamzeh, F; Harrington, W; Herndier, B; Kaplan, L; Lee, J; Levine, A; Ratner, L; Redden, D; Scadden, D; Straus, D; Tan, B; Tang, S, 2001
)
0.31
" CMV423 will probably affect CYP1A2 and 1A1 activities in vivo to some extent, but no other drug-drug interactions are expected."( In vitro metabolism and drug interaction potential of a new highly potent anti-cytomegalovirus molecule, CMV423 (2-chloro 3-pyridine 3-yl 5,6,7,8-tetrahydroindolizine I-carboxamide).
Boukaiba, R; Bournique, B; Lambert, N; Martinet, M, 2001
)
0.31
"We compared the efficacy and the toxicity of zidovudine (AZT) versus stavudine (d4T), in combination with lamivudine (3TC) and indinavir, in AZT-, dideoxyinosine (ddI)-, and/or dideoxycytosine (ddC)-experienced patients in a randomized comparative multicenter trial."( Efficacy of zidovudine compared to stavudine, both in combination with lamivudine and indinavir, in human immunodeficiency virus-infected nucleoside-experienced patients with no prior exposure to lamivudine, stavudine, or protease inhibitors (novavir tria
Aboulker, JP; Brun-Vezinet, F; Certain, A; Descamps, D; Flandre, P; Gastaut, JA; Goujard, C; Joly, V; Meiffredy, V; Remy, G; Ruffault, A; Yeni, P, 2002
)
0.31
"To determine the long-term antiretroviral efficacy and tolerability of dual protease inhibitor (PI) therapy with indinavir (IDV)/ritonavir (RTV) at 400/400 mg twice a day (BID) in combination with two nucleoside reverse trancriptase inhibitors (NRTIs)."( Long-term efficacy and safety of ritonavir/indinavir at 400/400 mg twice a day in combination with two nucleoside reverse transcriptase inhibitors as first line antiretroviral therapy.
Bergmann, F; Carls, H; Fätkenheuer, G; Fenske, S; Knechten, H; Lichterfeld, M; Nadler, M; Nischalke, HD; Oette, M; Rieke, A; Rockstroh, JK; Theisen, A; Wasmuth, JC; Wiesel, W, 2002
)
0.31
" Complications in treating depressed HIV-infected individuals include the use of multiple medications, additive side effects, and potentially significant drug-drug interactions."( A pharmacokinetic drug-drug interaction study of venlafaxine and indinavir.
Carson, SW; DeVane, CL; Eisele, G; Levin, GM; Nelson, LA; Preston, SL, 2001
)
0.31
"The authors studied the effect of zidovudine (ZDV) resistance mutation on virologic response to treatment with ZDV or stavudine (d4T) each in combination with lamivudine and indinavir."( Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine or stavudine, each in combination with lamivudine and indinavir.
Aboulker, JP; Brun-Vézinet, F; Descamps, D; Flandre, P; Harel, M; Izopet, J; Joly, V; Lastère, S; Meiffrédy, V; Peytavin, G; Tamalet, C; Yéni, P; Zeng, AF, 2002
)
0.31
"To evaluate the long-term efficacy and pharmacokinetics of indinavir (IDV)/ritonavir (RTV) 400/100 mg twice a day in combination with two nucleoside reverse transcriptase inhibitors."( Low-dose indinavir in combination with low-dose ritonavir: steady-state pharmacokinetics and long-term clinical outcome follow-up.
Justesen, US; Levring, AM; Lindberg, JA; Pedersen, C; Tauris, P; Thomsen, A, 2003
)
0.32
" This study evaluated the steady-state pharmacokinetics of indinavir/ritonavir at 800/100 mg twice daily (bid) in combination with efavirenz at 600 mg once daily (qd) in HIV-infected Thai subjects who used this nucleoside-sparing combination in The HIV Netherlands Australia Thailand Research Collaboration 009 study."( Pharmacokinetics of indinavir/ritonavir (800/100 mg) in combination with efavirenz (600 mg) in HIV-1-infected subjects.
Aarnoutse, RE; Boyd, MA; Burger, DM; Cooper, DA; Lange, JM; Phanuphak, P; Ruxrungtham, K; Stek, M; van Heeswijk, RP, 2003
)
0.32
"To evaluate the efficacy and tolerability of indinavir/ritonavir (IDV/RTV) 400/100 mg twice daily in combination with two nucleoside reverse transcriptase inhibitors in antiretroviral-naive patients."( Efficacy and safety of ritonavir/indinavir 100/400 mg twice daily in combination with two nucleoside analogues in antiretroviral treatment-naive HIV-infected individuals.
Agher, R; Ait-Mohand, H; Bricaire, F; Calvez, V; Costagliola, D; Duvivier, C; Ghosn, J; Katlama, C; Marcelin, AG; Myrto, A; Peytavin, G; Schneider, L, 2003
)
0.32
" We used the drug alone or in double and triple combination with AZT and ddC to assess whether IDV interferes with the previously observed immunomodulatory effects induced by AZT and ddC."( Effect of indinavir used alone or in double or triple combination with AZT and ddC on human immune functions.
Giordani, L; Mattioli, B; Quaranta, MG; Viora, M, 2004
)
0.32
"So far, no pediatric doses for indinavir combined with ritonavir have been defined."( Pharmacokinetics of indinavir combined with low-dose ritonavir in human immunodeficiency virus type 1-infected children.
Bergshoeff, AS; Burger, DM; de Groot, R; Fraaij, PL; Leavitt, RY; Nguyen, BY; van Rossum, AM; Verweel, G; Winchell, GA; Wynne, LH, 2004
)
0.32
"The aim of the study was to characterize the population pharmacokinetics of indinavir, define the relationship between the pharmacokinetics of indinavir and ritonavir, and to identify the factors influencing the pharmacokinetics of indinavir alone or when given with ritonavir."( Population pharmacokinetics of indinavir alone and in combination with ritonavir in HIV-1-infected patients.
Beijnen, JH; Huitema, AD; Kappelhoff, BS; Meenhorst, PL; Mulder, JW; Prins, JM; Sankatsing, SU; Van Gorp, EC, 2005
)
0.33
" When brecanavir was tested in combination with nucleoside reverse transcriptase inhibitors, the antiviral activity of brecanavir was synergistic with the effects of stavudine and additive to the effects of zidovudine, tenofovir, dideoxycytidine, didanosine, adefovir, abacavir, lamivudine, and emtricitabine."( In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV.
Boone, L; Craig, C; Ferris, R; Furfine, E; Griffin, P; Hale, M; Hanlon, M; Harvey, R; Hazen, R; Kaldor, I; Miller, J; Ray, J; Samano, V; Spaltenstein, A; St Clair, M; Tung, R; Yates, P, 2007
)
0.34
"Our objective was to identify possible differences in protease inhibitor plasma concentrations between and within three protease inhibitor regimens (indinavir, saquinavir and lopinavir all in combination with low-dose ritonavir) and to relate these differences to safety and efficacy."( Pharmacokinetics of two randomized trials evaluating the safety and efficacy of indinavir, saquinavir and lopinavir in combination with low-dose ritonavir: the MaxCmin1 and 2 trials.
Cahn, P; Castagna, A; Clumeck, N; Dragsted, UB; Fox, Z; Gerstoft, J; Justesen, US; Losso, M; Lundgren, JD; Obel, N; Pedersen, C; Peters, B, 2007
)
0.34
" In some patients on the nucleoside-sparing arm, the nucleoside-resistance mutation L74V was selected for in combination with the uncommonly occurring EFV-resistance mutations K103N+L100I; L74V was not detected as a minority variant, using clonal sequence analysis, when the nucleoside-sparing regimen was initiated."( Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience.
Bettendorf, D; DeGruttola, V; Demeter, LM; Eron, JJ; Eshleman, S; Fischl, M; Hammer, S; Koval, CE; Lustgarten, S; Nguyen, BY; Spreen, W; Squires, K,
)
0.13
" In addition, L74V, when combined with K103N+L100I, may confer a selective advantage to the virus that is independent of its effects on nucleoside resistance."( Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience.
Bettendorf, D; DeGruttola, V; Demeter, LM; Eron, JJ; Eshleman, S; Fischl, M; Hammer, S; Koval, CE; Lustgarten, S; Nguyen, BY; Spreen, W; Squires, K,
)
0.13
"The effects of omeprazole on indinavir when administered alone or in combination with ritonavir were evaluated."( Effect of omeprazole on the plasma concentrations of indinavir when administered alone and in combination with ritonavir.
Donovan, BJ; Hollowell, SB; Kashuba, AD; Min, SS; Raasch, RH; Rezk, NL; Rublein, JC; Smith, PC; Tallman, MN; Tappouni, HL; Theodore, D; Tien, HC, 2008
)
0.35
" After seven days, the single-dose pharmacokinetic profile of an 800-mg dose of indinavir alone or in combination with 200 mg of ritonavir was evaluated."( Effect of omeprazole on the plasma concentrations of indinavir when administered alone and in combination with ritonavir.
Donovan, BJ; Hollowell, SB; Kashuba, AD; Min, SS; Raasch, RH; Rezk, NL; Rublein, JC; Smith, PC; Tallman, MN; Tappouni, HL; Theodore, D; Tien, HC, 2008
)
0.35
" The addition of 200 mg of ritonavir to 800 mg of indinavir in combination with 40 mg of omeprazole significantly increased the mean indinavir AUC from 30."( Effect of omeprazole on the plasma concentrations of indinavir when administered alone and in combination with ritonavir.
Donovan, BJ; Hollowell, SB; Kashuba, AD; Min, SS; Raasch, RH; Rezk, NL; Rublein, JC; Smith, PC; Tallman, MN; Tappouni, HL; Theodore, D; Tien, HC, 2008
)
0.35
"A novel method for the prediction of drug-drug interaction has been established based on the in vitro metabolic stability in the "serum incubation method" using cryopreserved human hepatocytes suspended in 100% human serum."( A novel approach to the prediction of drug-drug interactions in humans based on the serum incubation method.
Chiba, M; Ishii, Y; Shibata, Y; Takahashi, H, 2008
)
0.35
"We aimed to investigate and compare the effects of erlotinib and gefitinib on UDP-glucuronosyltransferase (UGT) activities and to quantitatively evaluate their drug-drug interaction (DDI) potential due to UGT inhibition."( Comparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases.
House, L; Liu, Y; Ramírez, J; Ratain, MJ, 2010
)
0.36
" In view of these developments, we investigated whether a HAART drug combination of 3'-azido-2',3'-deoxythymidine (AZT) and indinavir (IDV) can alter the functionality of the blood-brain barrier (BBB) endothelial cells, thereby exacerbating this condition."( Highly active antiretroviral therapy drug combination induces oxidative stress and mitochondrial dysfunction in immortalized human blood-brain barrier endothelial cells.
Banerjee, A; Banks, WA; Ercal, N; Manda, KR, 2011
)
0.37
"No pharmacokinetic drug-drug interaction was demonstrated between venlafaxine XR and indinavir or between desvenlafaxine XR and indinvair."( Lack of a pharmacokinetic drug-drug interaction with venlafaxine extended-release/indinavir and desvenlafaxine extended-release/indinavir.
Jann, MW; Momary, K; Penzak, SR; Spratlin, V; Turner, D; VanDenBerg, C; Wright, A; Zhang, H, 2012
)
0.38
"The hepatic organic anion transporting polypeptides (OATPs) influence the pharmacokinetics of several drug classes and are involved in many clinical drug-drug interactions."( Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR, 2012
)
0.38
" The technique has potential to identify drug-drug interaction involving VX and O-DVX enantiomers while administering indinivar therapy."( Development of an enantioselective assay for simultaneous separation of venlafaxine and O-desmethylvenlafaxine by micellar electrokinetic chromatography-tandem mass spectrometry: Application to the analysis of drug-drug interaction.
Eap, CB; Jann, M; Liu, Y; Shamsi, SA; Vandenberg, C, 2015
)
0.42
" Concurrent HG and antiviral drug combination synergistically elevated BBB endothelial ROS induced by either condition alone."( Hyperglycemia exacerbates antiretroviral drug combination induced blood-brain barrier endothelial toxicity.
Cucullo, L; Kaisar, MA; Prasad, S; Sajja, RK, 2016
)
0.43

Bioavailability

ExcerptReferenceRelevance
"5) at 10 mg/kg, the bioavailability was approximately 16% for both dogs and rats."( pH-dependent oral absorption of L-735,524, a potent HIV protease inhibitor, in rats and dogs.
Chen, IW; Lin, JH; Ostovic, D; Vastag, KJ, 1995
)
0.29
"L-735,524 sulfate was well absorbed orally form a solution or capsule formulation if fasted animals' stomachs were preacidified with citric acid solution."( Regiospecific intestinal absorption of the HIV protease inhibitor L-735,524 in beagle dogs.
Chen, IW; Hettrick, LA; Higgins, RJ; Kwei, GY; Lin, JH; Loper, AE; Lui, CY; Novak, LB; Ostovic, D; Reiss, ER, 1995
)
0.29
"L-735,524 is a potent, orally bioavailable inhibitor of human immunodeficiency virus (HIV) protease currently in a Phase II clinical trial."( Crystal structure at 1.9-A resolution of human immunodeficiency virus (HIV) II protease complexed with L-735,524, an orally bioavailable inhibitor of the HIV proteases.
Chen, E; Chen, Z; Culberson, C; Darke, PL; Hall, DL; Kuo, LC; Li, Y; Shafer, JA, 1994
)
0.29
" L-735,524 is orally bioavailable in three animals models, using clinically acceptable formulations, and is currently in phase II human clinical trials."( L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor.
Darke, PL; Dorsey, BD; Emini, EA; Guare, JP; Levin, RB; McDaniel, SL; Quintero, JC; Schleif, WA; Vacca, JP; Zugay, JA, 1994
)
0.29
"To date, numerous inhibitors of the human immunodeficiency virus type 1 protease have been reported, but few have been studied extensively in humans, primarily as a consequence of poor oral bioavailability in animal models."( L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor.
Blahy, OM; Darke, PL; Dorsey, BD; Levin, RB; McDaniel, SL; Quintero, JC; Roth, E; Schleif, WA; Vacca, JP; Zugay, J, 1994
)
0.29
"A high-performance liquid chromatographic method coupled with liquid-liquid sample extraction and ultraviolet detection has been developed for the quantification of L-735,524 (I), a potent, highly selective and orally bioavailable inhibitor of recombinant human immunodeficiency virus (HIV) protease in rat, dog and monkey plasma."( High-performance liquid chromatographic determination of a potent and selective HIV protease inhibitor (L-735,524) in rat, dog and monkey plasma.
Chen, IW; Lin, JH; Vastag, KJ, 1995
)
0.29
" Significant differences in the bioavailability of indinavir also were observed."( Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor.
Balani, SK; Chen, IW; Chiba, M; Kwei, GY; Lin, JH; Nishime, JA; Vastag, KJ, 1996
)
0.29
" The assay was used to support a clinical study in which the stable isotope technique was used to determine the bioavailability of indinavir."( Simultaneous determination of unlabeled and deuterium-labeled indinavir in human plasma by high-performance liquid chromatography with tandem mass spectrometric detection.
Matuszewski, BK; Woolf, EJ, 1997
)
0.3
" These data demonstrate that P-glycoprotein limits the oral bioavailability and penetration of these agents into the brain."( The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.
Fromm, MF; Kim, RB; Leake, B; Roden, DM; Wandel, C; Wilkinson, GR; Wood, AJ, 1998
)
0.3
" Metabolic inactivation of CYP3A by ritonavir explains the improved bioavailability and pharmacokinetics of ritonavir and the sustained elevation of blood levels of other, concomitantly administered, substrates of CYP3A."( Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir.
Gangl, E; Gerber, N; Iatsimirskaia, E; Koudriakova, T; Marinina, J; Orza, D; Storozhuk, E; Utkin, I; Vouros, P, 1998
)
0.3
" Acylation of the (hydroxethyl)hydrazine dipeptide isostere with the L-tert-leucine derivative 29 increased the oral bioavailability significantly when compared to the corresponding L-valine or L-isoleucine derivatives."( New aza-dipeptide analogues as potent and orally absorbed HIV-1 protease inhibitors: candidates for clinical development.
Acemoglu, F; Beck, W; Bold, G; Boss, E; Capraro, HG; Cozens, R; Eschbach, M; Fässler, A; Hürlimann, T; Klimkait, T; Lang, M; Lazdins, J; Masso, E; Mestan, J; Poncioni, B; Rösel, J; Roussel, S; Stover, D; Tintelnot-Blomley, M; Ucci-Stoll, K; Wyss, D, 1998
)
0.3
" The drug transporting protein, P-glycoprotein (P-gp), which is highly expressed in the intestinal mucosa, could be responsible for the low oral bioavailability of these and other drugs which are substrates for this transporter."( Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells.
Blaschke, TF; Duran, GE; Man, MC; Sikic, BI; Washington, CB, 1998
)
0.3
" The ultimate success of DMP 850 and DMP 851 in clinical trials might depend on achieving or exceeding the oral bioavailability seen in dog."( Design and selection of DMP 850 and DMP 851: the next generation of cyclic urea HIV protease inhibitors.
Anderson, PS; Bacheler, LT; Chang, CH; Cordova, B; Erickson-Viitanen, S; Garber, S; Johnson, BL; Klabe, RM; Ko, SS; Lam, PY; Li, R; Reid, C; Rodgers, JD; Ru, Y; Seitz, SP; Trainor, GL; Wang, H; Wright, MR, 1998
)
0.3
" The bioavailability of indinavir was high (60-65%) and comparable between the 400- and 800-mg doses."( Simultaneous investigation of indinavir nonlinear pharmacokinetics and bioavailability in healthy volunteers using stable isotope labeling technique: study design and model-independent data analysis.
Carides, AD; Ju, WD; Rolan, P; Stone, JA; Woolf, E; Yeh, KC, 1999
)
0.3
"To study the influence of large-volume high-calorie protein, fat, and carbohydrate meals and a non-caloric hydroxypropylmethyl cellulose (HPMC) viscous meal on the oral bioavailability of indinavir in HIV-infected subjects."( Meal composition effects on the oral bioavailability of indinavir in HIV-infected patients.
Carver, PL; Fleisher, D; Kaul, D; Kazanjian, P; Li, C; Zhou, SY, 1999
)
0.3
" administration of indinavir, whereas DEX markedly altered the peak concentration (C(max)) and bioavailability of indinavir after oral dosing."( Effect of dexamethasone on the intestinal first-pass metabolism of indinavir in rats: evidence of cytochrome P-450 3A [correction of P-450 A] and p-glycoprotein induction .
Chen, IW; Chiba, M; deLuna, FA; Lin, JH; Lin, YJ; Nishime, JA; Yamazaki, M, 1999
)
0.3
" The poor bioavailability of the current saquinavir formulation also leads to risk of interactions."( The choice of HIV protease inhibitor: indinavir is currently the best option.
, 1999
)
0.3
"The objective of this study was to determine the effects of double-strength grapefruit juice on gastric pH and systemic bioavailability of indinavir in HIV-infected subjects receiving indinavir."( Effects of grapefruit juice on pharmacokinetic exposure to indinavir in HIV-positive subjects.
DiFrancesco, R; Hewitt, RG; Shelton, MJ; Wynn, HE, 2001
)
0.31
" However, two pharmacokinetic problems have been identified: suboptimal oral bioavailability of peptidic inhibitors; and reduced cellular uptake of inhibitor that has become bound to alpha-acid glycoprotein."( Update on HIV protease inhibitors.
Vella, S, 1995
)
0.29
" ACTG 333 tested the consequences of long-term use of hard capsule saquinavir, and found that it is poorly absorbed and there is only a very modest effect on HIV."( Spring cleaning in trial land.
Gilden, D, 1997
)
0.3
" Public Health Service also recommends against using saquinavir as a first protease inhibitor because it is poorly absorbed by the body."( Saquinavir update.
, 1997
)
0.3
" Toward this end, we previously identified a 4-hydroxy-5,6-dihydropyrone lead compound (CI-1029, 1) which possesses excellent activity against the protease enzyme, good antiviral efficacy in cellular assays, and promising bioavailability in several animal species."( 4-Hydroxy-5,6-dihydropyrones as inhibitors of HIV protease: the effect of heterocyclic substituents at C-6 on antiviral potency and pharmacokinetic parameters.
Brodfuehrer, J; Domagala, J; Gajda, C; Gracheck, SJ; Hagen, SE; Holler, T; Hupe, D; Lovdahl, M; Lunney, EA; Nouhan, C; Pavlovsky, A; Saunders, J; Tait, BD; Urumov, A; VanderRoest, S; Wise, E; Zeikus, E; Zeikus, G, 2001
)
0.31
" This study was undertaken to determine whether the enteric bead formulation of didanosine (Videx EC) influences the bioavailability of indinavir, ketoconazole, and ciprofloxacin, three drugs that are representative of a broader class of drugs affected by interaction with antacids."( Lack of effect of simultaneously administered didanosine encapsulated enteric bead formulation (Videx EC) on oral absorption of indinavir, ketoconazole, or ciprofloxacin.
Damle, BD; Kaul, S; Knupp, C; Mummaneni, V, 2002
)
0.31
" Inhibitors of CYP3A4 such as other protease inhibitors will substantially increase the bioavailability of saquinavir."( CYP3A4-mediated hepatic metabolism of the HIV-1 protease inhibitor saquinavir in vitro.
Back, DJ; Eagling, VA; Whitcombe, IW; Wiltshire, H, 2002
)
0.31
" These observations suggested that the oral bioavailability of amprenavir was not so affected by co-administration with saquinavir, nelfinavir or indinavir, compared with ritonavir, whereas amprenavir markedly affected the oral bioavailability of saquinavir and nelfinavir."( In-vitro and in-vivo pharmacokinetic interactions of amprenavir, an HIV protease inhibitor, with other current HIV protease inhibitors in rats.
Gao, W; Kishida, T; Okamoto, H; Shibata, N; Takada, K; Yoshikawa, Y, 2002
)
0.31
"Emergence of human immunodeficiency virus type-1 (HIV-1) genotypic drug resistance is generally attributed to noncompliance, poorly absorbed drugs, or drug-to-drug interaction."( In vivo emergence of drug-resistant mutations at less than 50 HIV-1 RNA copies/mL that are maintained at viral rebound in longitudinal plasma samples from human immunodeficiency virus type-1-infected patients on highly active antiretroviral therapy.
Benetti, MS; Bortolozzi, RL; Campodonico, ME; Chernoff, D; Dileanis, J; Elbeik, T; Fay, FF; Fay, OH; Hoo, BS; Marlowe, N; Ng, VL; Petrauskene, O; Smith, L,
)
0.13
"Various drug transporters of the ATP-binding cassette (ABC) family restrict the oral bioavailability and cellular, brain, testis, cerebrospinal fluid and fetal penetration of substrate drugs."( Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs.
Beijnen, JH; Crommentuyn, KM; Huisman, MT; Schinkel, AH; Smit, JW; Wiltshire, HR; Zelcer, N, 2002
)
0.31
" The most potent inhibitor (-)-7 displayed 13% oral bioavailability in dogs."( Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors.
Barbosa, J; Cantin, LD; Charnley, AK; Guise-Zawacki, L; Hirschmann, R; Kuo, LC; Munshi, S; Olsen, DB; Pasternak, A; Schleif, WA; Smith, AB; Sprengeler, PA; Yao, W, 2003
)
0.32
" As a potent inhibitor of this enzyme, ritonavir can increase the bioavailability and half-life of coadministered protease inhibitors."( A review of low-dose ritonavir in protease inhibitor combination therapy.
Cameron, DW; Cooper, CL; Gallicano, K; van Heeswijk, RP, 2003
)
0.32
" The results of this study are in agreement with the clinical observation that a high-calorie protein meal significantly reduces the oral bioavailability of indinavir in man, accompanying a pH elevation in the stomach."( In-vitro crystallization of indinavir in the presence of ritonavir and as a function of pH.
Fleisher, D; Heimbach, T; Li, LY; Rodríguez-Hornedo, N, 2003
)
0.32
" Inclusion of a gem-dimethyl substituent afforded compound 3 with 100% oral bioavailability (dogs) and more than double the t(1/2) of indinavir."( HIV protease inhibitors with picomolar potency against PI-Resistant HIV-1 by extension of the P3 substituent.
Chapman, KT; Duffy, JL; Emini, EA; Jin, L; Kevin, NJ; Kuo, LC; Lin, JH; Olsen, DB; Rano, TA; Rutkowski, CA; Schleif, WA; Stahlhut, M; Tata, JR, 2003
)
0.32
" The poor to modest bioavailability of these compounds may correlate in part to their aqueous solubility."( HIV-1 protease inhibitors with picomolar potency against PI-resistant HIV-1 by modification of the P1' substituent.
Chapman, KT; Duffy, JL; Emini, EA; Jin, L; Kevin, NJ; Kirk, BA; Kuo, LC; Lin, JH; Olsen, DB; Rutkowski, CA; Schleif, WA; Stahlhut, M; Tata, JR, 2003
)
0.32
" Indinavir, a widely prescribed HIV protease inhibitor, suffer from bioavailability problems where involvement of P-glycoprotein mediated drug efflux may play a significant role."( Reversed-phase liquid chromatography with ultraviolet detection for simultaneous quantitation of indinavir and propranolol from ex-vivo rat intestinal permeability studies.
Bansal, T; Kaul, CL; Panchagnula, R; Varma, MV, 2004
)
0.32
"To investigate whether P-glycoprotein (P-gp) and multidrug resistance proteins (MRPs), which limit the bioavailability of HIV protease inhibitors (PIs) and nucleoside reverse transcriptase inhibitors (NRTIs), modulate the anti-HIV activity of NRTIs, non-NRTIs and PIs in vitro."( ATP binding cassette multidrug transporters limit the anti-HIV activity of zidovudine and indinavir in infected human macrophages.
Becher, F; Benech, H; Clayette, P; Dereuddre-Bosquet, N; Dormont, D; Garrigues, A; Grassi, J; Jorajuria, S; Mabondzo, A; Martin, S; Orlowski, S; Porcheray, F, 2004
)
0.32
" Prodrugs have therefore been synthesized to increase protease inhibitor bioavailability and brain distribution."( Investigation of oral bioavailability and brain distribution of the Ind(8)-Val conjugate of indinavir in rodents.
Couet, W; Greiner, J; Olivier, JC; Pariat, C; Pereira de Oliveira, M; Roche, D; Vierling, P, 2005
)
0.33
" Values for the clearance, volume of distribution and the absorption rate constant were 46."( Population pharmacokinetics of indinavir alone and in combination with ritonavir in HIV-1-infected patients.
Beijnen, JH; Huitema, AD; Kappelhoff, BS; Meenhorst, PL; Mulder, JW; Prins, JM; Sankatsing, SU; Van Gorp, EC, 2005
)
0.33
" Methadone bioavailability was unchanged, despite inhibition of gastrointestinal P-glycoprotein activity, suggesting that this transporter does not limit methadone intestinal absorption."( Methadone pharmacokinetics are independent of cytochrome P4503A (CYP3A) activity and gastrointestinal drug transport: insights from methadone interactions with ritonavir/indinavir.
Bedynek, PS; Hoffer, C; Kharasch, ED; Walker, A; Whittington, D, 2009
)
0.35
" Indinavir and ritonavir absorption rate constants were found to be correlated, as well as their apparent volumes of distribution and clearances, indicating correlated bioavailability of the two drugs."( Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAART.
Auleley, S; Bertrand, J; Duval, X; Mentré, F; Panhard, X; Rey, E; Salmon-Céron, D; Tran, A; Treluyer, JM, 2009
)
0.35
" Further perfusion study demonstrated that both small intestine and the liver contributed significantly to the reduction of indinavir bioavailability and was flow rate-dependent."( Effects of St. John's wort extract on indinavir pharmacokinetics in rats: differentiation of intestinal and hepatic impacts.
Ho, YF; Hsueh, WC; Huang, DK; Lai, MY; Tsai, TH; Yu, HY, 2009
)
0.35
" From the clinical editor: This study characterizes indinavir bearing ethanolic liposomes (ethosomes), and investigate their enhanced transdermal delivery potential, demonstrating a potentially a suitable approach for transdermal delivery of this protease inhibitor for HIV treatment, which typically has been associated with limited bioavailability via the oral route."( Enhanced transdermal delivery of an anti-HIV agent via ethanolic liposomes.
Dubey, V; Jain, NK; Jain, V; Mishra, D; Nahar, M, 2010
)
0.36
" The processing led to faster dissolution that would improve the oral bioavailability of the drug."( Production of pure indinavir free base nanoparticles by a supercritical anti-solvent (SAS) method.
Bevilacqua, G; Imperiale, JC; Rosa, Pde T; Sosnik, A, 2014
)
0.4
" Finally, pharmacokinetics studies in mongrel dogs showed a dramatic 47- and 95-fold increase of the drug oral bioavailability and half-life, respectively, with respect to the free unprocessed drug."( Novel protease inhibitor-loaded Nanoparticle-in-Microparticle Delivery System leads to a dramatic improvement of the oral pharmacokinetics in dogs.
Del Sole, MJ; E Lanusse, C; Imperiale, JC; Nejamkin, P; Sosnik, A, 2015
)
0.42
" The bioavailability of indinavir in the presence and absence of the aloe leaf materials was determined in Sprague-Dawley rats."( Evaluation of Isolated Fractions of Aloe vera Gel Materials on Indinavir Pharmacokinetics: In vitro and in vivo Studies.
Abay, E; Ellis, S; Gouws, C; Hamman, J; Malan, M; Otto, DP; Steyn, D; Wallis, L; Wiesner, L, 2016
)
0.43
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" The antiviral drugs Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine also exhibited good bioavailability and drug-likeness properties."( Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach.
Al-Dhabi, NA; Arunagirinathan, N; Ignacimuthu, S; Indu, P; Rameshkumar, MR; Valan Arasu, M, 2020
)
0.56

Dosage Studied

ExcerptRelevanceReference
"L-735,524 free base or sulfate salt was administered orally as suspension, solution or in solid dosage forms to fasted or fed Beagle dogs."( Regiospecific intestinal absorption of the HIV protease inhibitor L-735,524 in beagle dogs.
Chen, IW; Hettrick, LA; Higgins, RJ; Kwei, GY; Lin, JH; Loper, AE; Lui, CY; Novak, LB; Ostovic, D; Reiss, ER, 1995
)
0.29
" Prototype extended release dosage forms of L-735,524 produced a reduction in peak plasma levels but failed to prolong absorption and extend plasma concentrations compared to an immediate release capsule."( Regiospecific intestinal absorption of the HIV protease inhibitor L-735,524 in beagle dogs.
Chen, IW; Hettrick, LA; Higgins, RJ; Kwei, GY; Lin, JH; Loper, AE; Lui, CY; Novak, LB; Ostovic, D; Reiss, ER, 1995
)
0.29
" Selecting the initial PI must be individualized, and factors to consider include proven activity, possible toxicities, dosing regimens, drug interactions, and costs."( HIV-1 protease inhibitors. A review for clinicians.
Deeks, SG; Holodniy, M; Kahn, JO; Smith, M, 1997
)
0.3
" Concurrent therapy must be evaluated before treatment, as many agents are either contraindicated or require dosage modification."( Drug interaction potential with inhibitors of HIV protease.
Fisher, EJ; Polk, RE; Van Cleef, GF,
)
0.13
" Furthermore, adverse effects, resistance, dosage and administration, clinical pharmacokinetics, pharmacokinetic-pharmacodynamic relationships, and drug interactions are discussed."( Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir.
Beijnen, JH; Burger, DM; Hoetelmans, RM; Koks, CH; Meenhorst, PL; Mulder, JW, 1997
)
0.3
"The pharmacology, pharmacokinetics, efficacy, adverse effects, drug interactions, and dosage and administration of protease inhibitors are reviewed."( Protease inhibitors for the treatment of human immunodeficiency virus infection.
Kakuda, TN; Piscitelli, SC; Struble, KA, 1998
)
0.3
" These results suggest that delavirdine inhibits metabolism of indinavir and support the possibility of a reduction in the magnitude or frequency of indinavir dosage when given in combination with delavirdine."( Pharmacokinetic drug-drug interaction study of delavirdine and indinavir in healthy volunteers.
Batts, DH; Carel, BJ; Carlson, GF; Ferry, JJ; Herman, BD, 1998
)
0.3
") dosing of this combination."( Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers.
Berg, J; Cao, G; Carothers, L; Dennis, S; El-Shourbagy, T; Erdman, K; Granneman, GR; Hsu, A; Japour, A; Leonard, JM; Sun, E, 1998
)
0.3
" These data suggest that indinavir dosing should be dependent on drug exposure and not on cotherapy with nevirapine."( Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1.
Dusek, A; Hall, DB; Lamson, M; Murphy, RL; Myers, M; Sommadossi, JP, 1999
)
0.3
" HAART was started at an initial dosage of 600 mg zidovudine (AZT), 300 mg lamivudine (3TC), and 2400 mg indinavir (IDV) daily."( Highly active antiretroviral therapy used to treat concurrent hepatitis B and human immunodeficiency virus infections.
Hosaka, H; Kubo, S; Nagai, K; Nakamura, N; Nonaka, H; Shinohara, M, 1999
)
0.3
" Due to toxicity risks, co-administration is contraindicated for various interacting drugs, whereas dosage adjustments may only be required for others."( [HIV protease inhibitors: drug interactions].
Dubreuil, L; Gérard, Y; Maulin, L; Mouton, Y, 1999
)
0.3
" This study illustrates three potential uses of indinavir monitoring: to assess individual dosing regimen, to assess patient compliance, and to monitor unusual indinavir levels caused by changed drug clearance."( Determination of indinavir, a HIV-1 protease inhibitor, in human plasma using ion-pair reversed-phase high-performance liquid chromatography.
Collier, AC; Coombs, RW; Li, W; Raisys, VA, 1999
)
0.3
"To explore the steady-state plasma pharmacokinetics of indinavir in twice daily dosing regimens with and without the co-administration of 100 mg ritonavir."( The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals.
Beijnen, JH; Hoetelmans, RM; Hsu, A; Lange, JM; Meenhorst, PL; Mulder, JW; Schreij, G; van Heeswijk, RP; Veldkamp, AI, 1999
)
0.3
"Significant differences were observed for indinavir pharmacokinetics between the dosing regimens indinavir 1200 mg twice daily alone and indinavir/ ritonavir 800/100 mg twice daily with respect to the mean trough concentration (0."( The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals.
Beijnen, JH; Hoetelmans, RM; Hsu, A; Lange, JM; Meenhorst, PL; Mulder, JW; Schreij, G; van Heeswijk, RP; Veldkamp, AI, 1999
)
0.3
"Combination of indinavir and 100 mg ritonavir in twice daily dosing regimens significantly affects the pharmacokinetic profile of indinavir."( The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals.
Beijnen, JH; Hoetelmans, RM; Hsu, A; Lange, JM; Meenhorst, PL; Mulder, JW; Schreij, G; van Heeswijk, RP; Veldkamp, AI, 1999
)
0.3
" Although protease inhibitor (PI) containing therapies are very potent, many problems have now been identified that reduce quality of life such as a high pill burden, multiple daily dosing and dietary constraints."( Review of NNRTIs: 'today and tomorrow'.
Katlama, C, 1999
)
0.3
" Stone prevention is based on drug withdrawal or change in dosage with additional measures including an increase of diuresis and, if necessary, changes in the urine pH."( [Drug-induced urinary calculi in 1999].
Daudon, M, 1999
)
0.3
"The indinavir dosage regimen currently used for human immunodeficiency virus (HIV)-infected children is not based on pharmacokinetic data obtained in the target patient population."( Indinavir pharmacokinetics and parmacodynamics in children with human immunodeficiency virus infection.
Bassetti, D; Bassetti, M; Gatti, G; Principi, N; Sala, N; Vella, S; Vigano', A, 2000
)
0.31
"The use of human immunodeficiency virus (HIV) protease inhibitors in children has lagged behind that in adults because of the lack of suitable pediatric formulations and information on safe and effective dosing regimens."( Pharmacologic characteristics of indinavir, didanosine, and stavudine in human immunodeficiency virus-infected children receiving combination therapy.
Brundage, RC; Calles, NR; Fletcher, CV; Kline, MW; Page, LM; Remmel, RP; Simon, C; Weller, D, 2000
)
0.31
" When alternate drug therapy is not possible, dosage adjustments, therapeutic drug monitoring, and careful clinical observation may help reduce adverse clinical consequences."( Carbamazepine--indinavir interaction causes antiretroviral therapy failure.
Brinkman, K; Burger, DM; Hekster, YA; Hugen, PW; Koopmans, PP; Schuurman, R; ter Hofstede, HJ, 2000
)
0.31
" Multiple compound dosing in vivo may also accelerate the identification of potential drug candidates."( Combinatorial diversification of indinavir: in vivo mixture dosing of an HIV protease inhibitor library.
Chapman, KT; Cheng, Y; Gabryelski, L; Huening, TT; King, R; Kuo, LC; Lin, JH; McLoughlin, DA; Olah, TV; Olsen, DB; Rano, TA; Schleif, WA; Tata, JR; Xu, X; Zhang, F, 2000
)
0.31
"8% in the whole dosing interval or with 98."( Saliva as a specimen for monitoring compliance but not for predicting plasma concentrations in patients with HIV treated with indinavir.
Brinkman, K; Burger, DM; de Graaff, M; Hekster, YA; Hoetelmans, RM; Hugen, PW; Koopmans, PP; Meenhorst, PL; Mulder, JW; ter Hofstede, HJ, 2000
)
0.31
"Three-times-daily indinavir appears more efficacious than two-times-daily dosing when administered with zidovudine and lamivudine."( Comparative studies of two-times-daily versus three-times-daily indinavir in combination with zidovudine and lamivudine.
Arathoon, E; Benetucci, L; Cahn, P; Chodakewitz, J; Chung, MO; Collier, AC; Currier, J; de Jesus Pedro, R; Gallant, JE; Haas, DW; Harvey, C; Lewi, DS; Mehrotra, D; Nguyen, BY; Noriega, LM; Paar, D; Ramirez-Ronda, CH; Thompson, MA; Uip, DE; Uribe, P; White, AC, 2000
)
0.31
" Trial designs include comparisons between the various licensed protease inhibitors, comparisons of protease inhibitors to other classes of potent antiretroviral drugs, investigations with new protease inhibitors, investigations of protease inhibitor-related toxicities and attempts at simplifying current dosing regimens."( Ongoing trials in HIV protease inhibitors.
Tavel, JA, 2000
)
0.31
" At 4-week intervals, plasma levels were measured and dosage of IND/RIT switched to 1000/100 mg daily and then 800/200 mg daily."( Dose-finding study of once-daily indinavir/ritonavir plus zidovudine and lamivudine in HIV-infected patients.
Arnaiz, JA; Blanco, JL; Carné, X; Codina, C; Cruceta, A; García-Viejo, MA; Gatell, JM; Giner, V; Mallolas, J; Martínez, E; Pumarola, T; Sarasa, M; Soriano, A; Soy, D; Tuset, M, 2000
)
0.31
" The objective of our study was to find a once-daily dosing regimen of a HIV-protease inhibitor, indinavir (IDV), by combining it with ritonavir (RTV)."( Dose-finding study of a once-daily indinavir/ritonavir regimen.
Burger, DM; Hekster, YA; Hugen, PW; Koopmans, PP; Lange, JM; Reiss, P; Stek, M; ter Hofstede, HJ, 2000
)
0.31
" Reducing the dosage of indinavir has been proposed, but this carries the risk of viral mutations with development of resistance."( Symptomatic crystalluria associated with indinavir.
De Simone, C; Di Toro, S; Famularo, G; Moretti, S, 2000
)
0.31
" However, since protease inhibitors are high clearance drugs, free drug concentration will likely remain unaffected in the presence of elevated AGP during chronic oral dosing although there will be an increase in total plasma drug concentration."( Effect of alpha1-acid glycoprotein on the intracellular accumulation of the HIV protease inhibitors saquinavir, ritonavir and indinavir in vitro.
Back, DJ; Hoggard, PG; Jones, K; Khoo, S; Maher, B, 2001
)
0.31
" Plasma trough levels of nelfinavir (NFV) and saquinavir (SQV), in a twice daily dosing regimen, were above the protein-corrected IC(95) in most patients despite the addition of an enzymatic inducer such as nevirapine, and peak levels were 2- and 5-fold increased with respect to standard doses."( Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure.
Antela, A; Casado, JL; Dehertogh, P; Dronda, F; Hertogs, K; Martí-Belda, P; Moreno, S; Sabido, R, 2001
)
0.31
"Indinavir + ritonavir regimens show improved pharmacokinetic properties, allowing twice-daily dosing with food."( A retrospective, cohort-based survey of patients using twice-daily indinavir + ritonavir combinations: pharmacokinetics, safety, and efficacy.
Aarnoutse, RE; Blok, WL; Burger, DM; Dieleman, JP; Hugen, PW; Lange, JM; Meenhorst, PL; Mulder, JW; Prins, JM; Reiss, P; ten Veen, JH; van der Meer, JT; van der Poll, T, 2001
)
0.31
"Demographics, dosage regimens, genotype data, viral RNA and CD4+ lymphocyte counts, adverse drug events (ADEs), laboratory tests, and compliance were evaluated over 3 years."( The safety and antiviral effect of protease inhibitors in children.
Koranyi, KI; Nahata, MC; Temple, ME, 2001
)
0.31
" When given in combination with indinavir (IDV) it increases the IDV trough concentrations (Cmin) allowing a lower IDV dosage in a twice a day regimen, independently of meals."( [Indinavir-ritonavir combination: pharmacologic results and tolerance in patients infected by HIV].
Bani-Sadr, F; Bernard, L; de Truchis, P; Melchior, JC; Perré, P; Perronne, C; Peytavin, G, 2001
)
0.31
" Markedly increasing the fluid intake above the recommended dosage may ameliorate or even reverse the process of tubulointerstitial disease."( Persistent flank pain, low-grade fever, and malaise in a woman treated with indinavir.
Sarcletti, M; Zangerle, R, 1999
)
0.3
" The author notes, however, that previous data on saquinavir at the suggested dosage levels to be used in this program have not been significant."( Protease inhibitor: Roche lottery deadline July 21.
, 1995
)
0.29
" Each drug trial demonstrates the relationship between dosing and resistance; patients are advised to adhere completely to dosing instructions."( Protease inhibitors and prevention of cross resistance.
Levin, J, 1995
)
0.29
" The background of this resistance, what is known about it, and questions concerning saquinavir dosage and formulation are discussed."( Protease inhibitors: drug resistance and cross resistance overview.
James, JS, 1995
)
0.29
" However, patients must continue taking the drugs once they begin therapy; stopping the treatment or reducing the dosage can lead to resistance."( Freedom of choice.
Vazquez, E,
)
0.13
" Dosage regimens are as follows: saquinavir, 3 capsules every 8 hours with food; ritonavir, 6 capsules every 12 hours with food; and indinavir, 2 capsules every 8 hours on an empty stomach."( A patient's guide to protease inhibitors.
Elperin, A; Sax, P, 1996
)
0.29
" Advertising that promoted the improved drug has been withdrawn at the request of Project Inform because of the lack of warning labels necessary due to dosing problems."( Update on antivirals.
, 1997
)
0.3
" Situations to avoid include using dosing schedules that do not sufficiently suppress the virus, waiting for viral load to return to pre-treatment levels before switching drugs, and not switching drugs to at least two new potent compounds when changing combination therapy."( Update on antivirals.
, 1997
)
0.3
" The Conference revealed two trends in protease inhibitor use: the increased simultaneous use of two protease inhibitors (PIs) and the switch to twice-daily dosing for some drugs."( Combinations of protease inhibitors.
, 1998
)
0.3
"Two studies examining twice-daily dosing of indinavir and nelfinavir are presented."( Indinavir, nelfinavir -- twice a day?
, 1998
)
0.3
" Two other studies examined different dosages of Nelfinavir or Indinavir and found that twice-a-day dosing may be as effective as three times a day."( Antiviral update.
, 1998
)
0.3
"Two studies examined the effectiveness of reducing the dosage of anti-HIV medications for patients who have achieved a viral load under 200 copies of HIV RNA."( Lower dose maintenance therapy?
, 1998
)
0.3
"As a result of a study that was testing dosing levels of Indinavir (Crixivan) with AZT/3TC, Merck & Co."( Crixivan warning: keep to three times a day.
Gilden, D, 1998
)
0.3
"A change in dosing of Indinavir (Crixivan) from two times per day to three times per day is recommended for patients who are taking Indinavir with nucleoside analogs."( Crixivan (Indinavir): three doses daily, not two, in most regimens.
James, JS, 1998
)
0.3
"Merck has discontinued testing the twice-daily dosing of its protease inhibitor Crixivan (Indinavir) in combination with reverse transcriptase inhibitors (RTIs)."( Merck discontinues twice-daily dosing of Crixivan.
, 1998
)
0.3
" has suspended a study of twice-daily dosing of Crixivan (Indinavir) in combination with AZT and 3TC."( Twice-daily dosing Crixivan study discontinued.
, 1998
)
0.3
"Efavirenz (Sustiva) is the first once-daily dosing anti-HIV drug approved by the Food and Drug Administration."( First once-daily drug simplifies dosing, offers new options in HIV-1 treatment.
, 1998
)
0.3
"Merck and Company has announced that it is discontinuing trials for the twice-daily dosage of Indinavir (Crixivan)."( Twice-daily Indinavir dosing not recommended.
Highleyman, L, 1998
)
0.3
" The new dosage formulation is important because a higher dose of 1000 mg every 8 hours is easier to manage with the 333 mg capsules than with the standard 400 mg capsules."( Indinavir (Crixivan): new packaging and strength.
, 1999
)
0.3
" Information on each drug, such as the name of the drug, the dosage normally prescribed, and cost of treatment is listed."( What they say about: protease inhibitors.
,
)
0.13
" The studies showed twice-daily dosing is inferior to taking the drug every 8 hours."( No more twice-a-day Crixivan.
Vazquez, E,
)
0.13
" Several studies of regimens that include protease inhibitors compare dosing twice daily to three times a day."( Antivirals update.
, 1998
)
0.3
" Protease inhibitors may require strict dosing schedules and food restrictions; most are associated with lipodystrophy (thinning of the arms, legs and face with fat accumulation in the breasts, stomach, and sometimes the upper back)."( What they say about protease inhibitors.
,
)
0.13
" This warning follows a study by the National Institutes of Health (NIH) on dosing and blood levels of indinavir in HIV-negative test subjects."( St. John's wort warning: do not combine with protease inhibitors, NNRTIs.
James, JS, 2000
)
0.31
" has recommended that patients taking the twice-daily dosage of the protease inhibitor Crixivan, in combination with reverse transcriptase inhibitors, switch to a regimen of 800 mg every 8 hours, or three times a day."( Twice-a-day Crixivan study discontinued.
,
)
0.13
" Indinavir and ritonavir plasma concentrations remained above respective inhibitory and effective concentrations (IC95 and EC50) (uncorrected for protein binding) throughout the 24-hour dosing interval for 6 of 10 and 8 of 10 subjects, respectively."( A pilot trial of indinavir, ritonavir, didanosine, and lamivudine in a once-daily four-drug regimen for HIV infection.
Holodniy, M; Mole, L; Schmidgall, D, 2001
)
0.31
"Our pilot study demonstrates excellent virologic suppression despite low minimum protease inhibitor concentrations during a dosing interval in some patients and is supportive of further study."( A pilot trial of indinavir, ritonavir, didanosine, and lamivudine in a once-daily four-drug regimen for HIV infection.
Holodniy, M; Mole, L; Schmidgall, D, 2001
)
0.31
" The concentrations at the end of the dosing interval were 10 to 25 times higher than that observed in the standard regimen of 800 mg of IDV q8h for IDV-RTV 800-100 and 800-200 mg regimens, respectively."( Pharmacokinetic profile and tolerability of indinavir-ritonavir combinations in healthy volunteers.
Deutsch, PJ; Nessly, ML; Rhodes, RR; Saah, AJ; Seniuk, MA; Winchell, GA, 2001
)
0.31
"Limited data are available on antiretroviral drug concentrations in seminal plasma during a dosing interval."( Pharmacokinetic profiles of nevirapine and indinavir in various fractions of seminal plasma.
de Vries, JW; Hoetelmans, RM; Lange, JM; Prins, JM; Repping, S; van Praag, RM, 2001
)
0.31
"The purpose of our study was to evaluate the efficacy of indinavir (IDV) in a twice daily dosing regimen with coadministration of 100 mg ritonavir (RTV) and to explore the influence of plasma drug levels in the rate of virologic response."( A clinical study of the combination of 100 mg ritonavir plus 800 mg indinavir as salvage therapy: influence of increased plasma drug levels in the rate of response.
Antela, A; Casado, JL; Dronda, F; Martí-Belda, P; Moreno, A; Moreno, S; Perez-Elías, MJ; Sabido, R,
)
0.13
"RTV/IDV 100/800 mg in a twice daily dosing regimen is associated with a significant virological response in patients with antiretroviral treatment failure."( A clinical study of the combination of 100 mg ritonavir plus 800 mg indinavir as salvage therapy: influence of increased plasma drug levels in the rate of response.
Antela, A; Casado, JL; Dronda, F; Martí-Belda, P; Moreno, A; Moreno, S; Perez-Elías, MJ; Sabido, R,
)
0.13
" The pharmacokinetics of the library was evaluated by dosing in dogs."( A combinatorial library of indinavir analogues and its in vitro and in vivo studies.
Chapman, KT; Cheng, Y; Gabryelski, L; Huening, TT; Jin, L; King, RC; Kuo, LC; Lin, JH; Lu, Z; McLoughlin, DA; Olah, TV; Olsen, DB; Rano, TA; Schleif, WA; Stahlhut, M; Tata, JR; Xu, X; Zhang, F, 2002
)
0.31
" There was no statistically significant difference between the number of patients below an IDV plasma concentration of 150 ng/ml in the various dosage regimens."( Therapeutic drug monitoring of indinavir in HIV-infected patients undergoing HAART.
Desch, S; Klinker, H; Langmann, P; Väth, T; Weissbrich, B; Zilly, M, 2002
)
0.31
" Among patients with indinavir trough concentration >500 ng/mL, 46 of 49 had a dosage adjustment and 17 have had more than two dosage adjustments."( High indinavir Cmin is associated with higher toxicity in patients on indinavir-ritonavir 800/100 mg twice-daily regimen.
Basso, S; Durand, A; Gallais, H; Gastaut, JA; Lacarelle, B; Poizot-Martin, I; Ravaux, I; Solas, C, 2002
)
0.31
" On the same day, the patient increased the risperidone dosage to 3 mg twice daily."( Extrapyramidal symptoms with ritonavir/indinavir plus risperidone.
Béïque, LC; Bowmer, MI; Kelly, DV, 2002
)
0.31
" This dosing and sampling were repeated after the subjects took milk thistle 175 mg (confirmed to contain silymarin 153 mg, the active ingredient) 3 times/day for 3 weeks."( Effect of milk thistle on the pharmacokinetics of indinavir in healthy volunteers.
Alfaro, R; Burstein, AH; Falloon, J; Formentini, E; Jagannatha, S; Piscitelli, SC, 2002
)
0.31
" The following pharmacokinetic parameters were determined: highest concentration (Cmax), hour-0 concentration, hour-8 concentration (C8), time to reach Cmax, and area under the plasma concentration-time curve over the 8-hour dosing interval (AUC8)."( Effect of milk thistle on the pharmacokinetics of indinavir in healthy volunteers.
Alfaro, R; Burstein, AH; Falloon, J; Formentini, E; Jagannatha, S; Piscitelli, SC, 2002
)
0.31
" Paired plasma and intracellular samples were collected over a full dosing interval from patients (13 on SQV, 6 on RTV, 8 on IDV, 16 on SQV plus RTV, 7 on IDV plus RTV) with a plasma viral load of <400 copies/ml."( Intracellular accumulation of human immunodeficiency virus protease inhibitors.
Back, DJ; Beeching, N; Carey, P; Hoggard, PG; Jones, K; Khoo, SH; Lloyd, J; Meaden, ER; Newton, P; Peters, B; Smith, A; Tjia, JF; Wilkins, EG; Williams, I, 2002
)
0.31
"To measure the unbound plasma concentrations of saquinavir (SQV) and indinavir (IDV) and to relate them to the total plasma concentrations in order to establish the unbound percentage of protease inhibitors in vivo during a full dosage interval profile."( The unbound percentage of saquinavir and indinavir remains constant throughout the dosing interval in HIV positive subjects.
Back, DJ; Boffito, M; Bonora, S; Di Perri, G; Hoggard, PG; Meaden, ER; Reynolds, HE; Sinicco, A, 2002
)
0.31
"925) remained constant as a proportion of total concentration over the full dosing profile."( The unbound percentage of saquinavir and indinavir remains constant throughout the dosing interval in HIV positive subjects.
Back, DJ; Boffito, M; Bonora, S; Di Perri, G; Hoggard, PG; Meaden, ER; Reynolds, HE; Sinicco, A, 2002
)
0.31
" The unbound percentage of both protease inhibitors remained constant over the dosing interval."( The unbound percentage of saquinavir and indinavir remains constant throughout the dosing interval in HIV positive subjects.
Back, DJ; Boffito, M; Bonora, S; Di Perri, G; Hoggard, PG; Meaden, ER; Reynolds, HE; Sinicco, A, 2002
)
0.31
" Over the next 9 days, venlafaxine was administered at a dosage of 50 mg every 8 hours following a brief titration."( A pharmacokinetic drug-drug interaction study of venlafaxine and indinavir.
Carson, SW; DeVane, CL; Eisele, G; Levin, GM; Nelson, LA; Preston, SL, 2001
)
0.31
" Therefore this study was designed to evaluate alternative dosing regimens."( Steady-state pharmacokinetic interaction of modified-dose indinavir and rifabutin.
Benson, C; Currier, J; Deutsch, P; Flexner, C; Gerber, J; Hamzeh, FM; Lee, J; McCrea, J; Ruan, P; Wu, H, 2003
)
0.32
"37) were similar regardless of the dosing regimen."( Indinavir, efavirenz, and abacavir pharmacokinetics in human immunodeficiency virus-infected subjects.
Cha, R; DiCenzo, R; Fischl, MA; Forrest, A; Hammer, SM; Morse, GD; Squires, KE; Wu, H, 2003
)
0.32
" Plasma indinavir levels declined rapidly while CSF levels remained stable throughout the 8-h dosing interval."( Suppression of cerebrospinal fluid HIV burden in antiretroviral naive patients on a potent four-drug antiretroviral regimen.
Davey, RT; Dewar, RL; Falloon, J; Feinberg, MB; Kovacs, JA; Masur, H; Metcalf, JA; Mican, JM; Piscitelli, SC; Polis, MA; Shen, JM; Suzman, DL; Yoder, CP, 2003
)
0.32
" This may warrant dosage adjustment during pregnancy."( Pharmacokinetics of nelfinavir and indinavir in HIV-1-infected pregnant women.
Aweeka, FT; Beckerman, KP; Hayashi, S; Homma, M; Kosel, BW, 2003
)
0.32
" Crystallization processes were studied for indinavir sulfate, indinavir free base and a commercial indinavir capsule dosage form, respectively."( In-vitro crystallization of indinavir in the presence of ritonavir and as a function of pH.
Fleisher, D; Heimbach, T; Li, LY; Rodríguez-Hornedo, N, 2003
)
0.58
"5, 1, 2, 3, 4, and 5 hours after indinavir dosing and assayed by high-performance liquid chromatography."( Coadministration of milk thistle and indinavir in healthy subjects.
DiCenzo, R; Forrest, A; Jordan, K; Koval, C; Morse, G; Reichman, R; Shelton, M, 2003
)
0.32
" PK sampling was repeated after dosage adjustment until the AUC(0-8) reached target values."( Changes in indinavir exposure over time: a case study in six HIV-1-infected children.
Bergshoeff, AS; Burger, DM; de Groot, R; Fraaij, PL; Hartwig, NG; van Rossum, AM, 2003
)
0.32
" Therapeutic drug monitoring should be carried out over time since this may prevent subtherapeutic dosing in children."( Changes in indinavir exposure over time: a case study in six HIV-1-infected children.
Bergshoeff, AS; Burger, DM; de Groot, R; Fraaij, PL; Hartwig, NG; van Rossum, AM, 2003
)
0.32
" For efavirenz, the concentrations at 12 hours and 24 hours (Cmin) after dosing were assessed."( Pharmacokinetics of indinavir/ritonavir (800/100 mg) in combination with efavirenz (600 mg) in HIV-1-infected subjects.
Aarnoutse, RE; Boyd, MA; Burger, DM; Cooper, DA; Lange, JM; Phanuphak, P; Ruxrungtham, K; Stek, M; van Heeswijk, RP, 2003
)
0.32
" In the latter study, drug-drug interactions, dosing errors, noncompliance and other important problems were identified and corrected."( Clinical use of a simultaneous HPLC assay for indinavir, saquinavir, ritonavir and nelfinavir in children and adults.
Brady, M; Cox, S; Crim, L; Gerber, N; Koranyi, K; Utkin, I; Walson, PD, 2003
)
0.32
"An HIV-infected male patient experienced photophobia after a change in dosing regimen that resulted in substantially higher indinavir plasma levels as compared with a reference population."( Photophobia in a patient with high indinavir plasma concentrations.
Beijnen, JH; Huitema, AD; Kuiper, RA; Meenhorst, PL; Mulder, JW, 2003
)
0.32
" Each dosage was taken twice daily for 2 weeks before 12 h pharmacokinetics were obtained."( Comparison of two reduced-dose regimens of indinavir (600 mg vs 400 mg twice daily) and ritonavir (100 mg twice daily) in healthy volunteers (COREDIR).
Burger, DM; la Porte, CJ; Rockstroh, JK; Schneider, K; Wasmuth, JC, 2004
)
0.32
"To compare dosing convenience and adherence with abacavir (ABC) 300 mg plus a fixed-dose lamivudine 150 mg/zidovudine 300 mg combination tablet (COM) twice daily versus indinavir (IDV) plus COM twice daily in treatment-naïve, HIV-1-infected adults; and to evaluate the association among difficulty taking antiretroviral regimens, adherence, and virologic efficacy."( Predictors of adherence and virologic outcome in HIV-infected patients treated with abacavir- or indinavir-based triple combination HAART also containing lamivudine/zidovudine.
Cahn, P; Carosi, G; Jordan, JC; Pharo, CE; Schechter, M; Smaill, F; Soto-Ramirez, L; Steel, HM; Thomas, NE; Vibhagool, A, 2004
)
0.32
" Dosage individualization based on plasma concentration monitoring might, however, be indicated."( Population pharmacokinetics of indinavir in patients infected with human immunodeficiency virus.
Biollaz, J; Buclin, T; Csajka, C; Décosterd, LA; Fattinger, K; Marzolini, C; Telenti, A, 2004
)
0.32
"This is the largest formal pharmacokinetic evaluation of 2 dosage combinations of IDV/RTV in HIV-infected individuals."( Comparison of two indinavir/ritonavir regimens in the treatment of HIV-infected individuals.
Acosta, EP; Eron, JJ; Ferguson, E; Fichtenbaum, CJ; Gerber, JG; Hammer, SM; Kuritzkes, DR; Neath, D; Pettinelli, C; Saah, AJ; Walawander, A; Wu, H; Yu, S, 2004
)
0.32
" In this study, dosing didanosine enteric-coated 400 mg once daily + indinavir/ritonavir 1200/400 mg once daily with breakfast indicated no decrease in the amount of absorption for either didanosine and indinavir and that this regimen could be administered with food."( Pharmacokinetic interaction study of indinavir/ritonavir and the enteric-coated capsule formulation of didanosine in healthy volunteers.
Aarnoutse, R; Burger, D; Hekster, Y; Koopmans, P; la Porte, C; Reiss, P; Stek, M; van Ewijk, N; Verweij-van Wissen, C, 2005
)
0.33
" All participants received initial dosing of indinavir, and baseline indinavir levels were obtained (AUC(0-8)) (phase I)."( Milk thistle and indinavir: a randomized controlled pharmacokinetics study and meta-analysis.
Clarke, M; DeGroot, N; Foster, B; Gallicano, K; Gold, W; Mills, E; Montori, VM; Myers, S; Phillips, E; Rachlis, B; Walker, S; Wilson, K, 2005
)
0.33
" Switching from 800/100 to 400/100 mg dosage improved adverse events in 16 of 20 patients."( Indinavir/ritonavir-based therapy in HIV-1-infected antiretroviral therapy-naive patients: comparison of 800/100 mg and 400/100 mg twice daily.
Clumeck, N; Crommentuyn, K; De Wit, S; Huitema, A; Konopnicki, D; Poll, B, 2005
)
0.33
"This study evaluated the feasibility of reducing the indinavir (IDV) dosage in Taiwanese patients receiving the standard IDV/ritonavir (RTV) dosage of 800/100 mg twice a day who had undetectable plasma human immunodeficiency virus type 1 (HIV-1) RNA but had developed IDV-related toxicities."( Dose reduction for the management of indinavir-related toxicity in human immunodeficiency virus type 1-infected patients in Taiwan: clinical and pharmacokinetic assessment.
Chang, SC; Chen, MY; Hsieh, SM; Huang, PF; Hung, CC; Pan, SC, 2005
)
0.33
" Seven patients received indinavir at a dosage of 800 mg three times daily and three patients received nelfinavir at a dosage of 750 mg three times daily."( Pharmacokinetic interaction between chemotherapy for non-Hodgkin's lymphoma and protease inhibitors in HIV-1-infected patients.
Bassetti, D; Bassetti, M; Cinelli, R; Cruciani, M; Di Gennaro, G; Gatti, G; Tirelli, U; Vaccher, E, 2005
)
0.33
" Before studying HAART in infected SCID mice, nonmanipulated SCID mice were treated with a single injection of the HAART cocktail (consisting of zidovudine, lamivudine, and indinavir) to determine optimum dosage and sampling time and to measure antiretroviral levels in the brain."( Highly active antiretroviral therapy and human immunodeficiency virus encephalitis.
Cook, JE; Dasgupta, S; Gorry, PR; Middaugh, LD; Terry, EC; Tyor, WR; Wesselingh, SL, 2005
)
0.33
" Indinavir dosing was then reduced to 400 mg (twice daily) and 1 week later an identical series of samples were drawn."( Low-doses of indinavir boosted with ritonavir in HIV-infected Thai patients: pharmacokinetics, efficacy and tolerability.
Cressey, TR; Jourdain, G; Kunkeaw, S; Lallemant, M; Leenasirimakul, P; Puttimit, C; Sukrakanchana, PO; Tod, M, 2005
)
0.33
" The applicability of the method was demonstrated by assessing indinavir in brain and testis of three mice dosed with intravenous bolus administration of indinavir (16."( LC-MS/MS determination of the HIV-1 protease inhibitor indinavir in brain and testis of mice.
Couet, W; Olivier, JC; Pereira de Oliveira, M; Venisse, N, 2006
)
0.33
" Discontinuation or reduction of the dosage of protease inhibitors associated with conventional conservative treatment is effective in reducing the symptoms and resolving the disease."( Adhesive capsulitis of the shoulder in human immunodeficiency virus-positive patients during highly active antiretroviral therapy.
De Ponti, A; Sansone, V; Taverna, E; Viganò, MG,
)
0.13
" A Bayesian approach is proposed to fit this model to clinical data from ACTG A5055, a study of two dosage regimens of indinavir (IDV) with ritonavir (RTV) in subjects failing their first protease inhibitor treatment."( Pharmacodynamics of antiretroviral agents in HIV-1 infected patients: using viral dynamic models that incorporate drug susceptibility and adherence.
Acosta, EP; Eron, JJ; Gerber, JG; Huang, Y; Kuritzkes, DR; Park, JG; Perelson, AS; Rosenkranz, SL; Wu, H; Yu, S, 2006
)
0.33
"The purpose of this study was to determine the pharmacokinetics and tolerability of three different indinavir and lopinavir/ritonavir dosing regimens."( Association of total bilirubin with indinavir and lopinavir plasma concentrations in HIV-infected patients receiving three different double-boosted dosing regimens.
Dicenzo, R; Larppanichpoonphol, P; Luque, A; Reichman, R, 2006
)
0.33
"HIV-infected adults receiving lopinavir/ritonavir 400/100 mg twice daily with food had nine plasma samples taken over a 12 h dosing interval at baseline (BL), after adding indinavir 600 mg twice daily for 10 days (R1), indinavir 800 mg twice daily for 5 days (R2) and lopinavir/ritonavir 533/133 mg plus indinavir 600 mg twice daily for 10 days (R3)."( Association of total bilirubin with indinavir and lopinavir plasma concentrations in HIV-infected patients receiving three different double-boosted dosing regimens.
Dicenzo, R; Larppanichpoonphol, P; Luque, A; Reichman, R, 2006
)
0.33
"Complex dosing regimens, costs, side effects, biodistribution limitations, and variable drug pharmacokinetic patterns have affected the long-term efficacy of antiretroviral medicines."( Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery.
Boska, MD; Chaubal, M; Destache, CJ; Dou, H; Gendelman, HE; Gorantla, S; Kingsley, J; Kipp, J; Morehead, JR; Mosley, RL; Nelson, JA; Poluektova, L; Rabinow, BE; Werling, J, 2006
)
0.33
" The lipid-associated IDV model was then used to determine the minimum dosing schedule needed to attain central or lymph drug concentrations comparable to the soluble form."( Feasibility of weekly HIV drug delivery to enhance drug localization in lymphoid tissues based on pharmacokinetic models of lipid-associated indinavir.
Ho, RJ; Snedecor, SJ; Sullivan, SM, 2006
)
0.33
"Association of IDV to lipid nanoparticles has a favorable half-life and tissue distribution and allows comparable minimum drug concentration in the lymph (where the majority of viral replication occurs) to be achieved with a dosing schedule of every 95."( Feasibility of weekly HIV drug delivery to enhance drug localization in lymphoid tissues based on pharmacokinetic models of lipid-associated indinavir.
Ho, RJ; Snedecor, SJ; Sullivan, SM, 2006
)
0.33
" These include non-compliance with the prescribed dosing regimen and inaccurate recollection of dosing history by patients as well as mistakes in recording data."( Improving data reliability using a non-compliance detection method versus using pharmacokinetic criteria.
Acosta, EP; Blaschke, TF; Krygowski, M; Kshirsagar, SA; Sheiner, LB; Verotta, D, 2007
)
0.34
" Prospective and early indinavir Cres determination should be recommended in the patient's care management and dosage adjustments."( Indinavir trough concentration as a determinant of early nephrolithiasis in HIV-1-infected adults.
Bouvet, E; Chêne, G; Collin, F; Duval, X; Garraffo, R; Mentré, F; Peytavin, G; Raffi, F; Retout, S; Salmon, D, 2007
)
0.34
" In clinical practice, it became common for clinicians to prescribe it with a ritonavir pharmacokinetic 'boost' to remove the food restriction, reduce the pill burden and enable a more convenient twice-daily dosing schedule."( Indinavir: the forgotten HIV-protease inhibitor. Does it still have a role?
Boyd, M, 2007
)
0.34
" Similar low dosing levels in children have also proven successful, but data in pregnant women remains limited."( Indinavir/ritonavir remains an important component of HAART for the treatment of HIV/AIDS, particularly in resource-limited settings.
Chokephaibulkit, K; Cressey, TR; Fregonese, F; Plipat, N, 2007
)
0.34
" The dosing was too low for 18% of the patients and too high for 39% of the patients."( Antiretroviral drug dosing errors in HIV-infected patients undergoing hemodialysis.
Bagnis, CI; Bessette, C; Deray, G; Karie, S; Launay-Vacher, V; Tézenas Du Montcel, S; Tostivint, I; Tourret, J; Vigneau, C, 2007
)
0.34
"Pharmacokinetic parameters were determined for indinavir, ritonavir, and amprenavir: area under the concentration-time curve from time 0 to 12 hours after dosing (AUC(0-12)), maximum plasma concentration (C(max)), and 12-hour plasma concentration (C(12))."( Pharmacokinetics of an indinavir-ritonavir-fosamprenavir regimen in patients with human immunodeficiency virus.
Acosta, EP; Easley, KA; Lennox, JL; Ofotokun, I; Pan, Y, 2008
)
0.35
"Pharmacokinetic studies in mice traditionally require one animal per time point, resulting in dosing and euthanizing a large number of animals and producing suboptimal quality of pharmacokinetic data due to inter-animal variability and dosing error."( Improved pharmacokinetic and bioavailability support of drug discovery using serial blood sampling in mice.
Hageman, W; Huebert, ND; Peng, SX; Rockafellow, BA; Skedzielewski, TM, 2009
)
0.35
" Ketoconazole strongly inhibited CYP3A4-mediated terfenadine metabolism in vitro, and the method predicted 6- to 37-fold increase of terfenadine AUC by the concomitant dosing of ketoconazole, which reasonably well agreed with the observed 13- to 59-fold increase of AUC in clinical studies."( A novel approach to the prediction of drug-drug interactions in humans based on the serum incubation method.
Chiba, M; Ishii, Y; Shibata, Y; Takahashi, H, 2008
)
0.35
" In the most challenging situations for the method, those where the targeted response corresponds to a region of the dose-response curve that is relatively flat, the algorithm can still perform satisfactorily."( Dynamic calibration of pharmacokinetic parameters in dose-finding studies.
Fenton, T; Hughes, MD; O'Quigley, J; Pei, L, 2010
)
0.36
" In turn, ART commonly requires complex dosing schedules and leads to the emergence of viral resistance and treatment failures."( Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages.
Balkundi, S; Bronich, T; Gendelman, HE; Kabanov, AV; Kanmogne, G; Martinez-Skinner, A; McMillan, J; Mosley, RL; Nowacek, AS; Roy, U, 2011
)
0.37
"Indinavir boosted with ritonavir (IDV/r) dosing with 400/100 mg, twice daily, is preferred in Thai adults, but this dose can lead to concentrations close to the boundaries of its therapeutic window."( Influence of body weight on achieving indinavir concentrations within its therapeutic window in HIV-infected Thai patients receiving indinavir boosted with ritonavir.
Bowonwatanuwong, C; Cressey, TR; Halue, G; Hirt, D; Jourdain, G; Lallemant, M; Leenasirimakul, P; Techapornroong, M; Treluyer, JM; Urien, S, 2011
)
0.37
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."( FDA-approved drug labeling for the study of drug-induced liver injury.
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011
)
0.37
" Starting on day 2, venlafaxine XR was dosed at 37."( Lack of a pharmacokinetic drug-drug interaction with venlafaxine extended-release/indinavir and desvenlafaxine extended-release/indinavir.
Jann, MW; Momary, K; Penzak, SR; Spratlin, V; Turner, D; VanDenBerg, C; Wright, A; Zhang, H, 2012
)
0.38
" Compared to the controls, multiple dosing of Sophora extract elevated both mRNA and protein levels of P-gp in the small intestine and liver."( Impact of the herbal medicine Sophora flavescens on the oral pharmacokinetics of indinavir in rats: the involvement of CYP3A and P-glycoprotein.
Chan, RC; Che, CT; Ip, SP; Lee, SS; Lin, ZX; Xian, Y; Yang, JM; Yeung, JH; Zhao, M, 2012
)
0.38
" As these anti-HIV lipid nanoparticles also prolonged plasma drug exposure, they hold promise as a long-acting dosage form for HIV patients in addressing residual virus in cells and tissue."( Anti-HIV drug-combination nanoparticles enhance plasma drug exposure duration as well as triple-drug combination levels in cells within lymph nodes and blood in primates.
Freeling, JP; Ho, RJ; Koehn, J; Shu, C; Sun, J, 2015
)
0.42
" Regardless of dosing conditions, less indinavir was in solution in the duodenum compared to the stomach."( Gastrointestinal dissolution, supersaturation and precipitation of the weak base indinavir in healthy volunteers.
Augustijns, P; Brouwers, J; Rubbens, J; Tack, J, 2016
)
0.43
" Data collected included demographic data, laboratory tests, antiretroviral treatment history, methadone dosing and drug abstinence."( Risk factors for kidney disease among HIV-1 positive persons in the methadone program.
Firląg-Burkacka, E; Grycner, E; Horban, A; Kowalska, JD; Matłosz, B; Pietraszkiewicz, E, 2019
)
0.51
"Adherence to antiretroviral therapy by pediatric patients is difficult because of the lack of dosage forms adequate for children."( Monoolein-based nanoparticles containing indinavir: a taste-masked drug delivery system.
Araújo, BV; Bianchin, MD; Colombo, M; Immich, MF; Koester, LS; Külkamp-Guerreiro, IC; Poletto, F; Prebianca, G; Teixeira, ML, 2021
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
HIV protease inhibitorAn inhibitor of HIV protease, an enzyme required for production of proteins needed for viral assembly.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
azaheterocycle sulfate salt
dicarboxylic acid diamide
N-(2-hydroxyethyl)piperazine
piperazinecarboxamide
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (96)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency89.12510.631035.7641100.0000AID504339
RAR-related orphan receptor gammaMus musculus (house mouse)Potency2.11320.006038.004119,952.5996AID1159521
TDP1 proteinHomo sapiens (human)Potency22.69190.000811.382244.6684AID686978; AID686979
AR proteinHomo sapiens (human)Potency28.67690.000221.22318,912.5098AID1259243; AID1259247; AID743035; AID743036; AID743042; AID743053; AID743054; AID743063
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency5.21830.01237.983543.2770AID1346984; AID1645841
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency26.83250.000214.376460.0339AID720691; AID720692; AID720719
pregnane X nuclear receptorHomo sapiens (human)Potency13.50560.005428.02631,258.9301AID1346982; AID1346985
estrogen nuclear receptor alphaHomo sapiens (human)Potency19.75130.000229.305416,493.5996AID743069; AID743075; AID743078; AID743079; AID743080
cytochrome P450 2D6Homo sapiens (human)Potency19.49710.00108.379861.1304AID1645840
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency40.42900.001723.839378.1014AID743083
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency23.46970.000323.4451159.6830AID743065; AID743067
gemininHomo sapiens (human)Potency0.79430.004611.374133.4983AID624297
Cellular tumor antigen p53Homo sapiens (human)Potency30.04740.002319.595674.0614AID651631; AID720552
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency26.60320.011917.942071.5630AID651632; AID720516
Ataxin-2Homo sapiens (human)Potency26.60320.011912.222168.7989AID651632
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency0.67410.01237.983543.2770AID1645841
GVesicular stomatitis virusPotency9.52210.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency37.90830.00108.379861.1304AID1645840
Interferon betaHomo sapiens (human)Potency9.52210.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency9.52210.01238.964839.8107AID1645842
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency9.52210.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency9.52210.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Protease Human immunodeficiency virus 1IC50 (µMol)0.00040.00010.22487.3200AID162065
Chain A, PROTEIN (PROTEASE)Human immunodeficiency virus 1Ki0.00030.00030.00030.0003AID977610
Chain B, PROTEIN (PROTEASE)Human immunodeficiency virus 1Ki0.00030.00030.00030.0003AID977610
Chain A, PROTEIN (PROTEASE)Human immunodeficiency virus 1Ki0.00030.00030.00030.0003AID977610
Chain B, PROTEIN (PROTEASE)Human immunodeficiency virus 1Ki0.00030.00030.00030.0003AID977610
Chain A, HIV-1 PROTEASEHuman immunodeficiency virus 1Ki0.00040.00040.00040.0004AID977610
Chain B, HIV-1 PROTEASEHuman immunodeficiency virus 1Ki0.00040.00040.00040.0004AID977610
Chain A, HIV-II PROTEASEHuman immunodeficiency virus 1Ki0.00040.00040.00040.0004AID977610
Chain B, HIV-II PROTEASEHuman immunodeficiency virus 1Ki0.00040.00040.00040.0004AID977610
Chain A, protease RETROPEPSINHuman immunodeficiency virus 1Ki0.00080.00010.00080.0018AID977610
Chain B, protease RETROPEPSINHuman immunodeficiency virus 1Ki0.00080.00010.00080.0018AID977610
Chain A, protease RETROPEPSINHuman immunodeficiency virus 1Ki0.00080.00010.00080.0018AID977610
Chain B, protease RETROPEPSINHuman immunodeficiency virus 1Ki0.00080.00010.00080.0018AID977610
Chain A, protease RETROPEPSINHuman immunodeficiency virus 1Ki0.00080.00010.00080.0018AID977610
Chain B, protease RETROPEPSINHuman immunodeficiency virus 1Ki0.00080.00010.00080.0018AID977610
Chain A, POL polyproteinHuman immunodeficiency virus 1Ki4.23500.93202.58354.2350AID977610
Chain B, POL polyproteinHuman immunodeficiency virus 1Ki4.23500.93202.58354.2350AID977610
Chain A, POL polyproteinHuman immunodeficiency virus 1Ki4.23500.93202.58354.2350AID977610
Chain B, POL polyproteinHuman immunodeficiency virus 1Ki4.23500.93202.58354.2350AID977610
Chain A, HIV-1 proteaseHuman immunodeficiency virus 1Ki0.00970.00058.605841.0000AID977610
Chain B, HIV-1 proteaseHuman immunodeficiency virus 1Ki0.00970.00058.605841.0000AID977610
Chain A, Pol polyproteinHuman immunodeficiency virus 1Ki0.00970.00058.605841.0000AID977610
Chain B, Pol polyproteinHuman immunodeficiency virus 1Ki0.00970.00058.605841.0000AID977610
Chain A, Pol polyproteinHuman immunodeficiency virus type 1 (BH5 ISOLATE)Ki0.00970.00058.605841.0000AID977610
Chain B, Pol polyproteinHuman immunodeficiency virus type 1 (BH5 ISOLATE)Ki0.00970.00058.605841.0000AID977610
Chain A, Pol polyproteinHuman immunodeficiency virus 1Ki0.00970.00058.605841.0000AID977610
Chain B, Pol polyproteinHuman immunodeficiency virus 1Ki0.00970.00058.605841.0000AID977610
Chain A, Pol polyproteinHuman immunodeficiency virus 1Ki0.00970.00058.605841.0000AID977610
Chain B, Pol polyproteinHuman immunodeficiency virus 1Ki0.00970.00058.605841.0000AID977610
Chain A, Hiv-1 ProteaseHuman immunodeficiency virus 1Ki0.00040.00040.00040.0004AID977610
Chain B, Hiv-1 ProteaseHuman immunodeficiency virus 1Ki0.00040.00040.00040.0004AID977610
Chain A, Hiv-1 ProteaseHuman immunodeficiency virus 1Ki0.00040.00040.00040.0004AID977610
Chain B, Hiv-1 ProteaseHuman immunodeficiency virus 1Ki0.00040.00040.00040.0004AID977610
Chain A, Hiv-1 ProteaseHuman immunodeficiency virus 1Ki0.00040.00040.00040.0004AID977610
Chain B, Hiv-1 ProteaseHuman immunodeficiency virus 1Ki0.00040.00040.00040.0004AID977610
Solute carrier family 22 member 2Homo sapiens (human)IC50 (µMol)142.00000.40003.10009.7000AID721751
Solute carrier family 22 member 1 Homo sapiens (human)IC50 (µMol)208.00000.21005.553710.0000AID721750
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)83.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Solute carrier family 22 member 3Homo sapiens (human)IC50 (µMol)500.00000.09003.72779.5000AID721749
Bile salt export pumpHomo sapiens (human)IC50 (µMol)21.20000.11007.190310.0000AID1443980; AID1443989; AID1473738
Gag-Pol polyproteinHuman immunodeficiency virus type 1 (BRU ISOLATE)IC50 (µMol)0.00040.00040.01100.0270AID1795266
Gag-Pol polyproteinHuman immunodeficiency virus type 1 (BRU ISOLATE)Ki0.07490.00000.08283.3000AID1795271; AID1796146; AID1796305; AID1797110; AID1797112
Gag-Pol polyproteinHuman immunodeficiency virus type 2 (ISOLATE ROD)Ki0.00200.00000.07851.0000AID1795269
Gag-Pol polyproteinHIV-1 M:B_HXB2RKi0.52460.00000.51449.0000AID1795269; AID1795276; AID1797107
Gag polyproteinHIV-1 M:B_MNIC50 (µMol)0.02000.01300.02380.0490AID1799450
Gag-Pol polyproteinHuman immunodeficiency virus type 1 (RF/HAT ISOLATE)Ki0.29800.00000.05051.6160AID1797110
ATP-dependent translocase ABCB1Homo sapiens (human)IC50 (µMol)72.00000.00022.318510.0000AID416864; AID681358
Cytochrome P450 3A4Homo sapiens (human)IC50 (µMol)0.20000.00011.753610.0000AID154273; AID54762; AID625251
Cytochrome P450 3A4Homo sapiens (human)Ki0.48000.00011.41629.9000AID589156
Replicase polyprotein 1abSevere acute respiratory syndrome-related coronavirusIC50 (µMol)22.53000.00402.92669.9600AID1805801
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2IC50 (µMol)22.53000.00022.45859.9600AID1805801
Cytochrome P450 2D6Homo sapiens (human)IC50 (µMol)30.00000.00002.015110.0000AID154271; AID54595
Gag-Pol polyproteinHuman immunodeficiency virus type 1 (NEW YORK-5 ISOLATE)IC50 (µMol)0.02610.00020.10421.7000AID1796197; AID1796287; AID1796288; AID1796290; AID1796295; AID1796296
Gag-Pol polyproteinHuman immunodeficiency virus type 1 (NEW YORK-5 ISOLATE)Ki0.00200.00000.12203.1000AID1795269
Alpha-1B adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)100.00000.00021.874210.0000AID416864
Substance-K receptorHomo sapiens (human)IC50 (µMol)5.10100.00013.12109.5530AID625227
Substance-K receptorHomo sapiens (human)Ki1.70000.00011.92429.7930AID625227
Alpha-1D adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)100.00000.00021.270410.0000AID416864
Thromboxane-A synthase Homo sapiens (human)IC50 (µMol)1.85100.00091.230410.0000AID625229
Gag-Pol polyproteinHuman immunodeficiency virus type 1 (STRAIN UGANDAN / ISOLATE U455)Ki0.29800.00000.05051.6160AID1797110
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)100.00000.00001.819410.0000AID416864
Genome polyprotein Human rhinovirus sp.Ki0.00330.00010.01650.1000AID160792
Solute carrier family 22 member 1Rattus norvegicus (Norway rat)IC50 (µMol)61.70000.18003.68578.8000AID679318
Protease Human immunodeficiency virus 1IC50 (µMol)0.03490.00010.22487.3200AID161867; AID161868; AID161870; AID161871; AID162026; AID162036; AID162066; AID162186; AID162187; AID162188; AID162192; AID162193; AID162195; AID162201; AID162206; AID162211; AID162213; AID162216; AID162217; AID162351; AID162352; AID162353; AID162355; AID162373; AID199077; AID199080; AID241213; AID242318; AID257496; AID260390; AID82627; AID82778; AID82781
Protease Human immunodeficiency virus 1Ki0.01290.00000.04433.1000AID160273; AID160300; AID160316; AID160455; AID160477; AID161524; AID162710; AID163487; AID219260; AID225562; AID225563; AID225564; AID238257; AID238682; AID260513; AID260514; AID260515; AID260516; AID260517; AID260518; AID343015; AID343016; AID343017; AID343018; AID343019; AID343020; AID343021
Multidrug and toxin extrusion protein 2Homo sapiens (human)IC50 (µMol)253.90000.16003.95718.6000AID721748; AID721752
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
Multidrug and toxin extrusion protein 1Homo sapiens (human)IC50 (µMol)3.80000.01002.765610.0000AID721746; AID721747; AID721754
Protease Human immunodeficiency virus 1IC50 (µMol)0.00440.00000.81769.8500AID1141883; AID1194842; AID309178; AID389439; AID510359
Protease Human immunodeficiency virus 1Ki0.00090.00000.02841.1000AID1182732; AID1254739; AID321338; AID321660; AID343014; AID374591; AID443165
Protease Human immunodeficiency virusKi0.00040.00040.00040.0004AID1393284
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Nuclear receptor subfamily 1 group I member 2Homo sapiens (human)EC50 (µMol)14.95000.00203.519610.0000AID1215086; AID1215087
Chain A, POL polyproteinHuman immunodeficiency virus 1Kd0.03300.03300.03300.0330AID977611
Chain B, POL polyproteinHuman immunodeficiency virus 1Kd0.03300.03300.03300.0330AID977611
Chain A, POL polyproteinHuman immunodeficiency virus 1Kd0.03300.03300.03300.0330AID977611
Chain B, POL polyproteinHuman immunodeficiency virus 1Kd0.03300.03300.03300.0330AID977611
Chain A, POL polyproteinHuman immunodeficiency virus 1Kd0.03300.03300.03300.0330AID977611
Chain B, POL polyproteinHuman immunodeficiency virus 1Kd0.03300.03300.03300.0330AID977611
Chain A, POL polyproteinHuman immunodeficiency virus 1Kd0.03300.03300.03300.0330AID977611
Chain B, POL polyproteinHuman immunodeficiency virus 1Kd0.03300.03300.03300.0330AID977611
Protease Human immunodeficiency virus 1Kd0.00110.00010.04120.5770AID162706; AID238043
Protease Human immunodeficiency virus 1Kd0.00270.00000.61178.1500AID673196; AID673197; AID673198
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Protease Human immunodeficiency virus 1IC95 (µMol)0.05000.00601.08686.0000AID162537
AlbuminHomo sapiens (human)KD2559.00006.00006.00006.0000AID239810
Thromboxane-A synthaseRattus norvegicus (Norway rat)IC90 (µMol)0.05000.01040.07030.1250AID210277
Protease Human immunodeficiency virus 1IC90 (µMol)0.05700.00200.67847.3000AID105206; AID199082; AID210277
Protease Human immunodeficiency virus 1IC95 (µMol)0.02500.00601.08686.0000AID161883; AID162538
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (332)

Processvia Protein(s)Taxonomy
negative regulation of DNA-templated transcriptionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
regulation of DNA-templated transcriptionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
xenobiotic metabolic processNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
signal transductionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
steroid metabolic processNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
positive regulation of gene expressionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
xenobiotic catabolic processNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
xenobiotic transportNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IINuclear receptor subfamily 1 group I member 2Homo sapiens (human)
cell differentiationNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor subfamily 1 group I member 2Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processSolute carrier family 22 member 2Homo sapiens (human)
positive regulation of gene expressionSolute carrier family 22 member 2Homo sapiens (human)
organic cation transportSolute carrier family 22 member 2Homo sapiens (human)
monoatomic cation transportSolute carrier family 22 member 2Homo sapiens (human)
neurotransmitter transportSolute carrier family 22 member 2Homo sapiens (human)
serotonin transportSolute carrier family 22 member 2Homo sapiens (human)
body fluid secretionSolute carrier family 22 member 2Homo sapiens (human)
organic cation transportSolute carrier family 22 member 2Homo sapiens (human)
quaternary ammonium group transportSolute carrier family 22 member 2Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 2Homo sapiens (human)
amine transportSolute carrier family 22 member 2Homo sapiens (human)
putrescine transportSolute carrier family 22 member 2Homo sapiens (human)
spermidine transportSolute carrier family 22 member 2Homo sapiens (human)
acetylcholine transportSolute carrier family 22 member 2Homo sapiens (human)
choline transportSolute carrier family 22 member 2Homo sapiens (human)
dopamine transportSolute carrier family 22 member 2Homo sapiens (human)
norepinephrine transportSolute carrier family 22 member 2Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 2Homo sapiens (human)
epinephrine transportSolute carrier family 22 member 2Homo sapiens (human)
histamine transportSolute carrier family 22 member 2Homo sapiens (human)
serotonin uptakeSolute carrier family 22 member 2Homo sapiens (human)
histamine uptakeSolute carrier family 22 member 2Homo sapiens (human)
norepinephrine uptakeSolute carrier family 22 member 2Homo sapiens (human)
thiamine transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
purine-containing compound transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
amino acid import across plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
dopamine uptakeSolute carrier family 22 member 2Homo sapiens (human)
L-arginine import across plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
export across plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 22 member 2Homo sapiens (human)
L-alpha-amino acid transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
spermidine transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
L-arginine transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
cellular detoxificationSolute carrier family 22 member 2Homo sapiens (human)
xenobiotic transport across blood-brain barrierSolute carrier family 22 member 2Homo sapiens (human)
xenobiotic metabolic processSolute carrier family 22 member 1 Homo sapiens (human)
neurotransmitter transportSolute carrier family 22 member 1 Homo sapiens (human)
serotonin transportSolute carrier family 22 member 1 Homo sapiens (human)
establishment or maintenance of transmembrane electrochemical gradientSolute carrier family 22 member 1 Homo sapiens (human)
organic cation transportSolute carrier family 22 member 1 Homo sapiens (human)
quaternary ammonium group transportSolute carrier family 22 member 1 Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 1 Homo sapiens (human)
monoamine transportSolute carrier family 22 member 1 Homo sapiens (human)
putrescine transportSolute carrier family 22 member 1 Homo sapiens (human)
spermidine transportSolute carrier family 22 member 1 Homo sapiens (human)
acetylcholine transportSolute carrier family 22 member 1 Homo sapiens (human)
dopamine transportSolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine transportSolute carrier family 22 member 1 Homo sapiens (human)
thiamine transportSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 1 Homo sapiens (human)
epinephrine transportSolute carrier family 22 member 1 Homo sapiens (human)
serotonin uptakeSolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine uptakeSolute carrier family 22 member 1 Homo sapiens (human)
thiamine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
metanephric proximal tubule developmentSolute carrier family 22 member 1 Homo sapiens (human)
purine-containing compound transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
dopamine uptakeSolute carrier family 22 member 1 Homo sapiens (human)
monoatomic cation transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 22 member 1 Homo sapiens (human)
(R)-carnitine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
acyl carnitine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
spermidine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
cellular detoxificationSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transport across blood-brain barrierSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
histamine metabolic processSolute carrier family 22 member 3Homo sapiens (human)
organic cation transportSolute carrier family 22 member 3Homo sapiens (human)
quaternary ammonium group transportSolute carrier family 22 member 3Homo sapiens (human)
monoatomic ion transportSolute carrier family 22 member 3Homo sapiens (human)
neurotransmitter transportSolute carrier family 22 member 3Homo sapiens (human)
serotonin transportSolute carrier family 22 member 3Homo sapiens (human)
organic cation transportSolute carrier family 22 member 3Homo sapiens (human)
quaternary ammonium group transportSolute carrier family 22 member 3Homo sapiens (human)
organic anion transportSolute carrier family 22 member 3Homo sapiens (human)
monocarboxylic acid transportSolute carrier family 22 member 3Homo sapiens (human)
monoamine transportSolute carrier family 22 member 3Homo sapiens (human)
spermidine transportSolute carrier family 22 member 3Homo sapiens (human)
dopamine transportSolute carrier family 22 member 3Homo sapiens (human)
norepinephrine transportSolute carrier family 22 member 3Homo sapiens (human)
regulation of appetiteSolute carrier family 22 member 3Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 3Homo sapiens (human)
epinephrine transportSolute carrier family 22 member 3Homo sapiens (human)
histamine transportSolute carrier family 22 member 3Homo sapiens (human)
serotonin uptakeSolute carrier family 22 member 3Homo sapiens (human)
histamine uptakeSolute carrier family 22 member 3Homo sapiens (human)
norepinephrine uptakeSolute carrier family 22 member 3Homo sapiens (human)
epinephrine uptakeSolute carrier family 22 member 3Homo sapiens (human)
purine-containing compound transmembrane transportSolute carrier family 22 member 3Homo sapiens (human)
dopamine uptakeSolute carrier family 22 member 3Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 22 member 3Homo sapiens (human)
spermidine transmembrane transportSolute carrier family 22 member 3Homo sapiens (human)
cellular detoxificationSolute carrier family 22 member 3Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cellular response to starvationAlbuminHomo sapiens (human)
negative regulation of mitochondrial depolarizationAlbuminHomo sapiens (human)
cellular response to calcium ion starvationAlbuminHomo sapiens (human)
cellular oxidant detoxificationAlbuminHomo sapiens (human)
transportAlbuminHomo sapiens (human)
viral life cycleGag-Pol polyproteinHIV-1 M:B_HXB2R
establishment of integrated proviral latencyGag-Pol polyproteinHIV-1 M:B_HXB2R
G2/M transition of mitotic cell cycleATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic metabolic processATP-dependent translocase ABCB1Homo sapiens (human)
response to xenobiotic stimulusATP-dependent translocase ABCB1Homo sapiens (human)
phospholipid translocationATP-dependent translocase ABCB1Homo sapiens (human)
terpenoid transportATP-dependent translocase ABCB1Homo sapiens (human)
regulation of response to osmotic stressATP-dependent translocase ABCB1Homo sapiens (human)
transmembrane transportATP-dependent translocase ABCB1Homo sapiens (human)
transepithelial transportATP-dependent translocase ABCB1Homo sapiens (human)
stem cell proliferationATP-dependent translocase ABCB1Homo sapiens (human)
ceramide translocationATP-dependent translocase ABCB1Homo sapiens (human)
export across plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
transport across blood-brain barrierATP-dependent translocase ABCB1Homo sapiens (human)
positive regulation of anion channel activityATP-dependent translocase ABCB1Homo sapiens (human)
carboxylic acid transmembrane transportATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic transport across blood-brain barrierATP-dependent translocase ABCB1Homo sapiens (human)
regulation of chloride transportATP-dependent translocase ABCB1Homo sapiens (human)
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
symbiont-mediated perturbation of host ubiquitin-like protein modificationReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
xenobiotic metabolic processCytochrome P450 2D6Homo sapiens (human)
steroid metabolic processCytochrome P450 2D6Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2D6Homo sapiens (human)
estrogen metabolic processCytochrome P450 2D6Homo sapiens (human)
coumarin metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid catabolic processCytochrome P450 2D6Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2D6Homo sapiens (human)
isoquinoline alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2D6Homo sapiens (human)
retinol metabolic processCytochrome P450 2D6Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2D6Homo sapiens (human)
negative regulation of bindingCytochrome P450 2D6Homo sapiens (human)
oxidative demethylationCytochrome P450 2D6Homo sapiens (human)
negative regulation of cellular organofluorine metabolic processCytochrome P450 2D6Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 2D6Homo sapiens (human)
muscle contractionSubstance-K receptorHomo sapiens (human)
tachykinin receptor signaling pathwaySubstance-K receptorHomo sapiens (human)
positive regulation of acetylcholine secretion, neurotransmissionSubstance-K receptorHomo sapiens (human)
intestine smooth muscle contractionSubstance-K receptorHomo sapiens (human)
negative regulation of luteinizing hormone secretionSubstance-K receptorHomo sapiens (human)
operant conditioningSubstance-K receptorHomo sapiens (human)
positive regulation of vascular permeabilitySubstance-K receptorHomo sapiens (human)
positive regulation of monoatomic ion transportSubstance-K receptorHomo sapiens (human)
positive regulation of smooth muscle contractionSubstance-K receptorHomo sapiens (human)
response to electrical stimulusSubstance-K receptorHomo sapiens (human)
prolactin secretionSubstance-K receptorHomo sapiens (human)
positive regulation of uterine smooth muscle contractionSubstance-K receptorHomo sapiens (human)
positive regulation of flagellated sperm motilitySubstance-K receptorHomo sapiens (human)
prostaglandin biosynthetic processThromboxane-A synthase Homo sapiens (human)
icosanoid metabolic processThromboxane-A synthase Homo sapiens (human)
cyclooxygenase pathwayThromboxane-A synthase Homo sapiens (human)
intracellular chloride ion homeostasisThromboxane-A synthase Homo sapiens (human)
response to ethanolThromboxane-A synthase Homo sapiens (human)
positive regulation of vasoconstrictionThromboxane-A synthase Homo sapiens (human)
response to fatty acidThromboxane-A synthase Homo sapiens (human)
organic cation transportMultidrug and toxin extrusion protein 2Homo sapiens (human)
transmembrane transportMultidrug and toxin extrusion protein 2Homo sapiens (human)
proton transmembrane transportMultidrug and toxin extrusion protein 2Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membraneMultidrug and toxin extrusion protein 2Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
organic cation transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
putrescine transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
xenobiotic transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
thiamine transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
amino acid import across plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
L-arginine import across plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
L-alpha-amino acid transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
proton transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
L-arginine transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (154)

Processvia Protein(s)Taxonomy
RNA polymerase II transcription regulatory region sequence-specific DNA bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nuclear receptor activityNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
protein bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
zinc ion bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nuclear receptor bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
amine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
acetylcholine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
neurotransmitter transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
monoamine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
organic cation transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
L-amino acid transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
pyrimidine nucleoside transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
choline transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
thiamine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
putrescine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
efflux transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
spermidine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
quaternary ammonium group transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
toxin transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
L-arginine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
acetylcholine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
neurotransmitter transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
dopamine:sodium symporter activitySolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine:sodium symporter activitySolute carrier family 22 member 1 Homo sapiens (human)
protein bindingSolute carrier family 22 member 1 Homo sapiens (human)
monoamine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
secondary active organic cation transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
organic cation transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
pyrimidine nucleoside transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
thiamine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
putrescine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
spermidine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
quaternary ammonium group transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
toxin transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
identical protein bindingSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
(R)-carnitine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
neurotransmitter transmembrane transporter activitySolute carrier family 22 member 3Homo sapiens (human)
protein bindingSolute carrier family 22 member 3Homo sapiens (human)
monoamine transmembrane transporter activitySolute carrier family 22 member 3Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 3Homo sapiens (human)
organic cation transmembrane transporter activitySolute carrier family 22 member 3Homo sapiens (human)
spermidine transmembrane transporter activitySolute carrier family 22 member 3Homo sapiens (human)
quaternary ammonium group transmembrane transporter activitySolute carrier family 22 member 3Homo sapiens (human)
toxin transmembrane transporter activitySolute carrier family 22 member 3Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
oxygen bindingAlbuminHomo sapiens (human)
DNA bindingAlbuminHomo sapiens (human)
fatty acid bindingAlbuminHomo sapiens (human)
copper ion bindingAlbuminHomo sapiens (human)
protein bindingAlbuminHomo sapiens (human)
toxic substance bindingAlbuminHomo sapiens (human)
antioxidant activityAlbuminHomo sapiens (human)
pyridoxal phosphate bindingAlbuminHomo sapiens (human)
identical protein bindingAlbuminHomo sapiens (human)
protein-folding chaperone bindingAlbuminHomo sapiens (human)
exogenous protein bindingAlbuminHomo sapiens (human)
enterobactin bindingAlbuminHomo sapiens (human)
peptidase activityGag-Pol polyproteinHIV-1 M:B_HXB2R
integrase activityGag-Pol polyproteinHIV-1 M:B_HXB2R
protein bindingATP-dependent translocase ABCB1Homo sapiens (human)
ATP bindingATP-dependent translocase ABCB1Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
efflux transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
ATP hydrolysis activityATP-dependent translocase ABCB1Homo sapiens (human)
transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
ubiquitin protein ligase bindingATP-dependent translocase ABCB1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
carboxylic acid transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
phosphatidylcholine floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
phosphatidylethanolamine flippase activityATP-dependent translocase ABCB1Homo sapiens (human)
ceramide floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
K63-linked deubiquitinase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
K48-linked deubiquitinase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA endonuclease activity, producing 3'-phosphomonoestersReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
ISG15-specific peptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
protein guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
monooxygenase activityCytochrome P450 2D6Homo sapiens (human)
iron ion bindingCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activityCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2D6Homo sapiens (human)
heme bindingCytochrome P450 2D6Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
tachykinin receptor activitySubstance-K receptorHomo sapiens (human)
protein bindingSubstance-K receptorHomo sapiens (human)
substance K receptor activitySubstance-K receptorHomo sapiens (human)
monooxygenase activityThromboxane-A synthase Homo sapiens (human)
thromboxane-A synthase activityThromboxane-A synthase Homo sapiens (human)
iron ion bindingThromboxane-A synthase Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygenThromboxane-A synthase Homo sapiens (human)
heme bindingThromboxane-A synthase Homo sapiens (human)
12-hydroxyheptadecatrienoic acid synthase activityThromboxane-A synthase Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityThromboxane-A synthase Homo sapiens (human)
organic cation transmembrane transporter activityMultidrug and toxin extrusion protein 2Homo sapiens (human)
antiporter activityMultidrug and toxin extrusion protein 2Homo sapiens (human)
transmembrane transporter activityMultidrug and toxin extrusion protein 2Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug and toxin extrusion protein 2Homo sapiens (human)
polyspecific organic cation:proton antiporter activityMultidrug and toxin extrusion protein 2Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
protein bindingMultidrug and toxin extrusion protein 1Homo sapiens (human)
organic cation transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
L-amino acid transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
thiamine transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
antiporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
putrescine transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
L-arginine transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
polyspecific organic cation:proton antiporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (66)

Processvia Protein(s)Taxonomy
nucleoplasmNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
transcription regulator complexNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nuclear bodyNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
intermediate filament cytoskeletonNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
chromatinNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nucleusNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
membraneSolute carrier family 22 member 2Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
extracellular exosomeSolute carrier family 22 member 2Homo sapiens (human)
presynapseSolute carrier family 22 member 2Homo sapiens (human)
plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
membraneSolute carrier family 22 member 1 Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
lateral plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
presynapseSolute carrier family 22 member 1 Homo sapiens (human)
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
nuclear outer membraneSolute carrier family 22 member 3Homo sapiens (human)
plasma membraneSolute carrier family 22 member 3Homo sapiens (human)
endomembrane systemSolute carrier family 22 member 3Homo sapiens (human)
membraneSolute carrier family 22 member 3Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 3Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 3Homo sapiens (human)
mitochondrial membraneSolute carrier family 22 member 3Homo sapiens (human)
neuronal cell bodySolute carrier family 22 member 3Homo sapiens (human)
presynapseSolute carrier family 22 member 3Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular regionAlbuminHomo sapiens (human)
extracellular spaceAlbuminHomo sapiens (human)
nucleusAlbuminHomo sapiens (human)
endoplasmic reticulumAlbuminHomo sapiens (human)
endoplasmic reticulum lumenAlbuminHomo sapiens (human)
Golgi apparatusAlbuminHomo sapiens (human)
platelet alpha granule lumenAlbuminHomo sapiens (human)
extracellular exosomeAlbuminHomo sapiens (human)
blood microparticleAlbuminHomo sapiens (human)
protein-containing complexAlbuminHomo sapiens (human)
cytoplasmAlbuminHomo sapiens (human)
cytoplasmATP-dependent translocase ABCB1Homo sapiens (human)
plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
cell surfaceATP-dependent translocase ABCB1Homo sapiens (human)
membraneATP-dependent translocase ABCB1Homo sapiens (human)
apical plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
extracellular exosomeATP-dependent translocase ABCB1Homo sapiens (human)
external side of apical plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mitochondrionCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulumCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2D6Homo sapiens (human)
cytoplasmCytochrome P450 2D6Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2D6Homo sapiens (human)
plasma membraneSubstance-K receptorHomo sapiens (human)
sperm flagellumSubstance-K receptorHomo sapiens (human)
sperm headSubstance-K receptorHomo sapiens (human)
sperm midpieceSubstance-K receptorHomo sapiens (human)
sperm midpieceSubstance-K receptorHomo sapiens (human)
plasma membraneSubstance-K receptorHomo sapiens (human)
endoplasmic reticulumThromboxane-A synthase Homo sapiens (human)
endoplasmic reticulum membraneThromboxane-A synthase Homo sapiens (human)
cytosolThromboxane-A synthase Homo sapiens (human)
plasma membraneMultidrug and toxin extrusion protein 2Homo sapiens (human)
apical plasma membraneMultidrug and toxin extrusion protein 2Homo sapiens (human)
membraneMultidrug and toxin extrusion protein 2Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
basolateral plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
apical plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (837)

Assay IDTitleYearJournalArticle
AID1215093Activation of rat PXR expressed in human HepG2 cells up to 46 uM after 24 hrs by luciferase reporter gene based luminescent analysis2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID371148Apparent permeability from apical to basolateral side of human Caco-2 cells at 175 uM in donor chamber after 3 hrs2008European journal of medicinal chemistry, Jul, Volume: 43, Issue:7
Synthesis and in vitro biological evaluation of valine-containing prodrugs derived from clinically used HIV-protease inhibitors.
AID371138Permeability from apical to basolateral side of human Caco-2 cells assessed as ratio of prodrug concentration in receiver to prodrug concentration in donor at 175 uM in donor chamber after 3 hrs2008European journal of medicinal chemistry, Jul, Volume: 43, Issue:7
Synthesis and in vitro biological evaluation of valine-containing prodrugs derived from clinically used HIV-protease inhibitors.
AID1215089Activation of human PXR expressed in human HepG2 (DPX-2) cells assessed as induction of CYP3A4 after 24 hrs by luminescent analysis relative to rifampicin2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID468239Antiviral activity against HIV1 infected human C8166 cells assessed as inhibition of viral replication after 4 days by p24 antigen capture ELISA2009Journal of natural products, Aug, Volume: 72, Issue:8
Isoprenylated chromone derivatives from the plant endophytic fungus Pestalotiopsis fici.
AID371164Apparent permeability from basolateral to apical side of human Caco-2 cells at 175 uM in donor chamber after 3 hrs2008European journal of medicinal chemistry, Jul, Volume: 43, Issue:7
Synthesis and in vitro biological evaluation of valine-containing prodrugs derived from clinically used HIV-protease inhibitors.
AID371127Antiviral activity against HTLV1 3B infected in human MT4 cells assessed as reverse transcriptase activity after 5 days by MTT assay2008European journal of medicinal chemistry, Jul, Volume: 43, Issue:7
Synthesis and in vitro biological evaluation of valine-containing prodrugs derived from clinically used HIV-protease inhibitors.
AID1215088Competitive binding affinity to human PXR LBD (111 to 434) up to 46 uM by TR-FRET assay2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID1215096Activation of human PXR expressed in human HepG2 (DPX-2) cells after 24 hrs by luciferase reporter gene based luminescent analysis relative to rifampicin2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID162065Inhibition of HIV-1 protease in vitro.2000Journal of medicinal chemistry, Sep-07, Volume: 43, Issue:18
Identification of MK-944a: a second clinical candidate from the hydroxylaminepentanamide isostere series of HIV protease inhibitors.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID385360Inhibition of HIV1 LAI replication in C8166 cells after 4 days by ELISA2008Journal of natural products, Apr, Volume: 71, Issue:4
Pestalotheols A-D, bioactive metabolites from the plant endophytic fungus Pestalotiopsis theae.
AID425039Antiviral activity against HIV-1 M:B_Lai replication in human C8166 cells assessed as inhibition of p24 antigen expression level after 4 days by ELISA2009Journal of natural products, May-22, Volume: 72, Issue:5
Breviane spiroditerpenoids from an extreme-tolerant Penicillium sp. isolated from a deep sea sediment sample.
AID371125Antiviral activity against HIV1 LAI infected in human CEM-SS cells assessed as reverse transcriptase activity after 5 days by MTT assay2008European journal of medicinal chemistry, Jul, Volume: 43, Issue:7
Synthesis and in vitro biological evaluation of valine-containing prodrugs derived from clinically used HIV-protease inhibitors.
AID347715Antiviral activity against HIV1 replication in human C8166 cells by ELISA2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Pestalofones A-E, bioactive cyclohexanone derivatives from the plant endophytic fungus Pestalotiopsis fici.
AID1215087Activation of human PXR expressed in human HepG2 (DPX-2) cells assessed as induction of CYP3A4 after 24 hrs by luminescent analysis2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID162537Inhibition of HIV-1 protease in vitro.2000Journal of medicinal chemistry, Sep-07, Volume: 43, Issue:18
Identification of MK-944a: a second clinical candidate from the hydroxylaminepentanamide isostere series of HIV protease inhibitors.
AID371126Cytotoxicity against human CEM-SS cells after 5 days by MTT assay2008European journal of medicinal chemistry, Jul, Volume: 43, Issue:7
Synthesis and in vitro biological evaluation of valine-containing prodrugs derived from clinically used HIV-protease inhibitors.
AID1215086Activation of human PXR expressed in human HepG2 (DPX-2) cells after 24 hrs by luciferase reporter gene based luminescent analysis2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID436279Antiviral activity against HIV1 LAI infected in human C8166 cells assessed as inhibition of viral replication by ELISA2008Journal of natural products, Nov, Volume: 71, Issue:11
Pestalazines and pestalamides, bioactive metabolites from the plant pathogenic fungus Pestalotiopsis theae.
AID371154Permeability from basolateral to apical side of human Caco-2 cells assessed as ratio of prodrug concentration in receiver to prodrug concentration in donor at 175 uM in donor chamber after 3 hrs2008European journal of medicinal chemistry, Jul, Volume: 43, Issue:7
Synthesis and in vitro biological evaluation of valine-containing prodrugs derived from clinically used HIV-protease inhibitors.
AID371128Cytotoxicity against human MT4 cells after 4 days by MTT assay2008European journal of medicinal chemistry, Jul, Volume: 43, Issue:7
Synthesis and in vitro biological evaluation of valine-containing prodrugs derived from clinically used HIV-protease inhibitors.
AID408740Antiviral activity against HIV1 in human C8116 cells assessed as reduction of p24 protein level after 4 days by ELISA2008Bioorganic & medicinal chemistry, Jun-01, Volume: 16, Issue:11
Pestaloficiols A-E, bioactive cyclopropane derivatives from the plant endophytic fungus Pestalotiopsis fici.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID220211Inhibition of cytochrome P450 2C9 at 100 uM2000Journal of medicinal chemistry, Mar-09, Volume: 43, Issue:5
5,6-Dihydropyran-2-ones possessing various sulfonyl functionalities: potent nonpeptidic inhibitors of HIV protease.
AID160792Binding affinity against HIV-2 protease enzyme.2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
Protease inhibitors: current status and future prospects.
AID519781Antiviral activity against HIV 2 subtype A clinical isolate expressing 14H-17D-43T-68N/D protease gene sequence from HIV2 infected patient plasma and PBMC obtained before compound treatment measured after 13 months2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors.
AID586626Antiviral activity against HIV1 harboring mutant protease with matrix Y79F mutant infected in HEK293T cells assessed as inhibition of viral replication after 48 hrs by luciferase assay2011Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3
Three residues in HIV-1 matrix contribute to protease inhibitor susceptibility and replication capacity.
AID624628Drug-stimulated Pgp ATPase activity ratio determined in MDR1-Sf9 cell membranes with test compound at a concentration of 20uM2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID557289Antiviral activity against HIV1 NL4-3 harboring M46I/V82F/I84V amino acid substitution in protease encoding region infected in human MT4 cells assessed as inhibition of p24 Gag protein production selected at 5 uM of ritonavir by ELISA2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.
AID557282Ratio of EC50 for HIV1 C harboring L10I/I15V/K20R/L24I/M36I/M46L/I54V/I62V/L63P/K70Q/V82A/L89M in protease encoding region to EC50 for HIV1 ERS104pre2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.
AID374600Antiviral activity against wild type HIV1 NL4-3 in HEK293 cells after 48 hrs by replication-deffective luciferase reporter gene-based phenotypic assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.
AID154271Inhibition of cytochrome P450 2D62002Bioorganic & medicinal chemistry letters, Sep-02, Volume: 12, Issue:17
Synthesis and activity of novel HIV protease inhibitors with improved potency against multiple PI-resistant viral strains.
AID9102Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog2002Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4
A combinatorial library of indinavir analogues and its in vitro and in vivo studies.
AID278964Antiviral activity against HIV1 A12 isolate with protease I84A mutation in HEK 293 cells relative to wild type2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Identification and structural characterization of I84C and I84A mutations that are associated with high-level resistance to human immunodeficiency virus protease inhibitors and impair viral replication.
AID322103Antiviral activity against ritonavir-resistant HIV1 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.
AID9351Oral bioavailability in dog (dose 10 mg/kg)2003Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15
HIV protease inhibitors with picomolar potency against PI-Resistant HIV-1 by extension of the P3 substituent.
AID553571Antiviral activity against HIV1 LAI infected in human MT2 cells after 7 days by MTT assay2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.
AID82746Fold increase in EC50 for antiviral activity against HIV Protease-Resistant strains with A protease amino acid substitutions2001Journal of medicinal chemistry, Jul-05, Volume: 44, Issue:14
4-Hydroxy-5,6-dihydropyrones as inhibitors of HIV protease: the effect of heterocyclic substituents at C-6 on antiviral potency and pharmacokinetic parameters.
AID105393Inhibition of the spread of HIV infection wild type(WT) in MT-4 human T-lymphoid cells2003Bioorganic & medicinal chemistry letters, May-19, Volume: 13, Issue:10
Design and synthesis of highly potent HIV protease inhibitors with activity against resistant virus.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID322111Antiviral activity against HIV1 GRL98065p40 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.
AID446205Selectivity ratio of IC50 for multidrug-resistant HIV1 isolate JSL to IC50 for wild type HIV1 isolate ERS104pre2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Design, synthesis, protein-ligand X-ray structure, and biological evaluation of a series of novel macrocyclic human immunodeficiency virus-1 protease inhibitors to combat drug resistance.
AID374623Resistance index, ratio of EC50 for HIV1 with protease 32I/46L/47V/84V mutation to EC50 for wild type HIV1 NL4-3 in HEK293 cells after 48 hrs by replication-deffective luciferase reporter gene-based phenotypic assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.
AID519793Antiviral activity against HIV 2 subtype B clinical isolate expressing 12T-14Y-19P-40N-41D-61N-62I-96S-99L protease gene sequence from HIV2 infected patient plasma and PBMC obtained before compound treatment measured after 13 months2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors.
AID279942AUC (0-8 hrs) in HIV1 infected pregnant woman during antepartum period at 800 mg three times/day2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Pharmacokinetics and safety of indinavir in human immunodeficiency virus-infected pregnant women.
AID519788Antiviral activity against HIV 2 subtype A clinical isolate expressing 10I-40D-43I-70K-82F-84V-85L-89V-90M-91T/L-98N/K protease gene sequence from HIV2 infected patient plasma and PBMC obtained at T1 during compound treatment measured after 13 months2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID257499Antiviral activity against mutant HIV isolate K-60C2005Bioorganic & medicinal chemistry letters, Dec-01, Volume: 15, Issue:23
Orally bioavailable highly potent HIV protease inhibitors against PI-resistant virus.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID374631Resistance index, ratio of EC50 for HIV1 with protease 46I/54V/82A/84V mutation to EC50 for wild type HIV1 NL4-3 in HEK293 cells after 48 hrs by replication-deffective luciferase reporter gene-based phenotypic assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.
AID589156Mechanism based inhibition of human cytochrome P450 3A4 measured by testosterone hydroxylation2005Current drug metabolism, Oct, Volume: 6, Issue:5
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID162186In vitro inhibitory concentration to prevent cleavage of a substrate by the protease enzyme2000Bioorganic & medicinal chemistry letters, Jul-17, Volume: 10, Issue:14
Combinatorial diversification of indinavir: in vivo mixture dosing of an HIV protease inhibitor library.
AID105166Antiviral activity of compound against spread of wild type V-18C virus infection in MT-4 human T-lymphoid cells2003Bioorganic & medicinal chemistry letters, Oct-06, Volume: 13, Issue:19
HIV-1 protease inhibitors with picomolar potency against PI-resistant HIV-1 by modification of the P1' substituent.
AID278974Antiviral activity against HIV1 C7 isolate with protease I84C mutation in HEK 293 cells relative to wild type2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Identification and structural characterization of I84C and I84A mutations that are associated with high-level resistance to human immunodeficiency virus protease inhibitors and impair viral replication.
AID161867Inhibitory activity against HIV-1 Protease from PI-resistant HIV-1 (strain K-60C)2003Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15
HIV protease inhibitors with picomolar potency against PI-Resistant HIV-1 by extension of the P3 substituent.
AID278960Antiviral activity against HIV1 A8 isolate with protease I84A mutation in HEK 293 cells relative to wild type2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Identification and structural characterization of I84C and I84A mutations that are associated with high-level resistance to human immunodeficiency virus protease inhibitors and impair viral replication.
AID1221962Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY3359792011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID374624Resistance index, ratio of EC50 for HIV1 with protease 33F/54L/82A/84V mutation to EC50 for wild type HIV1 NL4-3 in HEK293 cells after 48 hrs by replication-deffective luciferase reporter gene-based phenotypic assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.
AID278956Antiviral activity against HIV1 A4 isolate with protease I84A mutation in HEK 293 cells relative to wild type2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Identification and structural characterization of I84C and I84A mutations that are associated with high-level resistance to human immunodeficiency virus protease inhibitors and impair viral replication.
AID446203Selectivity ratio of IC50 for multidrug-resistant HIV1 isolate TM to IC50 for wild type HIV1 isolate ERS104pre2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Design, synthesis, protein-ligand X-ray structure, and biological evaluation of a series of novel macrocyclic human immunodeficiency virus-1 protease inhibitors to combat drug resistance.
AID372186Resistance index, ratio of EC50 for HIV1 with protease 54V/84V mutation to EC50 for wild type HIV1 NL4-3 in HEK293 cells after 48 hrs by replication-deffective luciferase reporter gene-based phenotypic assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.
AID105902Compound was tested in vitro for inhibition of spread of viral infection in MT-4 human T-lymphoid cells infected with the IIIb isolate2000Bioorganic & medicinal chemistry letters, Jul-17, Volume: 10, Issue:14
Combinatorial diversification of indinavir: in vivo mixture dosing of an HIV protease inhibitor library.
AID321662Antiviral activity against HIV1 3B in presence of 50% human serum2008Bioorganic & medicinal chemistry, Feb-01, Volume: 16, Issue:3
Structure-activity relationships of novel HIV-1 protease inhibitors containing the 3-amino-2-chlorobenzoyl-allophenylnorstatine structure.
AID278976Antiviral activity against HIV1 C9 isolate with protease I84C mutation in HEK 293 cells relative to wild type2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Identification and structural characterization of I84C and I84A mutations that are associated with high-level resistance to human immunodeficiency virus protease inhibitors and impair viral replication.
AID322108Antiviral activity against amprenavir-resistant HIV1 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.
AID237956Percentage of remaining compound after 30 min incubation in human liver microsomes was determined as metabolic stability2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor.
AID278975Antiviral activity against HIV1 C8 isolate with protease I84C mutation in HEK 293 cells relative to wild type2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Identification and structural characterization of I84C and I84A mutations that are associated with high-level resistance to human immunodeficiency virus protease inhibitors and impair viral replication.
AID575060Antiviral activity against Human immunodeficiency virus 1 harboring protease inhibitor resistance-associated mutations and protease L76V mutation in viral protease assessed as fold change in drug susceptibility relative to wild type2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Prevalence, mutation patterns, and effects on protease inhibitor susceptibility of the L76V mutation in HIV-1 protease.
AID322109Antiviral activity against HIV1 GRL98065p20 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.
AID583853Antiviral activity against HIV1 NL4-3 infected in human MT2 cells assessed as inhibition of virus-induced cell death at 0.05 multiplicities of infection after 6 days2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID269315Antiviral activity against multi drug-resistant HIV1 EV variant in human PHA-PBMC cells2006Journal of medicinal chemistry, Aug-24, Volume: 49, Issue:17
Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance.
AID278959Antiviral activity against HIV1 A7 isolate with protease I84A mutation in HEK 293 cells relative to wild type2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Identification and structural characterization of I84C and I84A mutations that are associated with high-level resistance to human immunodeficiency virus protease inhibitors and impair viral replication.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID321699Ratio of EC50 for HIV1 mutant strain 7 to EC50 for wild type HIV12008Bioorganic & medicinal chemistry, Feb-01, Volume: 16, Issue:3
Structure-activity relationships of novel HIV-1 protease inhibitors containing the 3-amino-2-chlorobenzoyl-allophenylnorstatine structure.
AID220216Inhibition of cytochrome P4502D6 at 1 uM2000Journal of medicinal chemistry, Mar-09, Volume: 43, Issue:5
5,6-Dihydropyran-2-ones possessing various sulfonyl functionalities: potent nonpeptidic inhibitors of HIV protease.
AID681154TP_TRANSPORTER: cell accumulation in KB-3-1 and KB-V1 cells2001The Journal of pharmacology and experimental therapeutics, Mar, Volume: 296, Issue:3
In vitro substrate identification studies for p-glycoprotein-mediated transport: species difference and predictability of in vivo results.
AID54579Inhibition of human liver microsome Cytochrome P450 2D62003Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15
The design, synthesis and evaluation of novel HIV-1 protease inhibitors with high potency against PI-resistant viral strains.
AID257500Antiviral activity against mutant HIV isolate V-18C2005Bioorganic & medicinal chemistry letters, Dec-01, Volume: 15, Issue:23
Orally bioavailable highly potent HIV protease inhibitors against PI-resistant virus.
AID1129361Unbound fraction in HEK293 cell homogenate at 0.1 uM by equilibrium dialysis based UPLC-MS/MS analysis2014Journal of medicinal chemistry, Apr-10, Volume: 57, Issue:7
A high-throughput cell-based method to predict the unbound drug fraction in the brain.
AID369953Antiviral activity against HIV2 ROD with protease V47A mutation infected in human CEM cells assessed as inhibition of virus production after 7 days by Lenti-RT activity assay2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir.
AID369942Antiviral activity against HIV2 CBL-23 infected in human PBMC assessed as inhibition of virus production after 5 days by Lenti-RT activity assay2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir.
AID557291Antiviral activity against HIV1 NL4-3 harboring L23I/K43I/M46I/I50L/G51A/A71V amino acid substitution in protease encoding region infected in human MT4 cells assessed as inhibition of p24 Gag protein production selected at 1 uM of atazanavir by ELISA2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.
AID239810Equilibrium dissociation constant for the interaction between the compound and serum albumin2005Journal of medicinal chemistry, May-19, Volume: 48, Issue:10
Early absorption and distribution analysis of antitumor and anti-AIDS drugs: lipid membrane and plasma protein interactions.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID557293Ratio of EC50 for HIV1 NL4-3 harboring L10I/G48V/I54V/L90M amino acid substitution in protease encoding region to EC50 for HIV1 NL4-32009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.
AID82748Fold increase in EC50 for antiviral activity against HIV Protease-Resistant strains with C protease amino acid substitutions2001Journal of medicinal chemistry, Jul-05, Volume: 44, Issue:14
4-Hydroxy-5,6-dihydropyrones as inhibitors of HIV protease: the effect of heterocyclic substituents at C-6 on antiviral potency and pharmacokinetic parameters.
AID210277Inhibition of HIV RNA synthesis in T-cell line1997Journal of medicinal chemistry, Dec-05, Volume: 40, Issue:25
Nonsymmetrically substituted cyclic urea HIV protease inhibitors.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID162213Inhibitory activity of compound against HIV-1 protease in HIV-1 (Q-60C) strain2003Bioorganic & medicinal chemistry letters, Oct-06, Volume: 13, Issue:19
HIV-1 protease inhibitors with picomolar potency against PI-resistant HIV-1 by modification of the P1' substituent.
AID343021Inhibition of HIV1 recombinant protease L10F/L19I/K20R/L33F/E35D/M36I/R41K/F53L/I54V/L63P/H69K/A71V/T74P/I84V/L89M/L90M/I93L mutant expressed in Escherichia coli by spectrophotometric assay2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Inorganic polyhedral metallacarborane inhibitors of HIV protease: a new approach to overcoming antiviral resistance.
AID374618Resistance index, ratio of EC50 for HIV1 with protease 33F/46I/84V/88D/90M mutation to EC50 for wild type HIV1 NL4-3 in HEK293 cells after 48 hrs by replication-deffective luciferase reporter gene-based phenotypic assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.
AID105389Concentration required to inhibit the spread of viral infection in MT-4 human T-lymphoid cells infected by the NL4-3 virus2002Bioorganic & medicinal chemistry letters, Sep-02, Volume: 12, Issue:17
Indinavir analogues with blocked metabolism sites as HIV protease inhibitors with improved pharmacological profiles and high potency against PI-resistant viral strains.
AID374611Resistance index, ratio of EC50 for HIV1 with protease 48V/54V/82A/90M mutation to EC50 for wild type HIV1 NL4-3 in HEK293 cells after 48 hrs by replication-deffective luciferase reporter gene-based phenotypic assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.
AID279344Antiviral activity against HIV2 isolate CBL20, CBL23, MVP15132 with 154M and L99F mutation in CBMCs2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors.
AID235096Resistance of constructed mutant 82F virus was calculated as (IC90 for a mutant virus / IC90 of wt HXB2 virus). 1997Journal of medicinal chemistry, Jan-17, Volume: 40, Issue:2
Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV.
AID375206Ratio of EC50 for multidrug-resistant HIV1 isolate C to EC50 for wild type HIV1 isolate ERS104pre2009Journal of medicinal chemistry, Jul-09, Volume: 52, Issue:13
Design of HIV-1 protease inhibitors with pyrrolidinones and oxazolidinones as novel P1'-ligands to enhance backbone-binding interactions with protease: synthesis, biological evaluation, and protein-ligand X-ray studies.
AID374604Resistance index, ratio of EC50 for HIV1 with protease 33F/54V/73S/82A/84V/90M mutation to EC50 for wild type HIV1 NL4-3 in HEK293 cells after 48 hrs by replication-deffective luciferase reporter gene-based phenotypic assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.
AID369952Antiviral activity against HIV2 ROD with protease G17N mutation infected in human CEM cells assessed as inhibition of virus production after 7 days by Lenti-RT activity assay2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir.
AID519606Antimicrobial activity against Plasmodium yoelii 265 liver infected in mammalian hepatocytes after 48 hrs2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
New active drugs against liver stages of Plasmodium predicted by molecular topology.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID322097Antiviral activity against HIV2 EHO in MT2 cells assessed as inhibition of p24 Gag protein expression by MTT assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.
AID557294Ratio of EC50 for HIV1 NL4-3 harboring L10F/V32I/M46I/I54M//A71V/I84V amino acid substitution in protease encoding region to EC50 for HIV1 NL4-32009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.
AID721748Inhibition of human MATE2K-mediated ASP+ uptake expressed in HEK293 cells up to 500 uM after 1.5 mins by fluorescence assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID279951Cmin in HIV1 infected pregnant woman during postpartum period at 800 mg three times/day2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Pharmacokinetics and safety of indinavir in human immunodeficiency virus-infected pregnant women.
AID160455Inhibition constant against HIV-1 Protease2002Journal of medicinal chemistry, Dec-05, Volume: 45, Issue:25
Relationships between structure and interaction kinetics for HIV-1 protease inhibitors.
AID162201Inhibitory activity against HIV-1 Protease2003Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15
The design, synthesis and evaluation of novel HIV-1 protease inhibitors with high potency against PI-resistant viral strains.
AID1660583Antiviral activity against HIV-1 assessed as reduction in viral replication at 0.1 uM2020Journal of natural products, 06-26, Volume: 83, Issue:6
Comatulins A-E, Taurine-Conjugated Anthraquinones from the Australian Crinoid
AID269311Antiviral activity against multi drug-resistant HIV1 B variant in human PHA-PBMC cells2006Journal of medicinal chemistry, Aug-24, Volume: 49, Issue:17
Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance.
AID105029Antiviral activity of compound against spread of wild type NL4-3 virus infection in MT-4 human T-lymphoid cells2003Bioorganic & medicinal chemistry letters, Oct-06, Volume: 13, Issue:19
HIV-1 protease inhibitors with picomolar potency against PI-resistant HIV-1 by modification of the P1' substituent.
AID321698Ratio of EC50 for HIV1 mutant strain 6 to EC50 for wild type HIV12008Bioorganic & medicinal chemistry, Feb-01, Volume: 16, Issue:3
Structure-activity relationships of novel HIV-1 protease inhibitors containing the 3-amino-2-chlorobenzoyl-allophenylnorstatine structure.
AID375204Ratio of EC50 for multidrug-resistant HIV1 isolate TM to EC50 for wild type HIV1 isolate ERS104pre2009Journal of medicinal chemistry, Jul-09, Volume: 52, Issue:13
Design of HIV-1 protease inhibitors with pyrrolidinones and oxazolidinones as novel P1'-ligands to enhance backbone-binding interactions with protease: synthesis, biological evaluation, and protein-ligand X-ray studies.
AID699541Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID519792Antiviral activity against HIV 2 subtype B clinical isolate expressing 14Y-19P-61N-64V-71I-90M-95I protease gene sequence from HIV2 infected patient plasma and PBMC obtained at T2 during compound treatment measured after 3 months2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors.
AID679665TP_TRANSPORTER: transepithelial transport (basal to apical) in MRP2-expressing MDCKII cells2002AIDS (London, England), Nov-22, Volume: 16, Issue:17
Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs.
AID372185Resistance index, ratio of EC50 for HIV1 with protease 46I/53L/82T/90M mutation to EC50 for wild type HIV1 NL4-3 in HEK293 cells after 48 hrs by replication-deffective luciferase reporter gene-based phenotypic assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.
AID105206Inhibitory concentration against accumulation of viral p24 antigen following infection of MT-4 cells1997Journal of medicinal chemistry, Jan-17, Volume: 40, Issue:2
Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV.
AID679318TP_TRANSPORTER: inhibition of TEA uptake (TEA: 10 uM) in OCT1-expressing HeLa cells2000Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 28, Issue:3
Interactions of HIV protease inhibitors with a human organic cation transporter in a mammalian expression system.
AID322099Cytotoxicity against human MT2 cells assessed as inhibition of p24 Gag protein expression by MTT assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.
AID343015Inhibition of HIV1 recombinant protease D30N/N88D mutant expressed in Escherichia coli by spectrophotometric assay2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Inorganic polyhedral metallacarborane inhibitors of HIV protease: a new approach to overcoming antiviral resistance.
AID519780Antiviral activity against HIV 2 subtype H expressing 10I-34E-40P-41Y-60H-63N-70T-73G-82F-89L-92E protease gene sequence from HIV2 infected patient plasma and PBMC obtained at T1 during compound treatment measured after 13 months2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors.
AID321685Antiviral activity against wild type HIV12008Bioorganic & medicinal chemistry, Feb-01, Volume: 16, Issue:3
Structure-activity relationships of novel HIV-1 protease inhibitors containing the 3-amino-2-chlorobenzoyl-allophenylnorstatine structure.
AID369954Antiviral activity against HIV2 ROD with protease G17N/V47A mutation infected in human CEM cells assessed as inhibition of virus production after 7 days by Lenti-RT activity assay2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir.
AID161870Inhibitory activity against HIV-1 Protease from PI-resistant HIV-1 (strain V-60C)2003Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15
HIV protease inhibitors with picomolar potency against PI-Resistant HIV-1 by extension of the P3 substituent.
AID391271Antiviral activity against multidrug-resistant HIV1/A with protease mutation in phytohemagglutininin-activated PBMC assessed as inhibition of p24G protein production2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Flexible cyclic ethers/polyethers as novel P2-ligands for HIV-1 protease inhibitors: design, synthesis, biological evaluation, and protein-ligand X-ray studies.
AID15489Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid2000Journal of medicinal chemistry, Sep-07, Volume: 43, Issue:18
Identification of MK-944a: a second clinical candidate from the hydroxylaminepentanamide isostere series of HIV protease inhibitors.
AID586625Antiviral activity against HIV1 harboring mutant protease with matrix K76R mutant infected in HEK293T cells assessed as inhibition of viral replication after 48 hrs by luciferase assay2011Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3
Three residues in HIV-1 matrix contribute to protease inhibitor susceptibility and replication capacity.
AID519573Antiviral activity against HIV1 P15 infected in human MT4 cells derived from viral passages with A-790742 harboring protease L33L/F, K45I, V82L, and I84V mutation assessed as reduction in viral cytopathogenicity treated 1 hr post infection measured 5 days2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Characterization of a novel human immunodeficiency virus type 1 protease inhibitor, A-790742.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID374593Cytotoxicity against human MT4 cells after 6 days by MTT assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.
AID321661Antiviral activity against HIV1 3B2008Bioorganic & medicinal chemistry, Feb-01, Volume: 16, Issue:3
Structure-activity relationships of novel HIV-1 protease inhibitors containing the 3-amino-2-chlorobenzoyl-allophenylnorstatine structure.
AID510361Inhibition of HIV1 integrase after 1 hr2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Tricyclononene carboxamide derivatives as novel anti-HIV-1 agents.
AID242318inhibitory concentration against HIV-1 protease from PI-resistant clinical isolate (V18)2004Bioorganic & medicinal chemistry letters, Sep-20, Volume: 14, Issue:18
P1' oxadiazole protease inhibitors with excellent activity against native and protease inhibitor-resistant HIV-1.
AID374615Resistance index, ratio of EC50 for HIV1 with protease 46I/47A/84V mutation to EC50 for wild type HIV1 NL4-3 in HEK293 cells after 48 hrs by replication-deffective luciferase reporter gene-based phenotypic assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.
AID105030Antiviral activity of compound against spread of wild type Q-60C virus infection in MT-4 human T-lymphoid cells2003Bioorganic & medicinal chemistry letters, Oct-06, Volume: 13, Issue:19
HIV-1 protease inhibitors with picomolar potency against PI-resistant HIV-1 by modification of the P1' substituent.
AID9125Bioavailability2002Bioorganic & medicinal chemistry letters, Sep-02, Volume: 12, Issue:17
Indinavir analogues with blocked metabolism sites as HIV protease inhibitors with improved pharmacological profiles and high potency against PI-resistant viral strains.
AID29722Tmax value of the compound2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
Protease inhibitors: current status and future prospects.
AID372181Resistance index, ratio of EC50 for HIV1 with protease 46I/50L/54V/82A mutation to EC50 for wild type HIV1 NL4-3 in HEK293 cells after 48 hrs by replication-deffective luciferase reporter gene-based phenotypic assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.
AID374613Resistance index, ratio of EC50 for non-B type HIV1 with protease 32I/47A mutation to EC50 for wild type HIV1 NL4-3 in HEK293 cells after 48 hrs by replication-deffective luciferase reporter gene-based phenotypic assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.
AID681610TP_TRANSPORTER: increase in brain concentration in mdr1a(-/-) mouse2001The Journal of pharmacology and experimental therapeutics, Mar, Volume: 296, Issue:3
In vitro substrate identification studies for p-glycoprotein-mediated transport: species difference and predictability of in vivo results.
AID54762In vitro inhibition of Cytochrome P450 3A42003Bioorganic & medicinal chemistry letters, Nov-17, Volume: 13, Issue:22
Novel HIV-1 protease inhibitors active against multiple PI-resistant viral strains: coadministration with indinavir.
AID1221965Transporter substrate index of efflux ratio in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY3359792011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1254739Inhibition of HIV1 protease assessed as cleavage of Lys-Ala-Arg-Val-Nle-NphGlu-Ala-Nle-NH22015Journal of medicinal chemistry, Nov-12, Volume: 58, Issue:21
Applications of Fluorine in Medicinal Chemistry.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID104958Viral spread inhibitory concentration against HIV-1 strain NL4-3 in MT-4 human T-lymphoid cells2003Bioorganic & medicinal chemistry letters, Nov-17, Volume: 13, Issue:22
Novel HIV-1 protease inhibitors active against multiple PI-resistant viral strains: coadministration with indinavir.
AID678713Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID519791Antiviral activity against HIV 2 subtype B clinical isolate expressing 14Y-19P-33I-61N-71I-75M-84V-90M protease gene sequence from HIV2 infected patient plasma and PBMC obtained at T1 during compound treatment measured after 13 months2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors.
AID680120TP_TRANSPORTER: transepithelial transport (basal to apical) in MDR1-expressing LLC-PK1 cells1998The Journal of clinical investigation, Jan-15, Volume: 101, Issue:2
The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.
AID152974Effective concentration required for antiviral activity against HIV-1 144-44 in PBMC cells2000Journal of medicinal chemistry, Mar-09, Volume: 43, Issue:5
5,6-Dihydropyran-2-ones possessing various sulfonyl functionalities: potent nonpeptidic inhibitors of HIV protease.
AID416864Inhibition of human MDR1-dependent accumulation of calcein-AM expressed in MDCK2 cells2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro.
AID162710Affinity against HIV protease1997Journal of medicinal chemistry, Dec-05, Volume: 40, Issue:25
Nonsymmetrically substituted cyclic urea HIV protease inhibitors.
AID260517Binding affinity to HIV1 protease I84V2006Journal of medicinal chemistry, Feb-23, Volume: 49, Issue:4
Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V, and L90M.
AID279947Cmax in HIV1 infected pregnant woman during postpartum period at 800 mg three times/day2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Pharmacokinetics and safety of indinavir in human immunodeficiency virus-infected pregnant women.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID557288Antiviral activity against HIV1 NL4-3 harboring L10F/D30N/K45I/A71V/T74S amino acid substitution in protease encoding region infected in human MT4 cells assessed as inhibition of p24 Gag protein production selected at 5 uM of nelfinavir by ELISA2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.
AID1193135Antimalarial activity against Plasmodium knowlesi infected Chinese rhesus macaques assessed as parasitemia level in blood smears at 40 mg/kg, intragastric treated 5 days before infection measured between day 0 to 7 by Giemsa-staining in presence of ritona2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Ritonavir-boosted indinavir but not lopinavir inhibits erythrocytic stage Plasmodium knowlesi malaria in rhesus macaques.
AID721746Inhibition of human MATE1-mediated [14]-metformin uptake expressed in polarized MDCK2 cells after 5 mins by liquid scintillation counting analysis2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID154273Inhibition of cytochrome P450 3A42002Bioorganic & medicinal chemistry letters, Sep-02, Volume: 12, Issue:17
Synthesis and activity of novel HIV protease inhibitors with improved potency against multiple PI-resistant viral strains.
AID105377Ability to inhibit spread of viral infection in MT-4 human T-lymphoidcell infected by PI-resistant HIV-1 (strain 4X Virus)2003Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15
The design, synthesis and evaluation of novel HIV-1 protease inhibitors with high potency against PI-resistant viral strains.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID162026Inhibition of HIV-1 protease1997Journal of medicinal chemistry, Aug-01, Volume: 40, Issue:16
An orally bioavailable pyrrolinone inhibitor of HIV-1 protease: computational analysis and X-ray crystal structure of the enzyme complex.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID82749Fold increase in EC50 for antiviral activity against HIV Protease-Resistant strains with D protease amino acid substitutions2001Journal of medicinal chemistry, Jul-05, Volume: 44, Issue:14
4-Hydroxy-5,6-dihydropyrones as inhibitors of HIV protease: the effect of heterocyclic substituents at C-6 on antiviral potency and pharmacokinetic parameters.
AID374633Resistance index, ratio of EC50 for HIV1 with protease 46I/82A/84V/90M mutation to EC50 for wild type HIV1 NL4-3 in HEK293 cells after 48 hrs by replication-deffective luciferase reporter gene-based phenotypic assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.
AID279952Protein binding in human plasma2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Pharmacokinetics and safety of indinavir in human immunodeficiency virus-infected pregnant women.
AID510359Inhibition of HIV1 recombinant protease2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Tricyclononene carboxamide derivatives as novel anti-HIV-1 agents.
AID249499Toxicity value against wild type HIV-1 IIIB was determined2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Design of HIV-1 protease inhibitors active on multidrug-resistant virus.
AID557300Ratio of EC50 for HIV1 NL4-3 harboring L10F/L33F/M46I/I47V/Q58E/V82I/I84V/I85V amino acid substitution in protease encoding region to EC50 for HIV1 NL4-32009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.
AID15498Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )2000Journal of medicinal chemistry, Sep-07, Volume: 43, Issue:18
Identification of MK-944a: a second clinical candidate from the hydroxylaminepentanamide isostere series of HIV protease inhibitors.
AID278970Antiviral activity against HIV1 C3 isolate with protease I84C mutation in HEK 293 cells relative to wild type2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Identification and structural characterization of I84C and I84A mutations that are associated with high-level resistance to human immunodeficiency virus protease inhibitors and impair viral replication.
AID1585151Antiviral activity against HIV1 NL4-3 infected in human MT4 cells after 7 days by MTT assay2018European journal of medicinal chemistry, Dec-05, Volume: 160Design, synthesis, and X-ray studies of potent HIV-1 protease inhibitors incorporating aminothiochromane and aminotetrahydronaphthalene carboxamide derivatives as the P2 ligands.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID540230Dose normalised AUC in rat after po administration2005Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
AID7372Tested for the half life period in dog2002Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4
A combinatorial library of indinavir analogues and its in vitro and in vivo studies.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID510360Inhibition of HIV1 reverse transcriptase after 1 hr by ELISA2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Tricyclononene carboxamide derivatives as novel anti-HIV-1 agents.
AID699539Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID152972Effective concentration required for antiviral activity against HIV-1 1002-60 in PBMC cells2000Journal of medicinal chemistry, Mar-09, Volume: 43, Issue:5
5,6-Dihydropyran-2-ones possessing various sulfonyl functionalities: potent nonpeptidic inhibitors of HIV protease.
AID1182732Inhibition of HIV1 protease2014Journal of medicinal chemistry, Jul-24, Volume: 57, Issue:14
Structural basis for HTLV-1 protease inhibition by the HIV-1 protease inhibitor indinavir.
AID553575Antiviral activity against HIV1 MOKW infected in human PHA-PBC assessed as inhibition of p24 Gag protein production by ELISA2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.
AID246965Effective dose of compound required to inhibit replication of human immunodeficiency virus type 1 in MT-4 cells2004Journal of medicinal chemistry, Nov-18, Volume: 47, Issue:24
Improved structure-activity relationship analysis of HIV-1 protease inhibitors using interaction kinetic data.
AID557283Ratio of EC50 for HIV1 G harboring L10I/V11I/T12E/I15V/L19I/R41K/M46L/L63P/A71T/V82A/L90M in protease encoding region to EC50 for HIV1 ERS104pre2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.
AID279946Cmax in HIV1 infected pregnant woman during antepartum period at 800 mg three times/day2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Pharmacokinetics and safety of indinavir in human immunodeficiency virus-infected pregnant women.
AID519790Antiviral activity against HIV 2 subtype B clinical isolate expressing 14Y-61N-99L protease gene sequence from HIV2 infected patient plasma and PBMC obtained before compound treatment measured after 13 months2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors.
AID263207Antiviral activity against HIV1 HXB2 in MT4 cells2006Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7
Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID446199Antiviral activity against multidrug-resistant HIV1 isolate JSL infected in PHA-stimulated human PBMC assessed as inhibition of p24 gap protein production2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Design, synthesis, protein-ligand X-ray structure, and biological evaluation of a series of novel macrocyclic human immunodeficiency virus-1 protease inhibitors to combat drug resistance.
AID9733Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog2002Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4
A combinatorial library of indinavir analogues and its in vitro and in vivo studies.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1393284Inhibition of recombinant HIV protease expressed in inclusion bodies of Escherichia coli BL21 (DE3)2018Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9
Quest for Novel Chemical Entities through Incorporation of Silicon in Drug Scaffolds.
AID237358Partition coefficient in octanol/water2005Bioorganic & medicinal chemistry letters, Aug-15, Volume: 15, Issue:16
Hydrophobicity in the design of P2/P2' tetrahydropyrimidinone HIV protease inhibitors.
AID28084Cmax value at the period of 800 mg po for every 8 hr.2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
Protease inhibitors: current status and future prospects.
AID279948Tmax in HIV1 infected pregnant woman during antepartum period at 800 mg three times/day2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Pharmacokinetics and safety of indinavir in human immunodeficiency virus-infected pregnant women.
AID575064Antiviral activity against Human immunodeficiency virus 1 harboring M46I and L76V mutations in viral protease assessed as fold change in drug susceptibility relative to wild type2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Prevalence, mutation patterns, and effects on protease inhibitor susceptibility of the L76V mutation in HIV-1 protease.
AID322098Antiviral activity against HIV2 ROD in MT2 cells assessed as inhibition of p24 Gag protein expression by MTT assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.
AID279343Antiviral activity against HIV2 isolate CBL20, CBL23, MVP15132 with 154M and 184V mutation in CBMCs2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors.
AID322119Antiviral activity against HIV1 92UG029 X4 subtype A in phytohemagglutininin-activated PBMCs assessed as inhibition of p24 Gag protein expression by MTT assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.
AID235097Resistance of constructed mutant 84V virus was calculated as (IC90 for a mutant virus / IC90 of wt HXB2 virus). 1997Journal of medicinal chemistry, Jan-17, Volume: 40, Issue:2
Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV.
AID232360Ratio of CIC95 to IC50 values1997Journal of medicinal chemistry, Aug-01, Volume: 40, Issue:16
An orally bioavailable pyrrolinone inhibitor of HIV-1 protease: computational analysis and X-ray crystal structure of the enzyme complex.
AID257496Inhibitory activity against HIV protease2005Bioorganic & medicinal chemistry letters, Dec-01, Volume: 15, Issue:23
Orally bioavailable highly potent HIV protease inhibitors against PI-resistant virus.
AID519782Antiviral activity against HIV 2 subtype A clinical isolate expressing 5L/F-14Y/H-17G/D-43T-54I/M-62V/A-70R/K-71I protease gene sequence from HIV2 infected patient plasma and PBMC obtained at T1 during compound treatment measured after 13 months2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors.
AID372188Resistance index, ratio of EC50 for HIV1 with protease 46L mutation to EC50 for wild type HIV1 NL4-3 in HEK293 cells after 48 hrs by replication-deffective luciferase reporter gene-based phenotypic assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.
AID279348Antiviral activity against HIV1 isolate 5512 with M36I/M and V82T mutation in CBMCs2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors.
AID162706Equilibrium constant for the interaction between inhibitor and HIV-1 Protease2002Journal of medicinal chemistry, Dec-05, Volume: 45, Issue:25
Relationships between structure and interaction kinetics for HIV-1 protease inhibitors.
AID519577Antiviral activity against HIV1 clone2 infected in HEK293 cells harboring A-790742-selected protease V82L mutation assessed as reduction in viral replication by luciferase reporter gene assay relative to wild type HIV1 pNL4-32008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Characterization of a novel human immunodeficiency virus type 1 protease inhibitor, A-790742.
AID557280Ratio of EC50 for HIV1 A harboring L10I/I15V/E35D/N37E/K45R/I54V/L63P/A71V/V82T/L90M/I93L/C95F in protease encoding region to EC50 for HIV1 ERS104pre2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID8760Cmax was determine after peroral administration at 10 mpk in dog2003Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15
HIV protease inhibitors with picomolar potency against PI-Resistant HIV-1 by extension of the P3 substituent.
AID246160Protease inhibitory activity against wild type HIV-1 IIIB was determined2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Design of HIV-1 protease inhibitors active on multidrug-resistant virus.
AID374637Resistance index, ratio of EC50 for HIV1 with protease 46L/48V/82A/84V mutation to EC50 for wild type HIV1 NL4-3 in HEK293 cells after 48 hrs by replication-deffective luciferase reporter gene-based phenotypic assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.
AID519786Antiviral activity against HIV 2 subtype A clinical isolate expressing 10I-17D-40D-43I-45K/R-46V-54M-64I/V-69K/R-71V/I-90M protease gene sequence from HIV2 infected patient plasma and PBMC obtained at T1 during compound treatment measured after 13 months2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors.
AID446194Antiviral activity against multidrug-resistant HIV1 isolate B infected in PHA-stimulated human PBMC assessed as inhibition of p24 gap protein production2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Design, synthesis, protein-ligand X-ray structure, and biological evaluation of a series of novel macrocyclic human immunodeficiency virus-1 protease inhibitors to combat drug resistance.
AID225564Dissociation constant obtained by inhibition of mutant HIV-protease (V-18)2000Journal of medicinal chemistry, Sep-07, Volume: 43, Issue:18
Identification of MK-944a: a second clinical candidate from the hydroxylaminepentanamide isostere series of HIV protease inhibitors.
AID278977Antiviral activity against HIV1 C10 isolate with protease I84C mutation in HEK 293 cells relative to wild type2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Identification and structural characterization of I84C and I84A mutations that are associated with high-level resistance to human immunodeficiency virus protease inhibitors and impair viral replication.
AID160477Inhibitory activity against HIV-1 protease2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Reduction of peptide character of HIV protease inhibitors that exhibit nanomolar potency against multidrug resistant HIV-1 strains.
AID540233Dose normalised AUC in human after po administration2005Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
AID322107Antiviral activity against lopinavir-resistant HIV1 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.
AID105172Compound was tested for their ability to inhibit spread of PI-resistant HIV-1 (strain Q-18C) viral infection in MT-4 human T-lymphoidcell2003Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15
HIV protease inhibitors with picomolar potency against PI-Resistant HIV-1 by extension of the P3 substituent.
AID161871Inhibitory activity against HIV-1 Protease from wild-type NL4-3 virus2003Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15
HIV protease inhibitors with picomolar potency against PI-Resistant HIV-1 by extension of the P3 substituent.
AID372191Resistance index, ratio of EC50 for HIV1 with protease 46I/50V/90M mutation to EC50 for wild type HIV1 NL4-3 in HEK293 cells after 48 hrs by replication-deffective luciferase reporter gene-based phenotypic assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.
AID575059Antiviral activity against Human immunodeficiency virus 1 harboring protease inhibitor resistance-associated mutations assessed as fold change in drug susceptibility relative to wild type2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Prevalence, mutation patterns, and effects on protease inhibitor susceptibility of the L76V mutation in HIV-1 protease.
AID343016Inhibition of HIV1 recombinant protease M46I/A71V/V82T/I84V mutant expressed in Escherichia coli by spectrophotometric assay2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Inorganic polyhedral metallacarborane inhibitors of HIV protease: a new approach to overcoming antiviral resistance.
AID374630Resistance index, ratio of EC50 for HIV1 with protease 46L/54V/82A/90M mutation to EC50 for wild type HIV1 NL4-3 in HEK293 cells after 48 hrs by replication-deffective luciferase reporter gene-based phenotypic assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.
AID321687Antiviral activity against HIV1 mutant strain 22008Bioorganic & medicinal chemistry, Feb-01, Volume: 16, Issue:3
Structure-activity relationships of novel HIV-1 protease inhibitors containing the 3-amino-2-chlorobenzoyl-allophenylnorstatine structure.
AID8152Area under curve was determined2002Bioorganic & medicinal chemistry letters, Sep-02, Volume: 12, Issue:17
Indinavir analogues with blocked metabolism sites as HIV protease inhibitors with improved pharmacological profiles and high potency against PI-resistant viral strains.
AID678717Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID721751Inhibition of human OCT2-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID152973Effective concentration required for antiviral activity against HIV-1 1026-60 in PBMC cells2000Journal of medicinal chemistry, Mar-09, Volume: 43, Issue:5
5,6-Dihydropyran-2-ones possessing various sulfonyl functionalities: potent nonpeptidic inhibitors of HIV protease.
AID104960Viral spread inhibitory concentration against HIV-1 strain V-18C in MT-4 human T-lymphoid cells2003Bioorganic & medicinal chemistry letters, Nov-17, Volume: 13, Issue:22
Novel HIV-1 protease inhibitors active against multiple PI-resistant viral strains: coadministration with indinavir.
AID162066Evaluated for the inhibition of Protease2000Journal of medicinal chemistry, Sep-07, Volume: 43, Issue:18
Identification of MK-944a: a second clinical candidate from the hydroxylaminepentanamide isostere series of HIV protease inhibitors.
AID278985Resistance to HIV1 with protease 46I, 54M/V and I84A mutation in HEK 293 relative to similar background2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Identification and structural characterization of I84C and I84A mutations that are associated with high-level resistance to human immunodeficiency virus protease inhibitors and impair viral replication.
AID322120Antiviral activity against HIV1 92UG037 subtype A R5 in phytohemagglutininin-activated PBMCs assessed as inhibition of p24 Gag protein expression by MTT assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.
AID248546Inhibitory concentration against wild type Human immuno deficiency virus (HXB2) was determined in an MT-4 cell line2005Bioorganic & medicinal chemistry letters, Aug-01, Volume: 15, Issue:15
Novel P1 chain-extended HIV protease inhibitors possessing potent anti-HIV activity and remarkable inverse antiviral resistance profiles.
AID1636356Drug activation in human Hep3B cells assessed as human CYP2C9-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID246195Protease inhibitory activity against HIV-1 r13363 mutant strain was determined2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Design of HIV-1 protease inhibitors active on multidrug-resistant virus.
AID564044Antiviral activity against multidrug-resistant HIV1 isolate C containing protease L10I, I15V, K20R, L24I, M36I, M46L, I54V, I62V, L63P, K70Q, V82A, and L89M mutant infected in human PHA-PBMC cells by MTT assay2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Novel protease inhibitors (PIs) containing macrocyclic components and 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane that are potent against multi-PI-resistant HIV-1 variants in vitro.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID278973Antiviral activity against HIV1 C6 isolate with protease I84C mutation in HEK 293 cells relative to wild type2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Identification and structural characterization of I84C and I84A mutations that are associated with high-level resistance to human immunodeficiency virus protease inhibitors and impair viral replication.
AID239819Association rate constant for human immunodeficiency virus type 1 protease2004Journal of medicinal chemistry, Nov-18, Volume: 47, Issue:24
Improved structure-activity relationship analysis of HIV-1 protease inhibitors using interaction kinetic data.
AID721743Ratio of Cmax unbound to IC50 for human MATE1-mediated [14]-metformin uptake expressed in HEK293 cells2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID322104Antiviral activity against idinavir-resistant HIV1 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID278958Antiviral activity against HIV1 A6 isolate with protease I84A mutation in HEK 293 cells relative to wild type2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Identification and structural characterization of I84C and I84A mutations that are associated with high-level resistance to human immunodeficiency virus protease inhibitors and impair viral replication.
AID161883Cellular antiviral activity against HIV-1 Protease1997Journal of medicinal chemistry, Aug-01, Volume: 40, Issue:16
An orally bioavailable pyrrolinone inhibitor of HIV-1 protease: computational analysis and X-ray crystal structure of the enzyme complex.
AID260391Antiviral activity in cells infected with wild-type HIV12006Bioorganic & medicinal chemistry letters, Feb-15, Volume: 16, Issue:4
Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors possessing augmented P2' side chains.
AID369944Ratio of EC50 for HIV2 MS to EC50 for HIV1 NL4-3 infected in human MT4 cells2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir.
AID404304Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
AID278969Antiviral activity against HIV1 C2 isolate with protease I84C mutation in HEK 293 cells relative to wild type2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Identification and structural characterization of I84C and I84A mutations that are associated with high-level resistance to human immunodeficiency virus protease inhibitors and impair viral replication.
AID279340Antiviral activity against HIV2 isolate CBL20, CBL23, MVP15132 with 150V mutation in CBMCs2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors.
AID557296Ratio of EC50 for HIV1 NL4-3 harboring L10F/D30N/K45I/A71V/T74S amino acid substitution in protease encoding region to EC50 for HIV1 NL4-32009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.
AID152979Tested for cytotoxic activity against HIV-1 1002-60 in PBMC cells2000Journal of medicinal chemistry, Mar-09, Volume: 43, Issue:5
5,6-Dihydropyran-2-ones possessing various sulfonyl functionalities: potent nonpeptidic inhibitors of HIV protease.
AID678722Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID278980Resistance to HIV1 with protease 46M, 54I and I84C mutation in HEK 293 cells relative to similar background2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Identification and structural characterization of I84C and I84A mutations that are associated with high-level resistance to human immunodeficiency virus protease inhibitors and impair viral replication.
AID557279Ratio of EC50 for HIV1 JSL harboring L10I/L24I/L33F/E35D/M36I/N37S/M46L/I54V/R57K/I62V/L63P/A71V/G73S/82A in protease encoding region to EC50 for HIV1 ERS104pre2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.
AID162187In vitro inhibitory activity against mutant HIV-1 (A-44)protease2002Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4
A combinatorial library of indinavir analogues and its in vitro and in vivo studies.
AID322105Antiviral activity against nelfinavir-resistant HIV1 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.
AID374627Resistance index, ratio of EC50 for HIV1 with protease 33F/54V/82T/84V/90M mutation to EC50 for wild type HIV1 NL4-3 in HEK293 cells after 48 hrs by replication-deffective luciferase reporter gene-based phenotypic assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.
AID374626Resistance index, ratio of EC50 for HIV1 with protease 33F/46I/53L/82A/84V mutation to EC50 for wild type HIV1 NL4-3 in HEK293 cells after 48 hrs by replication-deffective luciferase reporter gene-based phenotypic assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.
AID396259Antiviral activity against HIV1 drug resistant mutant isolates from protease inhibitor treated HIV patient2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV.
AID446198Antiviral activity against multidrug-resistant HIV1 isolate MM infected in PHA-stimulated human PBMC assessed as inhibition of p24 gap protein production2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Design, synthesis, protein-ligand X-ray structure, and biological evaluation of a series of novel macrocyclic human immunodeficiency virus-1 protease inhibitors to combat drug resistance.
AID321691Antiviral activity against HIV1 mutant strain 62008Bioorganic & medicinal chemistry, Feb-01, Volume: 16, Issue:3
Structure-activity relationships of novel HIV-1 protease inhibitors containing the 3-amino-2-chlorobenzoyl-allophenylnorstatine structure.
AID248545Inhibitory concentration against wild type Human immuno deficiency virus (EP13) was determined in an MT-4 cell line2005Bioorganic & medicinal chemistry letters, Aug-01, Volume: 15, Issue:15
Novel P1 chain-extended HIV protease inhibitors possessing potent anti-HIV activity and remarkable inverse antiviral resistance profiles.
AID369941Antiviral activity against HIV2 MS infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir.
AID586624Antiviral activity against HIV1 harboring wild type 8.9NSX with mutant amino acid 116 insertion infected in HEK293T cells assessed as inhibition of viral replication after 48 hrs by luciferase assay2011Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3
Three residues in HIV-1 matrix contribute to protease inhibitor susceptibility and replication capacity.
AID519785Antiviral activity against HIV 2 subtype A clinical isolate expressing 10I-17D-40D-43I-46V-66V/A-70R/K protease gene sequence from HIV2 infected patient plasma and PBMC obtained before compound treatment measured after 13 months2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors.
AID81078Potency against PI-resistant viral isolate construct HIV Q-60C2002Bioorganic & medicinal chemistry letters, Sep-02, Volume: 12, Issue:17
Synthesis and activity of novel HIV protease inhibitors with improved potency against multiple PI-resistant viral strains.
AID673196Binding affinity to Human immunodeficiency virus 1 protease by SPR biosensor interaction analysis at pH 7.42012Bioorganic & medicinal chemistry, Aug-01, Volume: 20, Issue:15
Experimental and 'in silico' analysis of the effect of pH on HIV-1 protease inhibitor affinity: implications for the charge state of the protein ionogenic groups.
AID553577Antiviral activity against HIV1 MM harboring L10I/K43T/M46L/I54V/L63P/A71V/V82A/L90M/Q92K in protease encoding region infected in human PHA-PBC assessed as inhibition of p24 Gag protein production by ELISA2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.
AID161524Inhibition of HIV-1 Protease activity2004Bioorganic & medicinal chemistry letters, Feb-23, Volume: 14, Issue:4
Novel arylsulfonamides possessing sub-picomolar HIV protease activities and potent anti-HIV activity against wild-type and drug-resistant viral strains.
AID417020Effect on tenofovir disoproxil fumarate metabolism in ritonavir booster drug treated healthy human assessed as change in plasma AUC of tenofovir at 800 mg, po, TID co-administered with 300 mg once daily dose of tenofovir disoproxil fumarate2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro.
AID369945Ratio of EC50 for HIV2 CBL-23 infected in human PBMC to EC50 for HIV1 NL4-3 infected in human MT4 cells2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir.
AID679341TP_TRANSPORTER: increase in brain concentration in mdr1a(-/-) mouse1998The Journal of clinical investigation, Jan-15, Volume: 101, Issue:2
The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.
AID1474060Drug concentration at steady state in human at 800 mg, po TID after 8 hrs2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID278981Resistance to HIV1 with protease 46I, 54I and I84V mutation in HEK 293 cells relative to similar background2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Identification and structural characterization of I84C and I84A mutations that are associated with high-level resistance to human immunodeficiency virus protease inhibitors and impair viral replication.
AID269316Antiviral activity against multi drug-resistant HIV1 ES variant in human PHA-PBMC cells2006Journal of medicinal chemistry, Aug-24, Volume: 49, Issue:17
Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance.
AID374605Resistance index, ratio of EC50 for HIV1 with protease 33F/46L/54V/82A/84V/90M mutation to EC50 for wild type HIV1 NL4-3 in HEK293 cells after 48 hrs by replication-deffective luciferase reporter gene-based phenotypic assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.
AID279347Antiviral activity against HIV1 isolate 5512 with D30N, M461 and V771 mutation in CBMCs2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors.
AID322100Selectivity index, ratio of CC50 for MT2 cells to EC50 for HIV1 LAI2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.
AID415397Inhibition of HIV1 protease assessed as decrease in UV absorbance at 10 uM2009Bioorganic & medicinal chemistry, Apr-15, Volume: 17, Issue:8
Discovery of dual inhibitors targeting both HIV-1 capsid and human cyclophilin A to inhibit the assembly and uncoating of the viral capsid.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID721747Inhibition of human MATE1-mediated [14]-metformin uptake expressed in HEK293 cells after 1.5 mins by scintillation counting analysis2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID322102Antiviral activity against saquinavir-resistant HIV1 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.
AID1221958Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID242869Association rate constant for the interaction between the compound and serum albumin2005Journal of medicinal chemistry, May-19, Volume: 48, Issue:10
Early absorption and distribution analysis of antitumor and anti-AIDS drugs: lipid membrane and plasma protein interactions.
AID624623Apparent permeability (Papp) from basolateral to apical side determined in MDR1-MDCKII cells2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID162355Inhibitory activity against HIV-1 protease (V-18C strain)2003Bioorganic & medicinal chemistry letters, Nov-17, Volume: 13, Issue:22
Novel HIV-1 protease inhibitors active against multiple PI-resistant viral strains: coadministration with indinavir.
AID269306Antiviral activity against HIV1 BA-L isolate in human PHA-PBMC cells2006Journal of medicinal chemistry, Aug-24, Volume: 49, Issue:17
Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance.
AID374608Resistance index, ratio of EC50 for HIV1 with protease 33I/46I/84V/88D/90M mutation to EC50 for wild type HIV1 NL4-3 in HEK293 cells after 48 hrs by replication-deffective luciferase reporter gene-based phenotypic assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.
AID260402Antiviral activity in cells infected with wild-type HIV1 1026-60C mutant in presence of NHS2006Bioorganic & medicinal chemistry letters, Feb-15, Volume: 16, Issue:4
Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors possessing augmented P2' side chains.
AID162211Inhibitory activity of compound against HIV-1 protease in HIV-1 (K-60C) strain2003Bioorganic & medicinal chemistry letters, Oct-06, Volume: 13, Issue:19
HIV-1 protease inhibitors with picomolar potency against PI-resistant HIV-1 by modification of the P1' substituent.
AID343019Inhibition of HIV1 recombinant protease L10I/I15V/E35D/N37S/R41K/I62V/L63P/A71V/G73S/L90M mutant expressed in Escherichia coli by spectrophotometric assay2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Inorganic polyhedral metallacarborane inhibitors of HIV protease: a new approach to overcoming antiviral resistance.
AID557274Antiviral activity against HIV1 B harboring L10I/I15V/E35D/N37E/K45R/I54V/L63P/A71V/V82T/L90M/I93L/C95F in protease encoding region infected in human PHA-PBC assessed as inhibition of p24 Gag protein production by ELISA2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.
AID279945Oral clearance in HIV1 infected pregnant woman during postpartum period at 800 mg three times/day2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Pharmacokinetics and safety of indinavir in human immunodeficiency virus-infected pregnant women.
AID374639Resistance index, ratio of EC50 for HIV1 with protease 46L/50L/54V/82A mutation to EC50 for wild type HIV1 NL4-3 in HEK293 cells after 48 hrs by replication-deffective luciferase reporter gene-based phenotypic assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.
AID446193Antiviral activity against wild type HIV1 isolate ERS104pre infected in PHA-stimulated human PBMC assessed as inhibition of p24 gap protein production2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Design, synthesis, protein-ligand X-ray structure, and biological evaluation of a series of novel macrocyclic human immunodeficiency virus-1 protease inhibitors to combat drug resistance.
AID260395Antiviral activity in cells infected with wild-type HIV1 1002-60C mutant2006Bioorganic & medicinal chemistry letters, Feb-15, Volume: 16, Issue:4
Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors possessing augmented P2' side chains.
AID260398Antiviral activity in cells infected with wild-type HIV1 H93B in presence of NHS2006Bioorganic & medicinal chemistry letters, Feb-15, Volume: 16, Issue:4
Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors possessing augmented P2' side chains.
AID519784Antiviral activity against HIV 2 subtype A clinical isolate expressing 54M-65E-71I-74N-90M protease gene sequence from HIV2 infected patient plasma and PBMC obtained at T1 during compound treatment measured after 13 months2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors.
AID160766Dissociation rate constant for the interaction between inhibitor and HIV-1 protease2002Journal of medicinal chemistry, Dec-05, Volume: 45, Issue:25
Relationships between structure and interaction kinetics for HIV-1 protease inhibitors.
AID199077Inhibition of virion associated RT activity relative to untreated, infected control in MT2 cells infected with HIV-1 237288 strain2000Journal of medicinal chemistry, Sep-21, Volume: 43, Issue:19
Synthesis, stability, antiviral activity, and protease-bound structures of substrate-mimicking constrained macrocyclic inhibitors of HIV-1 protease.
AID309180Inhibition of HIV1 NL4-3 protease K60C mutant2007Bioorganic & medicinal chemistry letters, Oct-01, Volume: 17, Issue:19
Synthesis of novel HIV protease inhibitors (PI) with activity against PI-resistant virus.
AID721740Selectivity ratio of IC50 for human OCT2-mediated ASP+ uptake expressed in HEK293 cells to IC50 for human MATE1-mediated ASP+ uptake expressed in HEK293 cells2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID105174Compound was tested for their ability to inhibit spread of wild-type NL4-3 viral infection in MT-4 human T-lymphoidcell2003Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15
HIV protease inhibitors with picomolar potency against PI-Resistant HIV-1 by extension of the P3 substituent.
AID396260Antiviral activity against HIV1 NL4-32007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV.
AID521549Antiviral activity against HIV 2 subtype H expressing 10I-40P-41Y-60H-63N-70T-73G-89L-92E protease gene sequence from HIV2 infected patient plasma and PBMC obtained before compound treatment measured after 13 months2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors.
AID21133Solubility (pH 7.4 in micro g/ml)2000Journal of medicinal chemistry, Sep-07, Volume: 43, Issue:18
Identification of MK-944a: a second clinical candidate from the hydroxylaminepentanamide isostere series of HIV protease inhibitors.
AID81074Concentration required to control the spread of HIV mutant strain V-18C2002Bioorganic & medicinal chemistry letters, Sep-02, Volume: 12, Issue:17
Indinavir analogues with blocked metabolism sites as HIV protease inhibitors with improved pharmacological profiles and high potency against PI-resistant viral strains.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID260401Antiviral activity in cells infected with wild-type HIV1 4X mutant in presence of NHS2006Bioorganic & medicinal chemistry letters, Feb-15, Volume: 16, Issue:4
Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors possessing augmented P2' side chains.
AID279338Antiviral activity against HIV2 isolate CBL20, CBL23, MVP15132 with 182F mutation in CBMCs2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors.
AID557277Ratio of EC50 for HIV1 TM harboring L10I/K14R/R41K/M46L/I54V/L63P/A71V/V82A/L90M/I93L in protease encoding region to EC50 for HIV1 ERS104pre2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.
AID1443991Induction of mitochondrial dysfunction in Sprague-Dawley rat liver mitochondria assessed as inhibition of mitochondrial respiration per mg mitochondrial protein measured for 20 mins by A65N-1 oxygen probe based fluorescence assay2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID372187Resistance index, ratio of EC50 for HIV1 with protease 54V/82A mutation to EC50 for wild type HIV1 NL4-3 in HEK293 cells after 48 hrs by replication-deffective luciferase reporter gene-based phenotypic assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.
AID678840TP_TRANSPORTER: Western blot, LS-180V2000AIDS (London, England), Jun-16, Volume: 14, Issue:9
Induction of P-glycoprotein expression by HIV protease inhibitors in cell culture.
AID321693Ratio of EC50 for HIV1 mutant strain 1 to EC50 for wild type HIV12008Bioorganic & medicinal chemistry, Feb-01, Volume: 16, Issue:3
Structure-activity relationships of novel HIV-1 protease inhibitors containing the 3-amino-2-chlorobenzoyl-allophenylnorstatine structure.
AID162195Inhibition of wild type HIV protease2003Bioorganic & medicinal chemistry letters, May-19, Volume: 13, Issue:10
Design and synthesis of highly potent HIV protease inhibitors with activity against resistant virus.
AID278966Antiviral activity against HIV1 A14 isolate with protease I84A mutation in HEK 293 cells relative to wild type2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Identification and structural characterization of I84C and I84A mutations that are associated with high-level resistance to human immunodeficiency virus protease inhibitors and impair viral replication.
AID557278Ratio of EC50 for HIV1 MM harboring L10I/K43T/M46L/I54V/L63P/A71V/V82A/L90M/Q92K in protease encoding region infected to EC50 for HIV1 ERS104pre2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.
AID372183Resistance index, ratio of EC50 for HIV1 with protease 37S/41K/70E mutation to EC50 for wild type HIV1 NL4-3 in HEK293 cells after 48 hrs by replication-deffective luciferase reporter gene-based phenotypic assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.
AID235094Resistance of constructed mutant 48V/90M virus was calculated as (IC90 for a mutant virus / IC90 of wt HXB2 virus)1997Journal of medicinal chemistry, Jan-17, Volume: 40, Issue:2
Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV.
AID374612Resistance index, ratio of EC50 for HIV1 with protease 30N/88D/90M mutation to EC50 for wild type HIV1 NL4-3 in HEK293 cells after 48 hrs by replication-deffective luciferase reporter gene-based phenotypic assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.
AID519572Antiviral activity against HIV1 P9 infected in human MT4 cells derived from viral passages with A-790742 harboring protease V82V/L and I84V mutation assessed as reduction in viral cytopathogenicity treated 1 hr post infection measured 5 days post infectio2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Characterization of a novel human immunodeficiency virus type 1 protease inhibitor, A-790742.
AID322121Antiviral activity against HIV1 BaL R5 subtype B in phytohemagglutininin-activated PBMCs assessed as inhibition of p24 Gag protein expression by MTT assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.
AID680015TP_TRANSPORTER: inhibition of Fexofenadine uptake (Fexofenadine: 2 uM, Indinavir: 100 uM) in Xenopus laevis oocytes1999Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 27, Issue:8
OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1474059AUC in human at 800 mg, po TID after 8 hrs2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID162188In vitro inhibitory activity against wild type HIV-1 protease2002Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4
A combinatorial library of indinavir analogues and its in vitro and in vivo studies.
AID260397Antiviral activity in cells infected with wild-type HIV1 1026-60C mutant2006Bioorganic & medicinal chemistry letters, Feb-15, Volume: 16, Issue:4
Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors possessing augmented P2' side chains.
AID162036Evaluated for the inhibition of HIV protease1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor.
AID322106Antiviral activity against atazanavir-resistant HIV1 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.
AID278963Antiviral activity against HIV1 A11 isolate with protease I84A mutation in HEK 293 cells relative to wild type2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Identification and structural characterization of I84C and I84A mutations that are associated with high-level resistance to human immunodeficiency virus protease inhibitors and impair viral replication.
AID1221964Transporter substrate index ratio of permeability from basolateral to apical side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY3359792011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID162352In vitro inhibition of HIV-1 protease (NL4-3 strain).2003Bioorganic & medicinal chemistry letters, Nov-17, Volume: 13, Issue:22
Novel HIV-1 protease inhibitors active against multiple PI-resistant viral strains: coadministration with indinavir.
AID8150Area under curve was determine after peroral administration at 10 mpk in dog2003Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15
HIV protease inhibitors with picomolar potency against PI-Resistant HIV-1 by extension of the P3 substituent.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID242866Dissociation rate constant for human immunodeficiency virus type 1 protease2004Journal of medicinal chemistry, Nov-18, Volume: 47, Issue:24
Improved structure-activity relationship analysis of HIV-1 protease inhibitors using interaction kinetic data.
AID564046Antiviral activity against multidrug-resistant HIV1 isolate TM containing L10I, K14R, R41K, M46L, I54V, L63P, A71V, V82A, L90M, and I93L mutant infected in human PHA-PBMC cells by MTT assay2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Novel protease inhibitors (PIs) containing macrocyclic components and 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane that are potent against multi-PI-resistant HIV-1 variants in vitro.
AID321338Inhibition of HIV1 protease expressed in Escherichia coli2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Two-carbon-elongated HIV-1 protease inhibitors with a tertiary-alcohol-containing transition-state mimic.
AID105173Compound was tested for their ability to inhibit spread of PI-resistant HIV-1 (strain V-60C) viral infection in MT-4 human T-lymphoidcell2003Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15
HIV protease inhibitors with picomolar potency against PI-Resistant HIV-1 by extension of the P3 substituent.
AID586623Antiviral activity against 8gpNS with amino acid 116 insertion removed HIV1 infected in HEK293T cells assessed as inhibition of viral replication after 48 hrs by luciferase assay2011Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3
Three residues in HIV-1 matrix contribute to protease inhibitor susceptibility and replication capacity.
AID375200Antiviral activity against multidrug-resistant HIV1 isolate TM infected in PHA-stimulated PBMC assessed as inhibition of p24 gap protein2009Journal of medicinal chemistry, Jul-09, Volume: 52, Issue:13
Design of HIV-1 protease inhibitors with pyrrolidinones and oxazolidinones as novel P1'-ligands to enhance backbone-binding interactions with protease: synthesis, biological evaluation, and protein-ligand X-ray studies.
AID557290Antiviral activity against HIV1 NL4-3 harboring L10F/M46I/I54V/V82A amino acid substitution in protease encoding region infected in human MT4 cells assessed as inhibition of p24 Gag protein production selected at 1 uM of Lopinavir by ELISA2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.
AID309182Antiviral activity against HIV1 with protease K60C mutant in HeLa cells by viral spread assay2007Bioorganic & medicinal chemistry letters, Oct-01, Volume: 17, Issue:19
Synthesis of novel HIV protease inhibitors (PI) with activity against PI-resistant virus.
AID279345Antiviral activity against wild type HIV1 in CBMCs2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors.
AID321688Antiviral activity against HIV1 mutant strain 32008Bioorganic & medicinal chemistry, Feb-01, Volume: 16, Issue:3
Structure-activity relationships of novel HIV-1 protease inhibitors containing the 3-amino-2-chlorobenzoyl-allophenylnorstatine structure.
AID374628Resistance index, ratio of EC50 for HIV1 with protease 33F/46L/53L/54V/82A mutation to EC50 for wild type HIV1 NL4-3 in HEK293 cells after 48 hrs by replication-deffective luciferase reporter gene-based phenotypic assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.
AID279336Antiviral activity against wild type HIV2 in CBMCs2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors.
AID391268Antiviral activity against multidrug-resistant HIV1 with protease L10I, K14R, L33I, M36I, M46I, F53I, K55R, I62V, L63P, A71V, G73S, V82A, L90M, I93L mutation in phytohemagglutininin-activated PBMC assessed as inhibition of p24G protein production2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Flexible cyclic ethers/polyethers as novel P2-ligands for HIV-1 protease inhibitors: design, synthesis, biological evaluation, and protein-ligand X-ray studies.
AID54390Inhibition of human liver microsome Cytochrome P450 2C92003Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15
The design, synthesis and evaluation of novel HIV-1 protease inhibitors with high potency against PI-resistant viral strains.
AID163487Inhibitory activity against HIV-1 protease1996Journal of medicinal chemistry, Oct-11, Volume: 39, Issue:21
HIV protease inhibitory bis-benzamide cyclic ureas: a quantitative structure-activity relationship analysis.
AID162538Evaluated for the inhibition of Protease2000Journal of medicinal chemistry, Sep-07, Volume: 43, Issue:18
Identification of MK-944a: a second clinical candidate from the hydroxylaminepentanamide isostere series of HIV protease inhibitors.
AID417030Effect on tenofovir disoproxil fumarate metabolism in ritonavir booster drug treated healthy human assessed as change in plasma Cmax of tenofovir at 800 mg, po, TID co-administered with 300 mg once daily dose of tenofovir disoproxil fumarate2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro.
AID374616Resistance index, ratio of EC50 for HIV1 with protease 46I/88S mutation to EC50 for wild type HIV1 NL4-3 in HEK293 cells after 48 hrs by replication-deffective luciferase reporter gene-based phenotypic assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.
AID519574Antiviral activity against HIV1 P21 infected in human MT4 cells derived from viral passages with A-790742 harboring protease L23I, L33F, K45I, A71A/V, V77I, V82L, and I84V mutation assessed as reduction in viral cytopathogenicity treated 1 hr post infecti2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Characterization of a novel human immunodeficiency virus type 1 protease inhibitor, A-790742.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID678712Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID369956Ratio of EC50 for HIV2 ROD with protease V47A mutation to EC50 for wild type HIV2 ROD2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir.
AID557292Antiviral activity against HIV1 NL4-3 harboring L10F/L33F/M46I/I47V/Q58E/V82I/I84V/I85V amino acid substitution in protease encoding region infected in human MT4 cells assessed as inhibition of p24 Gag protein production selected at 5 uM of GRL-02031 by E2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.
AID681358TP_TRANSPORTER: inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 5 uM) in Caco-2 cells2000Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 28, Issue:6
Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes.
AID557273Antiviral activity against HIV1 A harboring L10I/I15V/E35D/N37E/K45R/I54V/L63P/A71V/V82T/L90M/I93L/C95F in protease encoding region infected in human PHA-PBC assessed as inhibition of p24 Gag protein production by ELISA2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.
AID372182Resistance index, ratio of EC50 for HIV1 with protease 33I/46I/84V/90M mutation to EC50 for wild type HIV1 NL4-3 in HEK293 cells after 48 hrs by replication-deffective luciferase reporter gene-based phenotypic assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.
AID598772Inhibition of wild type HIV1 protease expressed in Escherichia coli by fluorometric assay2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Design and synthesis of potent HIV-1 protease inhibitors incorporating hydroxyprolinamides as novel P2 ligands.
AID374614Resistance index, ratio of EC50 for non-B type HIV1 with protease 46I/47V/84V mutation to EC50 for wild type HIV1 NL4-3 in HEK293 cells after 48 hrs by replication-deffective luciferase reporter gene-based phenotypic assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.
AID682151TP_TRANSPORTER: increase in plasma concentration in mdr1a(-/-) mouse2001The Journal of pharmacology and experimental therapeutics, Mar, Volume: 296, Issue:3
In vitro substrate identification studies for p-glycoprotein-mediated transport: species difference and predictability of in vivo results.
AID153095Tested for cytotoxic activity against HIV-1 144-44 in PBMC cells2000Journal of medicinal chemistry, Mar-09, Volume: 43, Issue:5
5,6-Dihydropyran-2-ones possessing various sulfonyl functionalities: potent nonpeptidic inhibitors of HIV protease.
AID1071317Antiviral activity against HIV-1 NL4-3 assessed as reduction in viral infectivity in human TZM-bl cells after 48 hrs by firefly luciferase reporter gene assay2014Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3
High-affinity recognition of HIV-1 frameshift-stimulating RNA alters frameshifting in vitro and interferes with HIV-1 infectivity.
AID8341Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog2002Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4
A combinatorial library of indinavir analogues and its in vitro and in vivo studies.
AID417047Inhibition of esterase mediated-hydrolysis of tenofovir disoproxil fumarate in human intestinal sub cellular fraction S9 at 2 uM after 30 mins2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro.
AID1517762Inhibition of HIV-1 protease at 500 nM using synthetic peptide as substrate after 15 mins by fluorimetric based assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Discovery of 2-isoxazol-3-yl-acetamide analogues as heat shock protein 90 (HSP90) inhibitors with significant anti-HIV activity.
AID598809Inhibition of wild type HIV1 protease expressed in Escherichia coli at 10 nM by fluorometric assay2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Design and synthesis of potent HIV-1 protease inhibitors incorporating hydroxyprolinamides as novel P2 ligands.
AID1182735Inhibition of HTLV-1 protease at 8 uM using (RE(Edans)TKVLVVQPK(Dabsyl)R) substrate by fluorescence-based assay2014Journal of medicinal chemistry, Jul-24, Volume: 57, Issue:14
Structural basis for HTLV-1 protease inhibition by the HIV-1 protease inhibitor indinavir.
AID321692Antiviral activity against HIV1 mutant strain 72008Bioorganic & medicinal chemistry, Feb-01, Volume: 16, Issue:3
Structure-activity relationships of novel HIV-1 protease inhibitors containing the 3-amino-2-chlorobenzoyl-allophenylnorstatine structure.
AID309178Inhibition of wild type HIV1 NL4-3 protease2007Bioorganic & medicinal chemistry letters, Oct-01, Volume: 17, Issue:19
Synthesis of novel HIV protease inhibitors (PI) with activity against PI-resistant virus.
AID589167Mechanism based inhibition of human cytochrome P450 3A52005Current drug metabolism, Oct, Volume: 6, Issue:5
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID361270Binding affinity to recombinant CYP3A4 expressed in Escherichia coli assessed as spectral dissociation constant by spectrophotometric equilibrium binding titration method2007The Journal of biological chemistry, Mar-02, Volume: 282, Issue:9
Multiple sequential steps involved in the binding of inhibitors to cytochrome P450 3A4.
AID220213Inhibition of cytochrome P450 2C9 at 1 uM2000Journal of medicinal chemistry, Mar-09, Volume: 43, Issue:5
5,6-Dihydropyran-2-ones possessing various sulfonyl functionalities: potent nonpeptidic inhibitors of HIV protease.
AID160316Binding affinity to inhibit the purified wild-type HIV-1 Protease1997Journal of medicinal chemistry, Jan-17, Volume: 40, Issue:2
Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV.
AID279943AUC (0-8 hrs) in HIV1 infected pregnant woman during postpartum period at 800 mg three times/day2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Pharmacokinetics and safety of indinavir in human immunodeficiency virus-infected pregnant women.
AID105722Compound was evaluated for its antiviral inhibition in MT-4 cell culture2000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Novel inhibitors of HIV protease: design, synthesis and biological evaluation of picomolar inhibitors containing cyclic P1/P2 scaffolds.
AID162217Inhibitory activity of compound against HIV-1 protease in wild type NL4-3 virus2003Bioorganic & medicinal chemistry letters, Oct-06, Volume: 13, Issue:19
HIV-1 protease inhibitors with picomolar potency against PI-resistant HIV-1 by modification of the P1' substituent.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1323585Binding affinity to mouse anti-dsDNA monoclonal antibody R4A assessed as inhibition of RA4 binding to DWEYS peptide at 5 to 50 uM preincubated for 1 hr followed by DWEYS peptide addition measured after 1 hr by ELISA2016Journal of medicinal chemistry, 10-13, Volume: 59, Issue:19
Amending HIV Drugs: A Novel Small-Molecule Approach To Target Lupus Anti-DNA Antibodies.
AID519794Antiviral activity against HIV 2 subtype B clinical isolate expressing 12Q-14R-17G/D-19P-61N-62I-92A protease gene sequence from HIV2 infected patient plasma and PBMC obtained before compound treatment measured after 13 months2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors.
AID220214Inhibition of cytochrome P4502D6 at 100 uM2000Journal of medicinal chemistry, Mar-09, Volume: 43, Issue:5
5,6-Dihydropyran-2-ones possessing various sulfonyl functionalities: potent nonpeptidic inhibitors of HIV protease.
AID374609Resistance index, ratio of EC50 for HIV1 with protease 84V/90M mutation to EC50 for wild type HIV1 NL4-3 in HEK293 cells after 48 hrs by replication-deffective luciferase reporter gene-based phenotypic assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.
AID519789Antiviral activity against HIV 2 subtype A clinical isolate expressing 10V/I-40D-43I-56V-70K-82F-84V-89V-90M protease gene sequence from HIV2 infected patient plasma and PBMC obtained at T2 during compound treatment measured after 3 months2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors.
AID519795Antiviral activity against HIV 2 subtype B clinical isolate expressing 41D protease gene sequence from HIV2 infected patient plasma and PBMC obtained before compound treatment measured after 13 months2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors.
AID1636357Drug activation in human Hep3B cells assessed as human CYP3A4-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID1141884Inhibition of purified HIV-1 protease using [Arg-Glu(EDANS)-Ser-Gin-Asn-Tyr-Ile-Val-Gin-Lys(dabcyl)-Arg) as fluorogenic substrate at 10 nM by fluorescence assay2014Bioorganic & medicinal chemistry letters, Jun-01, Volume: 24, Issue:11
Design and synthesis of highly potent HIV-1 protease inhibitors with novel isosorbide-derived P2 ligands.
AID519787Antiviral activity against HIV 2 subtype A clinical isolate expressing 14H-40D-70K-72R/K-91T/S protease gene sequence from HIV2 infected patient plasma and PBMC obtained before compound treatment measured after 13 months2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors.
AID446202Selectivity ratio of IC50 for multidrug-resistant HIV1 isolate G to IC50 for wild type HIV1 isolate ERS104pre2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Design, synthesis, protein-ligand X-ray structure, and biological evaluation of a series of novel macrocyclic human immunodeficiency virus-1 protease inhibitors to combat drug resistance.
AID343028Ratio of Ki for HIV1 recombinant protease L10F/L19I/K20R/L33F/E35D/M36I/R41K/F53L/I54V/L63P/H69K/A71V/T74P/I84V/L89M/L90M/I93L mutant to Ki for wild-type HIV1 BH10 protease2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Inorganic polyhedral metallacarborane inhibitors of HIV protease: a new approach to overcoming antiviral resistance.
AID260514Binding affinity to HIV1 protease D30N2006Journal of medicinal chemistry, Feb-23, Volume: 49, Issue:4
Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V, and L90M.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID241213Inhibitory concentration against HIV-1 protease (NL4-3)2004Bioorganic & medicinal chemistry letters, Sep-20, Volume: 14, Issue:18
P1' oxadiazole protease inhibitors with excellent activity against native and protease inhibitor-resistant HIV-1.
AID269317Antiviral activity against multi drug-resistant HIV1 K variant in human PHA-PBMC cells2006Journal of medicinal chemistry, Aug-24, Volume: 49, Issue:17
Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance.
AID443165Inhibition of HIV1 protease expressed in Escherichia coli by fluorometric assay2010Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2
HIV-1 protease inhibitors with a transition-state mimic comprising a tertiary alcohol: improved antiviral activity in cells.
AID278968Antiviral activity against HIV1 C1 isolate with protease I84C mutation in HEK 293 cells relative to wild type2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Identification and structural characterization of I84C and I84A mutations that are associated with high-level resistance to human immunodeficiency virus protease inhibitors and impair viral replication.
AID446204Selectivity ratio of IC50 for multidrug-resistant HIV1 isolate MM to IC50 for wild type HIV1 isolate ERS104pre2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Design, synthesis, protein-ligand X-ray structure, and biological evaluation of a series of novel macrocyclic human immunodeficiency virus-1 protease inhibitors to combat drug resistance.
AID152964Concentration required for causing death in 10% or less of cells in the absence of virus in PBMC cells infected with HIV-1 237288 strain2000Journal of medicinal chemistry, Sep-21, Volume: 43, Issue:19
Synthesis, stability, antiviral activity, and protease-bound structures of substrate-mimicking constrained macrocyclic inhibitors of HIV-1 protease.
AID374607Resistance index, ratio of EC50 for HIV1 with protease 46I/82T/84V/90M mutation to EC50 for wild type HIV1 NL4-3 in HEK293 cells after 48 hrs by replication-deffective luciferase reporter gene-based phenotypic assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.
AID416853Inhibition of human MDR1-dependent accumulation of calcein-AM expressed in MDCK2 cells at 50 uM2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro.
AID105381Ability to inhibit spread of viral infection in MT-4 human T-lymphoidcell infected by PI-resistant HIV-1 (strain V-18C)2003Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15
The design, synthesis and evaluation of novel HIV-1 protease inhibitors with high potency against PI-resistant viral strains.
AID246193Protease inhibitory activity against HIV-1 r13025 mutant strain was determined2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Design of HIV-1 protease inhibitors active on multidrug-resistant virus.
AID105198Antiviral activity against wild-type HIV virus (HXB2) was determined in MT-4 cell line2004Bioorganic & medicinal chemistry letters, Feb-23, Volume: 14, Issue:4
Novel arylsulfonamides possessing sub-picomolar HIV protease activities and potent anti-HIV activity against wild-type and drug-resistant viral strains.
AID624626Ratio of apparent permeability from basolateral to apical side over apical to basolateral side determined in MDR1-MDCKII cells2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID105581In vitro anti-HIV activity in MT-4 cells by using an HIV cytopathic assay1998Journal of medicinal chemistry, Sep-24, Volume: 41, Issue:20
Design and synthesis of new potent C2-symmetric HIV-1 protease inhibitors. Use of L-mannaric acid as a peptidomimetic scaffold.
AID557281Ratio of EC50 for HIV1 B harboring L10I/I15V/E35D/N37E/K45R/I54V/L63P/A71V/V82T/L90M/I93L/C95F in protease encoding region to EC50 for HIV1 ERS104pre2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.
AID673198Binding affinity to Human immunodeficiency virus 1 protease by SPR biosensor interaction analysis at pH 4.12012Bioorganic & medicinal chemistry, Aug-01, Volume: 20, Issue:15
Experimental and 'in silico' analysis of the effect of pH on HIV-1 protease inhibitor affinity: implications for the charge state of the protein ionogenic groups.
AID104959Viral spread inhibitory concentration against HIV-1 strain Q-60C in MT-4 human T-lymphoid cells2003Bioorganic & medicinal chemistry letters, Nov-17, Volume: 13, Issue:22
Novel HIV-1 protease inhibitors active against multiple PI-resistant viral strains: coadministration with indinavir.
AID1221963Transporter substrate index ratio of permeability from apical to basolateral side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY3359792011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1141883Inhibition of purified HIV-1 protease using [Arg-Glu(EDANS)-Ser-Gin-Asn-Tyr-Ile-Val-Gin-Lys(dabcyl)-Arg) as fluorogenic substrate by fluorescence assay2014Bioorganic & medicinal chemistry letters, Jun-01, Volume: 24, Issue:11
Design and synthesis of highly potent HIV-1 protease inhibitors with novel isosorbide-derived P2 ligands.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID278967Antiviral activity against HIV1 A15 isolate with protease I84A mutation in HEK 293 cells relative to wild type2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Identification and structural characterization of I84C and I84A mutations that are associated with high-level resistance to human immunodeficiency virus protease inhibitors and impair viral replication.
AID369951Antiviral activity against wild type HIV2 ROD infected in human CEM cells assessed as inhibition of virus production after 7 days by Lenti-RT activity assay2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir.
AID374634Resistance index, ratio of EC50 for HIV1 with protease 33F/54V/82A/84V/90M mutation to EC50 for wild type HIV1 NL4-3 in HEK293 cells after 48 hrs by replication-deffective luciferase reporter gene-based phenotypic assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.
AID678721Metabolic stability in human liver microsomes assessed as GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID249222Concentration required to inhibit spread of native HIV-1(V18) protease obtained from PI-resistant clinical isolate in MT-4 human T-lymphoid cells2004Bioorganic & medicinal chemistry letters, Sep-20, Volume: 14, Issue:18
P1' oxadiazole protease inhibitors with excellent activity against native and protease inhibitor-resistant HIV-1.
AID374602Resistance index, ratio of EC50 for HIV1 with protease 24I/33F/46I/54L/82A mutation to EC50 for wild type HIV1 NL4-3 in HEK293 cells after 48 hrs by replication-deffective luciferase reporter gene-based phenotypic assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.
AID278965Antiviral activity against HIV1 A13 isolate with protease I84A mutation in HEK 293 cells relative to wild type2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Identification and structural characterization of I84C and I84A mutations that are associated with high-level resistance to human immunodeficiency virus protease inhibitors and impair viral replication.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID309181Inhibition of HIV1 NL4-3 protease V18C mutant2007Bioorganic & medicinal chemistry letters, Oct-01, Volume: 17, Issue:19
Synthesis of novel HIV protease inhibitors (PI) with activity against PI-resistant virus.
AID278983Resistance to HIV1 with protease 46I/L, 54I and I84C mutation in HEK 293 cells relative to similar background2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Identification and structural characterization of I84C and I84A mutations that are associated with high-level resistance to human immunodeficiency virus protease inhibitors and impair viral replication.
AID343027Ratio of Ki for HIV1 recombinant protease L10I/L24I/L33F/M46L/154V/L63P/A71V/V82A/I84V mutant to Ki for wild-type HIV1 BH10 protease expressed in Escherichia coli2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Inorganic polyhedral metallacarborane inhibitors of HIV protease: a new approach to overcoming antiviral resistance.
AID278961Antiviral activity against HIV1 A9 isolate with protease I84A mutation in HEK 293 cells relative to wild type2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Identification and structural characterization of I84C and I84A mutations that are associated with high-level resistance to human immunodeficiency virus protease inhibitors and impair viral replication.
AID81077Potency against PI-resistant viral isolate construct HIV K-60C2002Bioorganic & medicinal chemistry letters, Sep-02, Volume: 12, Issue:17
Synthesis and activity of novel HIV protease inhibitors with improved potency against multiple PI-resistant viral strains.
AID199080Inhibition of virion associated RT activity relative to untreated, infected control in PBMC cells infected with HIV-1 237288 strain2000Journal of medicinal chemistry, Sep-21, Volume: 43, Issue:19
Synthesis, stability, antiviral activity, and protease-bound structures of substrate-mimicking constrained macrocyclic inhibitors of HIV-1 protease.
AID521547Antiviral activity against Human immunodeficiency virus type 2 (ISOLATE ROD) after 13 months2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors.
AID625276FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of most concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID343025Ratio of Ki for HIV1 recombinant protease V32I/I47A mutant to Ki for wild-type HIV1 BH10 protease2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Inorganic polyhedral metallacarborane inhibitors of HIV protease: a new approach to overcoming antiviral resistance.
AID557297Ratio of EC50 for HIV1 NL4-3 harboring M46I/V82F/I84V amino acid substitution in protease encoding region to EC50 for HIV1 NL4-32009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.
AID263208Antiviral activity against HIV1 EP13 in MT4 cells2006Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7
Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385.
AID557287Antiviral activity against HIV1 NL4-3 harboring L10F/L24I/M46I/L63P/A71V/G73S/V82T amino acid substitution in protease encoding region infected in human MT4 cells assessed as inhibition of p24 Gag protein production selected at 5 uM of indinavir by ELISA2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.
AID564045Antiviral activity against multidrug-resistant HIV1 isolate G containing L10I, V11I, T12E, I15V, L19I,R41K, M46L, L63P, A71T, V82A, and L90M mutant infected in human PHA-PBMC cells by MTT assay2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Novel protease inhibitors (PIs) containing macrocyclic components and 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane that are potent against multi-PI-resistant HIV-1 variants in vitro.
AID375199Antiviral activity against wild type HIV1 isolate ERS104pre infected in PHA-stimulated PBMC assessed as inhibition of p24 gap protein2009Journal of medicinal chemistry, Jul-09, Volume: 52, Issue:13
Design of HIV-1 protease inhibitors with pyrrolidinones and oxazolidinones as novel P1'-ligands to enhance backbone-binding interactions with protease: synthesis, biological evaluation, and protein-ligand X-ray studies.
AID374603Resistance index, ratio of EC50 for HIV1 with protease 54V/82A/84V/90M mutation to EC50 for wild type HIV1 NL4-3 in HEK293 cells after 48 hrs by replication-deffective luciferase reporter gene-based phenotypic assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.
AID343018Inhibition of HIV1 recombinant protease V32I/I47A mutant expressed in Escherichia coli by spectrophotometric assay2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Inorganic polyhedral metallacarborane inhibitors of HIV protease: a new approach to overcoming antiviral resistance.
AID519579Antiviral activity against HIV1 clone4 infected in HEK293 cells harboring A-790742-selected protease L33F, A71V, G73S, V77I, V82L, and I84V mutation assessed as reduction in viral replication by luciferase reporter gene assay relative to wild type HIV1 pN2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Characterization of a novel human immunodeficiency virus type 1 protease inhibitor, A-790742.
AID279346Antiviral activity against HIV1 isolate 5512 with V321 and M46L mutation in CBMCs2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors.
AID81081Potency against PI-resistant virus HIV 4X2002Bioorganic & medicinal chemistry letters, Sep-02, Volume: 12, Issue:17
Synthesis and activity of novel HIV protease inhibitors with improved potency against multiple PI-resistant viral strains.
AID20786Oral bioavailability in dog2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
Protease inhibitors: current status and future prospects.
AID322112Antiviral activity against wild type HIV1 ERS104prc X4 in phytohemagglutininin-activated PBMCs assessed as inhibition of p24 Gag protein expression by MTT assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.
AID553574Antiviral activity against HIV1 ERS104pre infected in human PHA-PBC assessed as inhibition of p24 Gag protein production by ELISA2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.
AID161727In vitro inhibition of (HIV-1 IIIB) replication.2000Journal of medicinal chemistry, Dec-28, Volume: 43, Issue:26
4-Aryl-2,4-dioxobutanoic acid inhibitors of HIV-1 integrase and viral replication in cells.
AID81082Potency against PI-resistant virus HIV NL-42002Bioorganic & medicinal chemistry letters, Sep-02, Volume: 12, Issue:17
Synthesis and activity of novel HIV protease inhibitors with improved potency against multiple PI-resistant viral strains.
AID343024Ratio of Ki for HIV1 recombinant protease A71V/V82T/I84V mutant to Ki for wild-type HIV1 BH10 protease2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Inorganic polyhedral metallacarborane inhibitors of HIV protease: a new approach to overcoming antiviral resistance.
AID443166Antiviral activity against HIV1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 6 days by XTT assay2010Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2
HIV-1 protease inhibitors with a transition-state mimic comprising a tertiary alcohol: improved antiviral activity in cells.
AID391269Antiviral activity against multidrug-resistant HIV1 with protease L10I, V11I, T12E, I15V, L19I, R41K, M46L, L63P, A71T, V82A, L90M mutation in phytohemagglutininin-activated PBMC assessed as inhibition of p24G protein production2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Flexible cyclic ethers/polyethers as novel P2-ligands for HIV-1 protease inhibitors: design, synthesis, biological evaluation, and protein-ligand X-ray studies.
AID1443980Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-tauroch2010Toxicological sciences : an official journal of the Society of Toxicology, Dec, Volume: 118, Issue:2
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
AID54765Inhibition of human liver microsome Cytochrome P450 3A42003Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15
The design, synthesis and evaluation of novel HIV-1 protease inhibitors with high potency against PI-resistant viral strains.
AID519575Antiviral activity against HIV1 P13 infected in human MT4 cells derived from viral passages with A-790742 harboring protease M46I, L63P, A71V, and V82G mutation assessed as reduction in viral cytopathogenicity treated 1 hr post infection measured 5 days p2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Characterization of a novel human immunodeficiency virus type 1 protease inhibitor, A-790742.
AID82750Fold increase in EC50 for antiviral activity against HIV Protease-Resistant strains with E protease amino acid substitutions2001Journal of medicinal chemistry, Jul-05, Volume: 44, Issue:14
4-Hydroxy-5,6-dihydropyrones as inhibitors of HIV protease: the effect of heterocyclic substituents at C-6 on antiviral potency and pharmacokinetic parameters.
AID82627Compound was tested for inhibitory activity against HIV-1 protease2002Bioorganic & medicinal chemistry letters, Jul-08, Volume: 12, Issue:13
Structure-based design and synthesis of HIV-1 protease inhibitors employing beta-D-mannopyranoside scaffolds.
AID1194842Inhibition of HIV1 protease expressed in Escherichia coli incubated for 20 to 30 mins at room temperature using (Arg-Glu(EDANS)-Ser-Gln-Asn-Tyr-Pro-Ile-Val-Gln-Lys(DABCYL)-Arg) substrate by FRET method2015Bioorganic & medicinal chemistry letters, May-01, Volume: 25, Issue:9
Synthesis and biological evaluation of novel HIV-1 protease inhibitors using tertiary amine as P2-ligands.
AID309179Antiviral activity against HIV1 NL4-3 in MT4 cells by viral spread assay2007Bioorganic & medicinal chemistry letters, Oct-01, Volume: 17, Issue:19
Synthesis of novel HIV protease inhibitors (PI) with activity against PI-resistant virus.
AID278954Antiviral activity against HIV1 A2 isolate with protease I84A mutation in HEK 293 cells relative to wild type2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Identification and structural characterization of I84C and I84A mutations that are associated with high-level resistance to human immunodeficiency virus protease inhibitors and impair viral replication.
AID321660Inhibition of HIV1 protease2008Bioorganic & medicinal chemistry, Feb-01, Volume: 16, Issue:3
Structure-activity relationships of novel HIV-1 protease inhibitors containing the 3-amino-2-chlorobenzoyl-allophenylnorstatine structure.
AID446201Selectivity ratio of IC50 for multidrug-resistant HIV1 isolate C to IC50 for wild type HIV1 isolate ERS104pre2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Design, synthesis, protein-ligand X-ray structure, and biological evaluation of a series of novel macrocyclic human immunodeficiency virus-1 protease inhibitors to combat drug resistance.
AID564047Antiviral activity against multidrug-resistant HIV1 isolate MM containing L10I, K43T, M46L, I54V, L63P, A71V, V82A, L90M, and Q92K mutant infected in human PHA-PBMC cells by MTT assay2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Novel protease inhibitors (PIs) containing macrocyclic components and 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane that are potent against multi-PI-resistant HIV-1 variants in vitro.
AID242933Dissociation rate constant for the interaction between the compound and serum albumin2005Journal of medicinal chemistry, May-19, Volume: 48, Issue:10
Early absorption and distribution analysis of antitumor and anti-AIDS drugs: lipid membrane and plasma protein interactions.
AID260394Antiviral activity in cells infected with wild-type HIV1 NL4-3 in presence of FBS2006Bioorganic & medicinal chemistry letters, Feb-15, Volume: 16, Issue:4
Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors possessing augmented P2' side chains.
AID279949Tmax in HIV1 infected pregnant woman during postpartum period at 800 mg three times/day2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Pharmacokinetics and safety of indinavir in human immunodeficiency virus-infected pregnant women.
AID104951Compound was evaluated for the inhibition of the spread of HIV-1 IIIb infection in MT-4 human T-lymphoid cells; value ranges from 25-100 nM1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor.
AID1182733Inhibition of HTLV-1 protease at 80 uM using (RE(Edans)TKVLVVQPK(Dabsyl)R) substrate by fluorescence-based assay2014Journal of medicinal chemistry, Jul-24, Volume: 57, Issue:14
Structural basis for HTLV-1 protease inhibition by the HIV-1 protease inhibitor indinavir.
AID278978Antiviral activity against HIV1 C11 isolate with protease I84C mutation in HEK 293 cells relative to wild type2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Identification and structural characterization of I84C and I84A mutations that are associated with high-level resistance to human immunodeficiency virus protease inhibitors and impair viral replication.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID279950Cmin in HIV1 infected pregnant woman during antepartum period at 800 mg three times/day2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Pharmacokinetics and safety of indinavir in human immunodeficiency virus-infected pregnant women.
AID343017Inhibition of HIV1 recombinant protease A71V/V82T/I84V mutant expressed in Escherichia coli by spectrophotometric assay2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Inorganic polyhedral metallacarborane inhibitors of HIV protease: a new approach to overcoming antiviral resistance.
AID104957Viral spread inhibitory concentration against HIV-1 strain K-60C in MT-4 human T-lymphoid cells2003Bioorganic & medicinal chemistry letters, Nov-17, Volume: 13, Issue:22
Novel HIV-1 protease inhibitors active against multiple PI-resistant viral strains: coadministration with indinavir.
AID8925Maximum concentration was determined2002Bioorganic & medicinal chemistry letters, Sep-02, Volume: 12, Issue:17
Indinavir analogues with blocked metabolism sites as HIV protease inhibitors with improved pharmacological profiles and high potency against PI-resistant viral strains.
AID575061Antiviral activity against Human immunodeficiency virus 1 harboring M46I, M46L, I54V, and V82A mutations in viral protease assessed as fold change in drug susceptibility relative to wild type2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Prevalence, mutation patterns, and effects on protease inhibitor susceptibility of the L76V mutation in HIV-1 protease.
AID374610Resistance index, ratio of EC50 for HIV1 with protease 33F/50V mutation to EC50 for wild type HIV1 NL4-3 in HEK293 cells after 48 hrs by replication-deffective luciferase reporter gene-based phenotypic assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.
AID20930Compound was evaluated for the solubility at pH value of 7.41994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor.
AID220217Inhibition of cytochrome P4503A4 at 100 uM2000Journal of medicinal chemistry, Mar-09, Volume: 43, Issue:5
5,6-Dihydropyran-2-ones possessing various sulfonyl functionalities: potent nonpeptidic inhibitors of HIV protease.
AID553570Cytotoxicity against human MT2 cells by MTT assay2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.
AID343026Ratio of Ki for HIV1 recombinant protease L10I/I15V/E35D/N37S/R41K/I62V/L63P/A71V/G73S/L90M mutant to Ki for wild-type HIV1 BH10 protease2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Inorganic polyhedral metallacarborane inhibitors of HIV protease: a new approach to overcoming antiviral resistance.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID242932Dissociation rate constant for the interaction between the compound and serum albumin2005Journal of medicinal chemistry, May-19, Volume: 48, Issue:10
Early absorption and distribution analysis of antitumor and anti-AIDS drugs: lipid membrane and plasma protein interactions.
AID249221Concentration required to inhibit spread of native HIV-1(4X) protease obtained from PI-resistant clinical isolate in MT-4 human T-lymphoid cells2004Bioorganic & medicinal chemistry letters, Sep-20, Volume: 14, Issue:18
P1' oxadiazole protease inhibitors with excellent activity against native and protease inhibitor-resistant HIV-1.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID227879Ratio (CIC95/IC50) of cellular antiviral activity over the isolated enzyme potency2003Journal of medicinal chemistry, May-08, Volume: 46, Issue:10
Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors.
AID679261TP_TRANSPORTER: transepithelial transport (basal to apical) in Caco-2 cells2000The Journal of pharmacology and experimental therapeutics, Jan, Volume: 292, Issue:1
Influence of P-glycoprotein on the transport and metabolism of indinavir in Caco-2 cells expressing cytochrome P-450 3A4.
AID105382Ability to inhibit spread of viral infection in MT-4 human T-lymphoidcell infected by wild-type HIV-1(strain NL4-3)2003Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15
The design, synthesis and evaluation of novel HIV-1 protease inhibitors with high potency against PI-resistant viral strains.
AID586627Antiviral activity against HIV1 harboring mutant protease with matrix A81T mutant infected in HEK293T cells assessed as inhibition of viral replication after 48 hrs by luciferase assay2011Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3
Three residues in HIV-1 matrix contribute to protease inhibitor susceptibility and replication capacity.
AID278955Antiviral activity against HIV1 A3 isolate with protease I84A mutation in HEK 293 cells relative to wild type2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Identification and structural characterization of I84C and I84A mutations that are associated with high-level resistance to human immunodeficiency virus protease inhibitors and impair viral replication.
AID374625Resistance index, ratio of EC50 for HIV1 with protease 33F/54V/82A/84V mutation to EC50 for wild type HIV1 NL4-3 in HEK293 cells after 48 hrs by replication-deffective luciferase reporter gene-based phenotypic assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.
AID374638Resistance index, ratio of EC50 for HIV1 with protease 46L/48V/82A/90M mutation to EC50 for wild type HIV1 NL4-3 in HEK293 cells after 48 hrs by replication-deffective luciferase reporter gene-based phenotypic assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID417040Effect on tenofovir disoproxil fumarate metabolism in ritonavir booster drug treated healthy human assessed as change in plasma Cmin of tenofovir at 800 mg, po, TID co-administered with 300 mg once daily dose of tenofovir disoproxil fumarate2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro.
AID225562Dissociation constant obtained by inhibition of mutant HIV-protease (A-44)2000Journal of medicinal chemistry, Sep-07, Volume: 43, Issue:18
Identification of MK-944a: a second clinical candidate from the hydroxylaminepentanamide isostere series of HIV protease inhibitors.
AID10276Half life period was determine after peroral administration at 10 mpk in dog2003Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15
HIV protease inhibitors with picomolar potency against PI-Resistant HIV-1 by extension of the P3 substituent.
AID519783Antiviral activity against HIV 2 subtype A clinical isolate expressing 14H-60K/N-65E protease gene sequence from HIV2 infected patient plasma and PBMC obtained before compound treatment measured after 13 months2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors.
AID260393Antiviral activity in cells infected with wild-type HIV1 H93B in presence of FBS2006Bioorganic & medicinal chemistry letters, Feb-15, Volume: 16, Issue:4
Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors possessing augmented P2' side chains.
AID269313Antiviral activity against multi drug-resistant HIV1 G variant in human PHA-PBMC cells2006Journal of medicinal chemistry, Aug-24, Volume: 49, Issue:17
Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance.
AID82778Tested in vitro for potential potency against PI-resistant HIV virus by A-44 mutant enzyme variant2002Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4
A combinatorial library of indinavir analogues and its in vitro and in vivo studies.
AID1443995Hepatotoxicity in human assessed as drug-induced liver injury2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID260390Inhibitory activity against isolated wild-type HIV1 protease2006Bioorganic & medicinal chemistry letters, Feb-15, Volume: 16, Issue:4
Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors possessing augmented P2' side chains.
AID624622Apparent permeability (Papp) from apical to basolateral side determined in MDR1-MDCKII cells2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID242868Association rate constant for the interaction between the compound and serum albumin2005Journal of medicinal chemistry, May-19, Volume: 48, Issue:10
Early absorption and distribution analysis of antitumor and anti-AIDS drugs: lipid membrane and plasma protein interactions.
AID322115Antiviral activity against HIV1 MDR/JSL R5 in phytohemagglutininin-activated PBMCs assessed as inhibition of p24 Gag protein expression by MTT assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.
AID257498Antiviral activity against 4X HIV strain2005Bioorganic & medicinal chemistry letters, Dec-01, Volume: 15, Issue:23
Orally bioavailable highly potent HIV protease inhibitors against PI-resistant virus.
AID391265Antiviral activity against multidrug-resistant HIV1 with protease L10I, K14R, R41K, M46L, I54V, L63P, A71V, V82A, L90M, I93L mutation in phytohemagglutininin-activated PBMC assessed as inhibition of p24Gag protein production2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Flexible cyclic ethers/polyethers as novel P2-ligands for HIV-1 protease inhibitors: design, synthesis, biological evaluation, and protein-ligand X-ray studies.
AID260516Binding affinity to HIV1 protease V82A2006Journal of medicinal chemistry, Feb-23, Volume: 49, Issue:4
Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V, and L90M.
AID557285Antiviral activity against HIV1 NL4-3 harboring L10I/G48V/I54V/L90M amino acid substitution in protease encoding region infected in human MT4 cells assessed as inhibition of p24 Gag protein production selected at 5 uM of saquinavir by ELISA2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.
AID374591Inhibition of HIV1 protease2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.
AID322123Antiviral activity against HIV1 92TH019 R5 subtype E in phytohemagglutininin-activated PBMCs assessed as inhibition of p24 Gag protein expression by MTT assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.
AID1221957Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID82747Fold increase in EC50 for antiviral activity against HIV Protease-Resistant strains with B protease amino acid substitutions2001Journal of medicinal chemistry, Jul-05, Volume: 44, Issue:14
4-Hydroxy-5,6-dihydropyrones as inhibitors of HIV protease: the effect of heterocyclic substituents at C-6 on antiviral potency and pharmacokinetic parameters.
AID278984Resistance to HIV1 with protease 46I, 54V and I84V mutation in HEK 293 cells relative to similar background2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Identification and structural characterization of I84C and I84A mutations that are associated with high-level resistance to human immunodeficiency virus protease inhibitors and impair viral replication.
AID257497Antiviral activity in MT4 human T lymphoid cells infected with wild type NL4-3 HIV2005Bioorganic & medicinal chemistry letters, Dec-01, Volume: 15, Issue:23
Orally bioavailable highly potent HIV protease inhibitors against PI-resistant virus.
AID389439Inhibition of HIV1 protease2008Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
Design and synthesis of sulfoximine based inhibitors for HIV-1 protease.
AID375202Antiviral activity against multidrug-resistant HIV1 isolate C infected in PHA-stimulated PBMC assessed as inhibition of p24 gap protein2009Journal of medicinal chemistry, Jul-09, Volume: 52, Issue:13
Design of HIV-1 protease inhibitors with pyrrolidinones and oxazolidinones as novel P1'-ligands to enhance backbone-binding interactions with protease: synthesis, biological evaluation, and protein-ligand X-ray studies.
AID322122Antiviral activity against HIV1 97ZA003 R5 subtype C in phytohemagglutininin-activated PBMCs assessed as inhibition of p24 Gag protein expression by MTT assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.
AID248600Inhibitory concentration against wild type Human immuno deficiency virus (D545701) was determined in an MT-4 cell line2005Bioorganic & medicinal chemistry letters, Aug-01, Volume: 15, Issue:15
Novel P1 chain-extended HIV protease inhibitors possessing potent anti-HIV activity and remarkable inverse antiviral resistance profiles.
AID238043Binding affinity for human immunodeficiency virus type 1 protease2004Journal of medicinal chemistry, Nov-18, Volume: 47, Issue:24
Improved structure-activity relationship analysis of HIV-1 protease inhibitors using interaction kinetic data.
AID374629Resistance index, ratio of EC50 for HIV1 with protease 46L/54M/82L/84V/90M mutation to EC50 for wild type HIV1 NL4-3 in HEK293 cells after 48 hrs by replication-deffective luciferase reporter gene-based phenotypic assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.
AID246225Protease inhibitory activity against HIV-1 GSS004421 mutant strain was determined2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Design of HIV-1 protease inhibitors active on multidrug-resistant virus.
AID105194Antiviral activity against PI resistant virus D545701 was determined in MT-4 cell line2004Bioorganic & medicinal chemistry letters, Feb-23, Volume: 14, Issue:4
Novel arylsulfonamides possessing sub-picomolar HIV protease activities and potent anti-HIV activity against wild-type and drug-resistant viral strains.
AID446200Selectivity ratio of IC50 for multidrug-resistant HIV1 isolate B to IC50 for wild type HIV1 isolate ERS104pre2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Design, synthesis, protein-ligand X-ray structure, and biological evaluation of a series of novel macrocyclic human immunodeficiency virus-1 protease inhibitors to combat drug resistance.
AID624629Inhibition of Pgp expressed in MDR1-MDCKII cells measured by calcein-AM assay2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID7599In vitro intrinsic clearance in human liver microsome2003Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15
HIV protease inhibitors with picomolar potency against PI-Resistant HIV-1 by extension of the P3 substituent.
AID81434Compound was evaluated for Antiviral activity against HIV-12001Journal of medicinal chemistry, Oct-11, Volume: 44, Issue:21
Synthesis of potent C(2)-symmetric, diol-based hiv-1 protease inhibitors. Investigation of thioalkyl and thioaryl P1/P1' substituents.
AID1221956Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID321697Ratio of EC50 for HIV1 mutant strain 5 to EC50 for wild type HIV12008Bioorganic & medicinal chemistry, Feb-01, Volume: 16, Issue:3
Structure-activity relationships of novel HIV-1 protease inhibitors containing the 3-amino-2-chlorobenzoyl-allophenylnorstatine structure.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID519576Antiviral activity against HIV1 clone1 infected in HEK293 cells harboring A-790742-selected protease I84V mutation assessed as reduction in viral replication by luciferase reporter gene assay relative to wild type HIV1 pNL4-32008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Characterization of a novel human immunodeficiency virus type 1 protease inhibitor, A-790742.
AID343014Inhibition of wild-type HIV1 BH10 protease expressed in Escherichia coli by spectrophotometric assay2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Inorganic polyhedral metallacarborane inhibitors of HIV protease: a new approach to overcoming antiviral resistance.
AID81080Potency against PI-resistant viral isolate construct HIV V-18C2002Bioorganic & medicinal chemistry letters, Sep-02, Volume: 12, Issue:17
Synthesis and activity of novel HIV protease inhibitors with improved potency against multiple PI-resistant viral strains.
AID81072Concentration required to control the spread of HIV mutant strain K-60C2002Bioorganic & medicinal chemistry letters, Sep-02, Volume: 12, Issue:17
Indinavir analogues with blocked metabolism sites as HIV protease inhibitors with improved pharmacological profiles and high potency against PI-resistant viral strains.
AID519607Cytotoxicity against Hepatocyte cells assessed as cell viability by MTT assay2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
New active drugs against liver stages of Plasmodium predicted by molecular topology.
AID369943Antiviral activity against HIV2 CDC310319 isolate infected in human PBMC assessed as inhibition of virus production after 5 days by Lenti-RT activity assay2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir.
AID322113Antiviral activity against HIV1 MDR/TM X4 in phytohemagglutininin-activated PBMCs assessed as inhibition of p24 Gag protein expression by MTT assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.
AID220219Inhibition of cytochrome P4503A4 at 1 uM2000Journal of medicinal chemistry, Mar-09, Volume: 43, Issue:5
5,6-Dihydropyran-2-ones possessing various sulfonyl functionalities: potent nonpeptidic inhibitors of HIV protease.
AID343023Ratio of Ki for HIV1 recombinant protease M46I/A71V/V82T/I84V mutant to Ki for wild-type HIV1 BH10 protease2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Inorganic polyhedral metallacarborane inhibitors of HIV protease: a new approach to overcoming antiviral resistance.
AID721741Selectivity ratio of IC50 for human OCT1-mediated ASP+ uptake expressed in HEK293 cells to IC50 for human MATE1-mediated ASP+ uptake expressed in HEK293 cells2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID1474062Ratio of drug concentration at steady state in human at 800 mg, po TID after 8 hrs to IC50 for human MRP3 overexpressed in Sf9 insect cells2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID309183Antiviral activity against HIV1 with protease V18C mutant in HeLa cells by viral spread assay2007Bioorganic & medicinal chemistry letters, Oct-01, Volume: 17, Issue:19
Synthesis of novel HIV protease inhibitors (PI) with activity against PI-resistant virus.
AID278971Antiviral activity against HIV1 C4 isolate with protease I84C mutation in HEK 293 cells relative to wild type2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Identification and structural characterization of I84C and I84A mutations that are associated with high-level resistance to human immunodeficiency virus protease inhibitors and impair viral replication.
AID1182734Inhibition of HTLV-1 protease at 40 uM using (RE(Edans)TKVLVVQPK(Dabsyl)R) substrate by fluorescence-based assay2014Journal of medicinal chemistry, Jul-24, Volume: 57, Issue:14
Structural basis for HTLV-1 protease inhibition by the HIV-1 protease inhibitor indinavir.
AID721749Inhibition of human OCT3-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID160300Inhibition of HIV protease2000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Novel inhibitors of HIV protease: design, synthesis and biological evaluation of picomolar inhibitors containing cyclic P1/P2 scaffolds.
AID322117Antiviral activity against HIV1 MDR/C X4 in phytohemagglutininin-activated PBMCs assessed as inhibition of p24 Gag protein expression by MTT assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID260400Antiviral activity in cells infected with wild-type HIV1 1002-60C mutant in presence of NHS2006Bioorganic & medicinal chemistry letters, Feb-15, Volume: 16, Issue:4
Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors possessing augmented P2' side chains.
AID249225Concentration required to inhibit spread of native HIV-1(NL4-3) protease obtained from PI-resistant clinical isolate in MT-4 human T-lymphoid cells2004Bioorganic & medicinal chemistry letters, Sep-20, Volume: 14, Issue:18
P1' oxadiazole protease inhibitors with excellent activity against native and protease inhibitor-resistant HIV-1.
AID7598Plasma clearance in human liver microsomes2003Bioorganic & medicinal chemistry letters, Nov-17, Volume: 13, Issue:22
Novel HIV-1 protease inhibitors active against multiple PI-resistant viral strains: coadministration with indinavir.
AID249224Concentration required to inhibit spread of native HIV-1(Q-60) protease obtained from PI-resistant clinical isolate in MT-4 human T-lymphoid cells2004Bioorganic & medicinal chemistry letters, Sep-20, Volume: 14, Issue:18
P1' oxadiazole protease inhibitors with excellent activity against native and protease inhibitor-resistant HIV-1.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID278972Antiviral activity against HIV1 C5 isolate with protease I84C mutation in HEK 293 cells relative to wild type2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Identification and structural characterization of I84C and I84A mutations that are associated with high-level resistance to human immunodeficiency virus protease inhibitors and impair viral replication.
AID446195Antiviral activity against multidrug-resistant HIV1 isolate C infected in PHA-stimulated human PBMC assessed as inhibition of p24 gap protein production2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Design, synthesis, protein-ligand X-ray structure, and biological evaluation of a series of novel macrocyclic human immunodeficiency virus-1 protease inhibitors to combat drug resistance.
AID673197Binding affinity to Human immunodeficiency virus 1 protease by SPR biosensor interaction analysis at pH 5.12012Bioorganic & medicinal chemistry, Aug-01, Volume: 20, Issue:15
Experimental and 'in silico' analysis of the effect of pH on HIV-1 protease inhibitor affinity: implications for the charge state of the protein ionogenic groups.
AID321694Ratio of EC50 for HIV1 mutant strain 2 to EC50 for wild type HIV12008Bioorganic & medicinal chemistry, Feb-01, Volume: 16, Issue:3
Structure-activity relationships of novel HIV-1 protease inhibitors containing the 3-amino-2-chlorobenzoyl-allophenylnorstatine structure.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID396261Ratio of EC50 for HIV1 drug resistant mutant isolates from protease inhibitor treated HIV patient to EC50 for drug sensitive HIV1 NL4-32007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV.
AID391272Antiviral activity against HIV1 ERS104 with protease L63P mutation in phytohemagglutininin-activated PBMC assessed as inhibition of p24G protein production2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Flexible cyclic ethers/polyethers as novel P2-ligands for HIV-1 protease inhibitors: design, synthesis, biological evaluation, and protein-ligand X-ray studies.
AID721750Inhibition of human OCT1-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID557275Antiviral activity against HIV1 C harboring L10I/I15V/K20R/L24I/M36I/M46L/I54V/I62V/L63P/K70Q/V82A/L89M in protease encoding region infected in human PHA-PBC assessed as inhibition of p24 Gag protein production by ELISA2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID564042Antiviral activity against wild type HIV1 ERS104 containing protease L36P mutant infected in human PHA-PBMC cells by MTT assay2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Novel protease inhibitors (PIs) containing macrocyclic components and 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane that are potent against multi-PI-resistant HIV-1 variants in vitro.
AID586622Ratio of EC50 for HIV1 harboring HIV1 harboring wild type 8.9NSX with gag RF79F and T81A mutant to EC50 for wild type HIV12011Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3
Three residues in HIV-1 matrix contribute to protease inhibitor susceptibility and replication capacity.
AID343020Inhibition of HIV1 recombinant protease L10I/L24I/L33F/M46L/154V/L63P/A71V/V82A/I84V mutant expressed in Escherichia coli by spectrophotometric assay2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Inorganic polyhedral metallacarborane inhibitors of HIV protease: a new approach to overcoming antiviral resistance.
AID374622Resistance index, ratio of EC50 for HIV1 with protease 33F/54V/73S/82A/90M mutation to EC50 for wild type HIV1 NL4-3 in HEK293 cells after 48 hrs by replication-deffective luciferase reporter gene-based phenotypic assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.
AID162373Inhibitory concentration required to inhibit cleavage of a substrate by the wild-type HIV-1 Protease2002Bioorganic & medicinal chemistry letters, Sep-02, Volume: 12, Issue:17
Indinavir analogues with blocked metabolism sites as HIV protease inhibitors with improved pharmacological profiles and high potency against PI-resistant viral strains.
AID575062Antiviral activity against Human immunodeficiency virus 1 harboring M46I, M46L, I54V, V82A and L76V mutations in viral protease assessed as fold change in drug susceptibility relative to wild type2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Prevalence, mutation patterns, and effects on protease inhibitor susceptibility of the L76V mutation in HIV-1 protease.
AID1443992Total Cmax in human administered as single dose2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID1221966Ratio of plasma AUC in po dosed mdr1 knock out mouse to plasma AUC in po dosed wild type mouse2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID105171Compound was tested for their ability to inhibit spread of PI-resistant HIV-1 (strain K-60C) viral infection in MT-4 human T-lymphoidcell2003Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15
HIV protease inhibitors with picomolar potency against PI-Resistant HIV-1 by extension of the P3 substituent.
AID7600In vitro intrinsic clearance in human liver microsome2003Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15
The design, synthesis and evaluation of novel HIV-1 protease inhibitors with high potency against PI-resistant viral strains.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID681121TP_TRANSPORTER: inhibition of Calcein-AM efflux in MDR1-expressing MDCKII cells2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID220218Inhibition of cytochrome P4503A4 at 10 uM2000Journal of medicinal chemistry, Mar-09, Volume: 43, Issue:5
5,6-Dihydropyran-2-ones possessing various sulfonyl functionalities: potent nonpeptidic inhibitors of HIV protease.
AID322118Antiviral activity against HIV1 MDR/G X4 in phytohemagglutininin-activated PBMCs assessed as inhibition of p24 Gag protein expression by MTT assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.
AID162351Inhibitory activity against HIV-1 protease (K-60C strain)2003Bioorganic & medicinal chemistry letters, Nov-17, Volume: 13, Issue:22
Novel HIV-1 protease inhibitors active against multiple PI-resistant viral strains: coadministration with indinavir.
AID583852Antiviral activity against HIV1 NL4-3 infected in human MT2 cells assessed as inhibition of virus-induced cell death at 0.005 multiplicities of infection after 6 days2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID553578Antiviral activity against HIV1 JSL harboring L10I/L24I/L33F/E35D/M36I/N37S/M46L/I54V/R57K/I62V/L63P/A71V/G73S/82A in protease encoding region infected in human PHA-PBC assessed as inhibition of p24 Gag protein production by ELISA2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.
AID321696Ratio of EC50 for HIV1 mutant strain 4 to EC50 for wild type HIV12008Bioorganic & medicinal chemistry, Feb-01, Volume: 16, Issue:3
Structure-activity relationships of novel HIV-1 protease inhibitors containing the 3-amino-2-chlorobenzoyl-allophenylnorstatine structure.
AID374635Resistance index, ratio of EC50 for HIV1 with protease 46L/48V/82A/84V/90M mutation to EC50 for wild type HIV1 NL4-3 in HEK293 cells after 48 hrs by replication-deffective luciferase reporter gene-based phenotypic assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.
AID372184Resistance index, ratio of EC50 for HIV1 with protease 37T/41K/70E mutation to EC50 for wild type HIV1 NL4-3 in HEK293 cells after 48 hrs by replication-deffective luciferase reporter gene-based phenotypic assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.
AID446197Antiviral activity against multidrug-resistant HIV1 isolate TM infected in PHA-stimulated human PBMC assessed as inhibition of p24 gap protein production2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Design, synthesis, protein-ligand X-ray structure, and biological evaluation of a series of novel macrocyclic human immunodeficiency virus-1 protease inhibitors to combat drug resistance.
AID372190Resistance index, ratio of EC50 for HIV1 with protease 46I/50V/54V mutation to EC50 for wild type HIV1 NL4-3 in HEK293 cells after 48 hrs by replication-deffective luciferase reporter gene-based phenotypic assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.
AID1067639Inhibition of HIV-1 protease in human T cells assessed as increase in eGFP expression at 0.1 uM after 24 hrs by flow cytometry2013Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17
Modular construction of quaternary hemiaminal-based inhibitor candidates and their in cellulo assessment with HIV-1 protease.
AID322101Antiviral activity against HIV1 NL4-3 in MT4 cells by MTT assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.
AID81075Concentration required to control the spread of HIV mutant strain WT2002Bioorganic & medicinal chemistry letters, Sep-02, Volume: 12, Issue:17
Indinavir analogues with blocked metabolism sites as HIV protease inhibitors with improved pharmacological profiles and high potency against PI-resistant viral strains.
AID260513Binding affinity to HIV1 protease2006Journal of medicinal chemistry, Feb-23, Volume: 49, Issue:4
Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V, and L90M.
AID557295Ratio of EC50 for HIV1 NL4-3 harboring L10F/L24I/M46I/L63P/A71V/G73S/V82T amino acid substitution in protease encoding region to EC50 for HIV1 NL4-32009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.
AID1221960Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY3359792011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID160273Binding affinity against HIV-1 protease enzyme.2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
Protease inhibitors: current status and future prospects.
AID564048Antiviral activity against multidrug-resistant HIV1 isolate JSL containing L10I, L24I, I33F, E35D, M36I, N37S, M46L, I54V, R57K, I62V, L63P, A71V, G73S, and V82A mutant infected in human PHA-PBMC cells by MTT assay2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Novel protease inhibitors (PIs) containing macrocyclic components and 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane that are potent against multi-PI-resistant HIV-1 variants in vitro.
AID278957Antiviral activity against HIV1 A5 isolate with protease I84A mutation in HEK 293 cells relative to wild type2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Identification and structural characterization of I84C and I84A mutations that are associated with high-level resistance to human immunodeficiency virus protease inhibitors and impair viral replication.
AID1678478Inhibition of recombinant His6-tagged SARS-CoV-2 main protease assessed as residual enzyme activity at 100 uM using Dabcyl-KTSAVLQ-SGFRKM-E(Edans-NH2) as substrate preincubated for 15 mins followed by substrate addition by FRET based assay relative to con2020ACS medicinal chemistry letters, Dec-10, Volume: 11, Issue:12
Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2.
AID269305Antiviral activity against HIV1 LAI isolate in human PHA-PBMC cells2006Journal of medicinal chemistry, Aug-24, Volume: 49, Issue:17
Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance.
AID162206Inhibitory activity against HIV-1 protease was determined2003Journal of medicinal chemistry, May-08, Volume: 46, Issue:10
Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors.
AID1678479Inhibition of recombinant His6-tagged SARS-CoV-2 main protease using Dabcyl-KTSAVLQ-SGFRKM-E(Edans-NH2) as substrate preincubated for 15 mins followed by substrate addition by FRET based assay2020ACS medicinal chemistry letters, Dec-10, Volume: 11, Issue:12
Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2.
AID81073Concentration required to control the spread of HIV mutant strain Q-60C2002Bioorganic & medicinal chemistry letters, Sep-02, Volume: 12, Issue:17
Indinavir analogues with blocked metabolism sites as HIV protease inhibitors with improved pharmacological profiles and high potency against PI-resistant viral strains.
AID699540Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID162216Inhibitory activity of compound against HIV-1 protease in HIV-1 (V-18C) strain2003Bioorganic & medicinal chemistry letters, Oct-06, Volume: 13, Issue:19
HIV-1 protease inhibitors with picomolar potency against PI-resistant HIV-1 by modification of the P1' substituent.
AID104991Concentration required for causing death in 10% or less of cells in the absence of virus in MT2 cells infected with HIV-1 237288 strain2000Journal of medicinal chemistry, Sep-21, Volume: 43, Issue:19
Synthesis, stability, antiviral activity, and protease-bound structures of substrate-mimicking constrained macrocyclic inhibitors of HIV-1 protease.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID260399Antiviral activity in cells infected with wild-type HIV1 NL4-3 in presence of NHS2006Bioorganic & medicinal chemistry letters, Feb-15, Volume: 16, Issue:4
Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors possessing augmented P2' side chains.
AID105196Antiviral activity against PI resistant virus EP13 was determined in MT-4 cell line2004Bioorganic & medicinal chemistry letters, Feb-23, Volume: 14, Issue:4
Novel arylsulfonamides possessing sub-picomolar HIV protease activities and potent anti-HIV activity against wild-type and drug-resistant viral strains.
AID54761In vitro inhibition of human liver microsome Cytochrome P450 3A42003Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15
HIV protease inhibitors with picomolar potency against PI-Resistant HIV-1 by extension of the P3 substituent.
AID237954Percentage of remaining compound after 30 min incubation in dog liver microsomes was determined as metabolic stability2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor.
AID613954Antiviral activity against Human immunodeficiency virus 1 LAI infected in human MT2 cells assessed as inhibition of p24 Gag protein production2011Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16
Design of HIV-1 protease inhibitors with C3-substituted hexahydrocyclopentafuranyl urethanes as P2-ligands: synthesis, biological evaluation, and protein-ligand X-ray crystal structure.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID575063Antiviral activity against Human immunodeficiency virus 1 harboring M46I mutation in viral protease assessed as fold change in drug susceptibility relative to wild type2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Prevalence, mutation patterns, and effects on protease inhibitor susceptibility of the L76V mutation in HIV-1 protease.
AID249223Concentration required to inhibit spread of native HIV-1(K-60) protease obtained from PI-resistant clinical isolate in MT-4 human T-lymphoid cells2004Bioorganic & medicinal chemistry letters, Sep-20, Volume: 14, Issue:18
P1' oxadiazole protease inhibitors with excellent activity against native and protease inhibitor-resistant HIV-1.
AID374621Resistance index, ratio of EC50 for HIV1 with protease 33F/54L/82A/90M mutation to EC50 for wild type HIV1 NL4-3 in HEK293 cells after 48 hrs by replication-deffective luciferase reporter gene-based phenotypic assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.
AID243422log (1/Km) value for human liver microsome cytochrome P450 3A42005Bioorganic & medicinal chemistry letters, Sep-15, Volume: 15, Issue:18
Modeling K(m) values using electrotopological state: substrates for cytochrome P450 3A4-mediated metabolism.
AID681165TP_TRANSPORTER: transepithelial transport (basal to apical) in mdr1a-expressing LLC-PK1 cell2001The Journal of pharmacology and experimental therapeutics, Mar, Volume: 296, Issue:3
In vitro substrate identification studies for p-glycoprotein-mediated transport: species difference and predictability of in vivo results.
AID225563Dissociation constant obtained by inhibition of mutant HIV-protease (K-60)2000Journal of medicinal chemistry, Sep-07, Volume: 43, Issue:18
Identification of MK-944a: a second clinical candidate from the hydroxylaminepentanamide isostere series of HIV protease inhibitors.
AID521548Antiviral activity against Human immunodeficiency virus type 1 (BRU ISOLATE) after 13 months2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors.
AID220215Inhibition of cytochrome P4502D6 at 10 uM2000Journal of medicinal chemistry, Mar-09, Volume: 43, Issue:5
5,6-Dihydropyran-2-ones possessing various sulfonyl functionalities: potent nonpeptidic inhibitors of HIV protease.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID374594Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 NL4-32007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.
AID557286Antiviral activity against HIV1 NL4-3 harboring L10F/V32I/M46I/I54M//A71V/I84V amino acid substitution in protease encoding region infected in human MT4 cells assessed as inhibition of p24 Gag protein production selected at 5 uM of amprenavir by ELISA2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.
AID680739TP_TRANSPORTER: inhibition of E217betaG uptake (E217betaG: 0.5 uM, Indinavir: 10 uM) in OATP-C-expressing HeLa cells2003The Journal of pharmacology and experimental therapeutics, Jan, Volume: 304, Issue:1
Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation.
AID54389In vitro inhibition of human liver microsome Cytochrome P450 2C92003Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15
HIV protease inhibitors with picomolar potency against PI-Resistant HIV-1 by extension of the P3 substituent.
AID105378Ability to inhibit spread of viral infection in MT-4 human T-lymphoidcell infected by PI-resistant HIV-1 (strain K-60C)2003Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15
The design, synthesis and evaluation of novel HIV-1 protease inhibitors with high potency against PI-resistant viral strains.
AID104956Inhibition of the spread of viral infection in MT-4 human T-lymphoid cells infected by IIIb isolate2002Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4
A combinatorial library of indinavir analogues and its in vitro and in vivo studies.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID1636440Drug activation in human Hep3B cells assessed as human CYP2D6-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID372192Resistance index, ratio of EC50 for HIV1 with protease 46I/50V mutation to EC50 for wild type HIV1 NL4-3 in HEK293 cells after 48 hrs by replication-deffective luciferase reporter gene-based phenotypic assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.
AID278979Resistance to HIV1 with protease 46M, 54I and I84V mutation in HEK 293 cells relative to similar background2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Identification and structural characterization of I84C and I84A mutations that are associated with high-level resistance to human immunodeficiency virus protease inhibitors and impair viral replication.
AID566845Antiviral activity against HIV1 LAI infected in human MT2 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Design and synthesis of potent HIV-1 protease inhibitors incorporating hexahydrofuropyranol-derived high affinity P(2) ligands: structure-activity studies and biological evaluation.
AID374592Antiviral activity against wild type HIV1 NL4-3 infected in MT4 cells after 6 days by MTT assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.
AID375201Antiviral activity against multidrug-resistant HIV1 isolate MM infected in PHA-stimulated PBMC assessed as inhibition of p24 gap protein2009Journal of medicinal chemistry, Jul-09, Volume: 52, Issue:13
Design of HIV-1 protease inhibitors with pyrrolidinones and oxazolidinones as novel P1'-ligands to enhance backbone-binding interactions with protease: synthesis, biological evaluation, and protein-ligand X-ray studies.
AID557284Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of p24 gag protein production by ELISA2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.
AID237955Percentage of remaining compound after 30 min incubation in rat liver microsomes was determined as metabolic stability2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor.
AID321690Antiviral activity against HIV1 mutant strain 52008Bioorganic & medicinal chemistry, Feb-01, Volume: 16, Issue:3
Structure-activity relationships of novel HIV-1 protease inhibitors containing the 3-amino-2-chlorobenzoyl-allophenylnorstatine structure.
AID321686Antiviral activity against HIV1 mutant strain 12008Bioorganic & medicinal chemistry, Feb-01, Volume: 16, Issue:3
Structure-activity relationships of novel HIV-1 protease inhibitors containing the 3-amino-2-chlorobenzoyl-allophenylnorstatine structure.
AID369946Ratio of EC50 for HIV2 CDC310319 infected in human PBMC to EC50 for HIV1 NL4-3 infected in human MT4 cells2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir.
AID1221961Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY3359792011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID386623Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
AID678715Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID82781Tested in vitro for the ability to inhibit cleavage of a substrate by the wild type HIV-1 protease2002Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4
A combinatorial library of indinavir analogues and its in vitro and in vivo studies.
AID278962Antiviral activity against HIV1 A10 isolate with protease I84A mutation in HEK 293 cells relative to wild type2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Identification and structural characterization of I84C and I84A mutations that are associated with high-level resistance to human immunodeficiency virus protease inhibitors and impair viral replication.
AID372189Resistance index, ratio of EC50 for HIV1 with protease 46I mutation to EC50 for wild type HIV1 NL4-3 in HEK293 cells after 48 hrs by replication-deffective luciferase reporter gene-based phenotypic assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.
AID235099Resistance of constructed mutant MK639 virus was calculated as (IC90 for a mutant virus / IC90 of wt HXB2 virus). 1997Journal of medicinal chemistry, Jan-17, Volume: 40, Issue:2
Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV.
AID721739Selectivity ratio of IC50 for human OCT3-mediated ASP+ uptake expressed in HEK293 cells to IC50 for human MATE1-mediated ASP+ uptake expressed in HEK293 cells2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID553576Antiviral activity against HIV1 TM harboring L10I/K14R/R41K/M46L/I54V/L63P/A71V/V82A/L90M/I93L in protease encoding region infected in human PHA-PBC assessed as inhibition of p24 Gag protein production by ELISA2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.
AID721742Ratio of Cmax unbound to IC50 for human MATE1-mediated [14]-metformin uptake expressed in polarized MDCK2 cells2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID81071Concentration required to control the spread of HIV mutant strain 4X virus2002Bioorganic & medicinal chemistry letters, Sep-02, Volume: 12, Issue:17
Indinavir analogues with blocked metabolism sites as HIV protease inhibitors with improved pharmacological profiles and high potency against PI-resistant viral strains.
AID374620Resistance index, ratio of EC50 for HIV1 with protease 32I/46I/47V/50L mutation to EC50 for wild type HIV1 NL4-3 in HEK293 cells after 48 hrs by replication-deffective luciferase reporter gene-based phenotypic assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.
AID375203Antiviral activity against multidrug-resistant HIV1 isolate G infected in PHA-stimulated PBMC assessed as inhibition of p24 gap protein2009Journal of medicinal chemistry, Jul-09, Volume: 52, Issue:13
Design of HIV-1 protease inhibitors with pyrrolidinones and oxazolidinones as novel P1'-ligands to enhance backbone-binding interactions with protease: synthesis, biological evaluation, and protein-ligand X-ray studies.
AID269314Antiviral activity against multi drug-resistant HIV1 TM variant in human PHA-PBMC cells2006Journal of medicinal chemistry, Aug-24, Volume: 49, Issue:17
Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance.
AID1221982Fraction absorbed in human2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID8544Plasma clearance after peroral administration at 10 mpk in dog2003Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15
HIV protease inhibitors with picomolar potency against PI-Resistant HIV-1 by extension of the P3 substituent.
AID374606Resistance index, ratio of EC50 for HIV1 with protease 46I/82T/84V mutation to EC50 for wild type HIV1 NL4-3 in HEK293 cells after 48 hrs by replication-deffective luciferase reporter gene-based phenotypic assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.
AID278982Resistance to HIV1 with protease 46I, 54I and I84A mutation in HEK 293 cells relative to similar background2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Identification and structural characterization of I84C and I84A mutations that are associated with high-level resistance to human immunodeficiency virus protease inhibitors and impair viral replication.
AID269307Antiviral activity against HIV2 EHO isolate in human MT2 cells2006Journal of medicinal chemistry, Aug-24, Volume: 49, Issue:17
Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance.
AID321689Antiviral activity against HIV1 mutant strain 42008Bioorganic & medicinal chemistry, Feb-01, Volume: 16, Issue:3
Structure-activity relationships of novel HIV-1 protease inhibitors containing the 3-amino-2-chlorobenzoyl-allophenylnorstatine structure.
AID54595In vitro inhibition of Cytochrome P450 2D62003Bioorganic & medicinal chemistry letters, Nov-17, Volume: 13, Issue:22
Novel HIV-1 protease inhibitors active against multiple PI-resistant viral strains: coadministration with indinavir.
AID260392Ratio of inhibitory effect against HIV1 protease in cellular over isolated enzyme assay2006Bioorganic & medicinal chemistry letters, Feb-15, Volume: 16, Issue:4
Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors possessing augmented P2' side chains.
AID278953Antiviral activity against HIV1 A1 isolate with protease I84A mutation in HEK 293 cells relative to wild type2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Identification and structural characterization of I84C and I84A mutations that are associated with high-level resistance to human immunodeficiency virus protease inhibitors and impair viral replication.
AID369838Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir.
AID238682Inhibition constant for human immunodeficiency virus type 1 protease2004Journal of medicinal chemistry, Nov-18, Volume: 47, Issue:24
Improved structure-activity relationship analysis of HIV-1 protease inhibitors using interaction kinetic data.
AID721745Ratio of Cmax unbound to IC50 for human MATE1-mediated ASP+ uptake expressed in HEK293 cells2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID1474061Ratio of drug concentration at steady state in human at 800 mg, po TID after 8 hrs to IC50 for human BSEP overexpressed in Sf9 insect cells2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID519608Selectivity index, ratio of TC50 for hepatocytes to IC50 for Plasmodium yoelii 2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
New active drugs against liver stages of Plasmodium predicted by molecular topology.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID162193Inhibition of HIV protease of HIV V-18C mutant strain2003Bioorganic & medicinal chemistry letters, May-19, Volume: 13, Issue:10
Design and synthesis of highly potent HIV protease inhibitors with activity against resistant virus.
AID269304Antiviral activity against HIV1 LAI isolate in human MT2 cells2006Journal of medicinal chemistry, Aug-24, Volume: 49, Issue:17
Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance.
AID681297TP_TRANSPORTER: inhibition of Calcein efflux (Calcein: 0.05 micro;M, Indinavir: 0.114 uM) in UMCC-1/VP cells2002AIDS (London, England), Sep-06, Volume: 16, Issue:13
The protease inhibitor ritonavir inhibits the functional activity of the multidrug resistance related-protein 1 (MRP-1).
AID322114Antiviral activity against HIV1 MDR/MM R5 in phytohemagglutininin-activated PBMCs assessed as inhibition of p24 Gag protein expression by MTT assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.
AID162353Inhibitory activity against HIV-1 protease (Q-60C strain)2003Bioorganic & medicinal chemistry letters, Nov-17, Volume: 13, Issue:22
Novel HIV-1 protease inhibitors active against multiple PI-resistant viral strains: coadministration with indinavir.
AID19252Partition coefficient (logP)2000Journal of medicinal chemistry, Sep-07, Volume: 43, Issue:18
Identification of MK-944a: a second clinical candidate from the hydroxylaminepentanamide isostere series of HIV protease inhibitors.
AID269310Antiviral activity against multi drug-resistant HIV1 ET variant in human PHA-PBMC cells2006Journal of medicinal chemistry, Aug-24, Volume: 49, Issue:17
Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance.
AID105392Inhibition of the spread of HIV infection (V-18C) in MT-4 human T-lymphoid cells2003Bioorganic & medicinal chemistry letters, May-19, Volume: 13, Issue:10
Design and synthesis of highly potent HIV protease inhibitors with activity against resistant virus.
AID678714Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID279339Antiviral activity against HIV2 isolate CBL20, CBL23, MVP15132 with V62A and L99F mutation in CBMCs2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors.
AID721752Inhibition of human MATE2K-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID235316Selective index is the ratio of CC10 to that of IC902000Journal of medicinal chemistry, Sep-21, Volume: 43, Issue:19
Synthesis, stability, antiviral activity, and protease-bound structures of substrate-mimicking constrained macrocyclic inhibitors of HIV-1 protease.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID519578Antiviral activity against HIV1 clone3 infected in HEK293 cells harboring A-790742-selected protease L33F, K45I, V82L, and I84V mutation assessed as reduction in viral replication by luciferase reporter gene assay relative to wild type HIV1 pNL4-32008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Characterization of a novel human immunodeficiency virus type 1 protease inhibitor, A-790742.
AID583854Antiviral activity against HIV1 NL4-3 infected in human MT2 cells assessed as inhibition of virus-induced cell death at 0.5 multiplicities of infection after 6 days2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID374617Resistance index, ratio of EC50 for HIV1 with protease 33F/54L/88S/90M mutation to EC50 for wild type HIV1 NL4-3 in HEK293 cells after 48 hrs by replication-deffective luciferase reporter gene-based phenotypic assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.
AID161868Inhibitory activity against HIV-1 Protease from PI-resistant HIV-1 (strain Q-18C)2003Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15
HIV protease inhibitors with picomolar potency against PI-Resistant HIV-1 by extension of the P3 substituent.
AID540232Dose normalised AUC in monkey after po administration2005Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
AID322096Antiviral activity against HIV1 LAI in MT2 cells assessed as inhibition of p24 Gag protein expression by MTT assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.
AID153094Tested for cytotoxic activity against HIV-1 1026-60 in PBMC cells2000Journal of medicinal chemistry, Mar-09, Volume: 43, Issue:5
5,6-Dihydropyran-2-ones possessing various sulfonyl functionalities: potent nonpeptidic inhibitors of HIV protease.
AID10122Half life was determined2002Bioorganic & medicinal chemistry letters, Sep-02, Volume: 12, Issue:17
Indinavir analogues with blocked metabolism sites as HIV protease inhibitors with improved pharmacological profiles and high potency against PI-resistant viral strains.
AID279342Antiviral activity against HIV2 isolate CBL20, CBL23, MVP15132 with 154M and L90M mutation in CBMCs2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors.
AID1443989Inhibition of recombinant human BSEP expressed in baculovirus infected sf9 cell plasma membrane vesicles assessed as reduction in ATP-dependent [3H]-taurocholate uptake in to vesicles preincubated for 10 mins followed by ATP addition measured after 10 to 2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID564043Antiviral activity against multidrug-resistant HIV1 isolate B containing protease L10I, K14R, L33I, M36I,M46I, F53I, K55R, I62V, L63P, A71V, G73S, V82A, L90M, and I93L mutant infected in human PHA-PBMC cells by MTT assay2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Novel protease inhibitors (PIs) containing macrocyclic components and 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane that are potent against multi-PI-resistant HIV-1 variants in vitro.
AID374619Resistance index, ratio of EC50 for HIV1 with protease 30N/33F/46L/54L/84V/88D mutation to EC50 for wild type HIV1 NL4-3 in HEK293 cells after 48 hrs by replication-deffective luciferase reporter gene-based phenotypic assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.
AID162192Inhibition of HIV protease of HIV K-60C mutant strain2003Bioorganic & medicinal chemistry letters, May-19, Volume: 13, Issue:10
Design and synthesis of highly potent HIV protease inhibitors with activity against resistant virus.
AID260396Antiviral activity in cells infected with wild-type HIV1 4X mutant2006Bioorganic & medicinal chemistry letters, Feb-15, Volume: 16, Issue:4
Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors possessing augmented P2' side chains.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID235095Resistance of constructed mutant 82A virus was calculated as (IC90 for a mutant virus / IC90 of wt HXB2 virus). 1997Journal of medicinal chemistry, Jan-17, Volume: 40, Issue:2
Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV.
AID468214Inhibition of HIV1 viral replication infected in human C8166 cells assessed as suppression of virion-associated p24 antigen production after 4 days by ELISA2009Journal of natural products, Dec, Volume: 72, Issue:12
Diketopiperazines from the Cordyceps-colonizing fungus Epicoccum nigrum.
AID540231Dose normalised AUC in dog after po administration2005Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
AID678716Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID321339Antiviral activity against HIV1 in MT4 cells by XTT assay2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Two-carbon-elongated HIV-1 protease inhibitors with a tertiary-alcohol-containing transition-state mimic.
AID375207Ratio of EC50 for multidrug-resistant HIV1 isolate G to EC50 for wild type HIV1 isolate ERS104pre2009Journal of medicinal chemistry, Jul-09, Volume: 52, Issue:13
Design of HIV-1 protease inhibitors with pyrrolidinones and oxazolidinones as novel P1'-ligands to enhance backbone-binding interactions with protease: synthesis, biological evaluation, and protein-ligand X-ray studies.
AID269312Antiviral activity against multi drug-resistant HIV1 C variant in human PHA-PBMC cells2006Journal of medicinal chemistry, Aug-24, Volume: 49, Issue:17
Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance.
AID322110Antiviral activity against HIV1 GRL98065p30 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID369955Ratio of EC50 for HIV2 ROD with protease G17N mutation to EC50 for wild type HIV2 ROD2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir.
AID13686Compound was evaluated for maximum plasma concentration levels in dogs at 10 mg/kg (in 0.5M citric acid solution) po1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor.
AID391270Antiviral activity against multidrug-resistant HIV1/C with protease mutation in phytohemagglutininin-activated PBMC assessed as inhibition of p24G protein production2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Flexible cyclic ethers/polyethers as novel P2-ligands for HIV-1 protease inhibitors: design, synthesis, biological evaluation, and protein-ligand X-ray studies.
AID199082Inhibition of virion associated RT activity (90% decrease) relative to untreated, infected control in MT2 cells infected with HIV-1 237288 strain2000Journal of medicinal chemistry, Sep-21, Volume: 43, Issue:19
Synthesis, stability, antiviral activity, and protease-bound structures of substrate-mimicking constrained macrocyclic inhibitors of HIV-1 protease.
AID721754Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID279944Oral clearance in HIV1 infected pregnant woman during antepartum period at 800 mg three times/day2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Pharmacokinetics and safety of indinavir in human immunodeficiency virus-infected pregnant women.
AID105391Inhibition of the spread of HIV infection (K-60C) in MT-4 human T-lymphoid cells2003Bioorganic & medicinal chemistry letters, May-19, Volume: 13, Issue:10
Design and synthesis of highly potent HIV protease inhibitors with activity against resistant virus.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID246194Protease inhibitory activity against HIV-1 r13034 mutant strain was determined2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Design of HIV-1 protease inhibitors active on multidrug-resistant virus.
AID374632Resistance index, ratio of EC50 for HIV1 with protease 46L/54V/73C/84V/90M mutation to EC50 for wild type HIV1 NL4-3 in HEK293 cells after 48 hrs by replication-deffective luciferase reporter gene-based phenotypic assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.
AID219260Dissociation constant obtained by inhibition of Wild-type protease2000Journal of medicinal chemistry, Sep-07, Volume: 43, Issue:18
Identification of MK-944a: a second clinical candidate from the hydroxylaminepentanamide isostere series of HIV protease inhibitors.
AID374636Resistance index, ratio of EC50 for HIV1 with protease 48V/82A/84V/90M mutation to EC50 for wild type HIV1 NL4-3 in HEK293 cells after 48 hrs by replication-deffective luciferase reporter gene-based phenotypic assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.
AID375205Ratio of EC50 for multidrug-resistant HIV1 isolate MM to EC50 for wild type HIV1 isolate ERS104pre2009Journal of medicinal chemistry, Jul-09, Volume: 52, Issue:13
Design of HIV-1 protease inhibitors with pyrrolidinones and oxazolidinones as novel P1'-ligands to enhance backbone-binding interactions with protease: synthesis, biological evaluation, and protein-ligand X-ray studies.
AID279341Antiviral activity against HIV2 isolate CBL20, CBL23, MVP15132 with 154M mutation in CBMCs2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors.
AID238257Potency to inhibit HIV-1 protease2004Bioorganic & medicinal chemistry letters, Nov-15, Volume: 14, Issue:22
Potent inhibitors of the HIV-1 protease incorporating cyclic urea P1-P2 scaffold.
AID210298The concentration required to inhibit HIV-1 RNA synthesis by 90%. Viral RNA quantified by a sandwich hybridization assay1996Journal of medicinal chemistry, Oct-11, Volume: 39, Issue:21
HIV protease inhibitory bis-benzamide cyclic ureas: a quantitative structure-activity relationship analysis.
AID1901047Inhibition of HIV-1 protease at 500 nM using fluorophore-labelled peptide substrate by fluorescence assay relative to control2022Bioorganic & medicinal chemistry, 02-15, Volume: 56Synthesis and anti-HIV activity of a new isoxazole containing disubstituted 1,2,4-oxadiazoles analogs.
AID260518Binding affinity to HIV1 protease L90M2006Journal of medicinal chemistry, Feb-23, Volume: 49, Issue:4
Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V, and L90M.
AID257501Antiviral activity against mutant HIV isolate Q-60C2005Bioorganic & medicinal chemistry letters, Dec-01, Volume: 15, Issue:23
Orally bioavailable highly potent HIV protease inhibitors against PI-resistant virus.
AID239809Equilibrium dissociation constant for the interaction between the compound and serum albumin2005Journal of medicinal chemistry, May-19, Volume: 48, Issue:10
Early absorption and distribution analysis of antitumor and anti-AIDS drugs: lipid membrane and plasma protein interactions.
AID54576In vitro inhibition of human liver microsome Cytochrome P450 2D62003Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15
HIV protease inhibitors with picomolar potency against PI-Resistant HIV-1 by extension of the P3 substituent.
AID557298Ratio of EC50 for HIV1 NL4-3 harboring L10F/M46I/I54V/V82A amino acid substitution in protease encoding region to EC50 for HIV1 NL4-32009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.
AID81070Anti-viral activity was determined2003Journal of medicinal chemistry, May-08, Volume: 46, Issue:10
Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors.
AID220212Inhibition of cytochrome P450 at 10 uM2000Journal of medicinal chemistry, Mar-09, Volume: 43, Issue:5
5,6-Dihydropyran-2-ones possessing various sulfonyl functionalities: potent nonpeptidic inhibitors of HIV protease.
AID322116Antiviral activity against HIV1 MDR/B X4 in phytohemagglutininin-activated PBMCs assessed as inhibition of p24 Gag protein expression by MTT assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.
AID321695Ratio of EC50 for HIV1 mutant strain 3 to EC50 for wild type HIV12008Bioorganic & medicinal chemistry, Feb-01, Volume: 16, Issue:3
Structure-activity relationships of novel HIV-1 protease inhibitors containing the 3-amino-2-chlorobenzoyl-allophenylnorstatine structure.
AID105380Ability to inhibit spread of viral infection in MT-4 human T-lymphoidcell infected by PI-resistant HIV-1 (strain Q-60C)2003Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15
The design, synthesis and evaluation of novel HIV-1 protease inhibitors with high potency against PI-resistant viral strains.
AID1182731Inhibition of HTLV-1 protease2014Journal of medicinal chemistry, Jul-24, Volume: 57, Issue:14
Structural basis for HTLV-1 protease inhibition by the HIV-1 protease inhibitor indinavir.
AID391267Antiviral activity against multidrug-resistant HIV1 with protease L10I, L24I, I33F, E35D, M36I, N37S, M46L, I54V, R57K, I62V, L63P, A71V, G73S, V82A mutation in phytohemagglutininin-activated PBMC assessed as inhibition of p24G protein production2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Flexible cyclic ethers/polyethers as novel P2-ligands for HIV-1 protease inhibitors: design, synthesis, biological evaluation, and protein-ligand X-ray studies.
AID557299Ratio of EC50 for HIV1 NL4-3 harboring L23I/K43I/M46I/I50L/G51A/A71V amino acid substitution in protease encoding region to EC50 for HIV1 NL4-32009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.
AID8897Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg)2003Bioorganic & medicinal chemistry letters, Nov-17, Volume: 13, Issue:22
Novel HIV-1 protease inhibitors active against multiple PI-resistant viral strains: coadministration with indinavir.
AID8144Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg)2003Bioorganic & medicinal chemistry letters, Nov-17, Volume: 13, Issue:22
Novel HIV-1 protease inhibitors active against multiple PI-resistant viral strains: coadministration with indinavir.
AID263209Antiviral activity against HIV D545701 in MT4 cells2006Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7
Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385.
AID519580Antiviral activity against HIV1 clone5 infected in HEK293 cells harboring A-790742-selected protease L63P, A71V, and V82G mutation assessed as reduction in viral replication by luciferase reporter gene assay relative to wild type HIV1 RF2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Characterization of a novel human immunodeficiency virus type 1 protease inhibitor, A-790742.
AID279337Antiviral activity against HIV2 isolate CBL20, CBL23, MVP15132 with 182L mutation in CBMCs2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors.
AID160767Association rate constant for the interaction between inhibitor and HIV-1 protease2002Journal of medicinal chemistry, Dec-05, Volume: 45, Issue:25
Relationships between structure and interaction kinetics for HIV-1 protease inhibitors.
AID235093Resistance of constructed mutant 461/47V/50V virus was calculated as (IC90 for a mutant virus / IC90 of wt HXB2 virus). 1997Journal of medicinal chemistry, Jan-17, Volume: 40, Issue:2
Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID553568Selectivity index, ratio of CC50 for human MT2 cells to EC50 for HIV1 LAI2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.
AID681132TP_TRANSPORTER: ATP hydrolysis in MDR1-expressing Sf9 cells2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID26774Partition coefficient of the compound was evaluated1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor.
AID105028Antiviral activity of compound against spread of wild type K-60C virus infection in MT-4 human T-lymphoid cells2003Bioorganic & medicinal chemistry letters, Oct-06, Volume: 13, Issue:19
HIV-1 protease inhibitors with picomolar potency against PI-resistant HIV-1 by modification of the P1' substituent.
AID770194Antiviral activity against HIV1 LAI infected in human MT2 cells by MTT assay2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
Highly potent HIV-1 protease inhibitors with novel tricyclic P2 ligands: design, synthesis, and protein-ligand X-ray studies.
AID391266Antiviral activity against multidrug-resistant HIV1 with protease L10I, K43T, M46L, I54V, L63P, A71V, V82A, L90M, Q92K mutation in phytohemagglutininin-activated PBMC assessed as inhibition of p24G protein production2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Flexible cyclic ethers/polyethers as novel P2-ligands for HIV-1 protease inhibitors: design, synthesis, biological evaluation, and protein-ligand X-ray studies.
AID557276Antiviral activity against HIV1 G harboring L10I/V11I/T12E/I15V/L19I/R41K/M46L/L63P/A71T/V82A/L90M in protease encoding region infected in human PHA-PBC assessed as inhibition of p24 Gag protein production by ELISA2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.
AID374601Resistance index, ratio of EC50 for HIV1 with protease 24I/33F/54V/82A/84V mutation to EC50 for wild type HIV1 NL4-3 in HEK293 cells after 48 hrs by replication-deffective luciferase reporter gene-based phenotypic assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.
AID343022Ratio of Ki for HIV1 recombinant protease D30N/N88D mutant to Ki for wild-type HIV1 BH10 protease2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Inorganic polyhedral metallacarborane inhibitors of HIV protease: a new approach to overcoming antiviral resistance.
AID369957Ratio of EC50 for HIV2 ROD with protease G17N/V47A mutation to EC50 for wild type HIV2 ROD2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir.
AID260515Binding affinity to HIV1 protease I50V2006Journal of medicinal chemistry, Feb-23, Volume: 49, Issue:4
Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V, and L90M.
AID235098Resistance of constructed mutant ABT538 virus was calculated as (IC90 for a mutant virus / IC90 of wt HXB2 virus)1997Journal of medicinal chemistry, Jan-17, Volume: 40, Issue:2
Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV.
AID446196Antiviral activity against multidrug-resistant HIV1 isolate G infected in PHA-stimulated human PBMC assessed as inhibition of p24 gap protein production2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Design, synthesis, protein-ligand X-ray structure, and biological evaluation of a series of novel macrocyclic human immunodeficiency virus-1 protease inhibitors to combat drug resistance.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1795276Protease Inhibition Assay from Article 10.1021/bi027019u: \\A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance.\\2003Biochemistry, Jan-28, Volume: 42, Issue:3
A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance.
AID1796146Protease Inhibition Assay from Article 10.1021/jm050943c: \\Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V, and L90M.\\2006Journal of medicinal chemistry, Feb-23, Volume: 49, Issue:4
Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V, and L90M.
AID1795269Protease Inhibition Assay from Article 10.1073/pnas.91.9.4096: \\L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor.\\1994Proceedings of the National Academy of Sciences of the United States of America, Apr-26, Volume: 91, Issue:9
L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor.
AID1796290Protease Inhibition Assay from Article 10.1016/j.bmcl.2003.08.049: \\Novel HIV-1 protease inhibitors active against multiple PI-resistant viral strains: coadministration with indinavir.\\2003Bioorganic & medicinal chemistry letters, Nov-17, Volume: 13, Issue:22
Novel HIV-1 protease inhibitors active against multiple PI-resistant viral strains: coadministration with indinavir.
AID1797107Protease Inhibition Assay from Article 10.1021/bi049459m: \\Comparing the accumulation of active- and nonactive-site mutations in the HIV-1 protease.\\2004Biochemistry, Sep-28, Volume: 43, Issue:38
Comparing the accumulation of active- and nonactive-site mutations in the HIV-1 protease.
AID1795266Protease Inhibition Assay from Article 10.1021/jm0204587: \\Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors.\\2003Journal of medicinal chemistry, May-08, Volume: 46, Issue:10
Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors.
AID1795271Protease Inhibition Assay from Article 10.1021/bi035701y: \\Secondary mutations M36I and A71V in the human immunodeficiency virus type 1 protease can provide an advantage for the emergence of the primary mutation D30N.\\2003Biochemistry, Dec-30, Volume: 42, Issue:51
Secondary mutations M36I and A71V in the human immunodeficiency virus type 1 protease can provide an advantage for the emergence of the primary mutation D30N.
AID1796296Protease Inhibition Assay from Article 10.1016/s0960-894x(03)00475-x: \\HIV protease inhibitors with picomolar potency against PI-Resistant HIV-1 by extension of the P3 substituent.\\2003Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15
HIV protease inhibitors with picomolar potency against PI-Resistant HIV-1 by extension of the P3 substituent.
AID1797110Protease Inhibition Assay from Article 10.1021/bi051886s: \\Analysis of HIV-1 CRF_01 A/E protease inhibitor resistance: structural determinants for maintaining sensitivity and developing resistance to atazanavir.\\2006Biochemistry, May-02, Volume: 45, Issue:17
Analysis of HIV-1 CRF_01 A/E protease inhibitor resistance: structural determinants for maintaining sensitivity and developing resistance to atazanavir.
AID1796295Protease Inhibition Assay from Article 10.1016/s0960-894x(03)00474-8: \\The design, synthesis and evaluation of novel HIV-1 protease inhibitors with high potency against PI-resistant viral strains.\\2003Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15
The design, synthesis and evaluation of novel HIV-1 protease inhibitors with high potency against PI-resistant viral strains.
AID1797112Protease Inhibition Assay from Article 10.1016/j.jmb.2005.09.095: \\Kinetic, stability, and structural changes in high-resolution crystal structures of HIV-1 protease with drug-resistant mutations L24I, I50V, and G73S.\\2005Journal of molecular biology, Dec-09, Volume: 354, Issue:4
Kinetic, stability, and structural changes in high-resolution crystal structures of HIV-1 protease with drug-resistant mutations L24I, I50V, and G73S.
AID1796288Protease Inhibition Assay from Article 10.1016/j.bmcl.2004.06.092: \\P1' oxadiazole protease inhibitors with excellent activity against native and protease inhibitor-resistant HIV-1.\\2004Bioorganic & medicinal chemistry letters, Sep-20, Volume: 14, Issue:18
P1' oxadiazole protease inhibitors with excellent activity against native and protease inhibitor-resistant HIV-1.
AID1796197Protease Inhibition Assay from Article 10.1016/j.bmcl.2005.11.011: \\Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors possessing augmented P2' side chains.\\2006Bioorganic & medicinal chemistry letters, Feb-15, Volume: 16, Issue:4
Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors possessing augmented P2' side chains.
AID1799449Protease Inhibtion Assay from Article 10.1016/s1074-5521(98)90117-x: \\Design and selection of DMP 850 and DMP 851: the next generation of cyclic urea HIV protease inhibitors.\\1998Chemistry & biology, Oct, Volume: 5, Issue:10
Design and selection of DMP 850 and DMP 851: the next generation of cyclic urea HIV protease inhibitors.
AID1799450Enzyme Inhibtion Assay from Article 10.1016/s1074-5521(98)90117-x: \\Design and selection of DMP 850 and DMP 851: the next generation of cyclic urea HIV protease inhibitors.\\1998Chemistry & biology, Oct, Volume: 5, Issue:10
Design and selection of DMP 850 and DMP 851: the next generation of cyclic urea HIV protease inhibitors.
AID1796287Protease Inhibition Assay from Article 10.1016/j.bmcl.2005.08.072: \\Orally bioavailable highly potent HIV protease inhibitors against PI-resistant virus.\\2005Bioorganic & medicinal chemistry letters, Dec-01, Volume: 15, Issue:23
Orally bioavailable highly potent HIV protease inhibitors against PI-resistant virus.
AID1799475Enzyme Inhibition Assay from Article 10.1016/S1074-5521(01)00079-5: \\Drug design with a new transition state analog of the hydrated carbonyl: silicon-based inhibitors of the HIV protease.\\2001Chemistry & biology, Dec, Volume: 8, Issue:12
Drug design with a new transition state analog of the hydrated carbonyl: silicon-based inhibitors of the HIV protease.
AID1796305Protease Inhibition Assay from Article 10.1016/s0960-894x(00)00163-3: \\Novel inhibitors of HIV protease: design, synthesis and biological evaluation of picomolar inhibitors containing cyclic P1/P2 scaffolds.\\2000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Novel inhibitors of HIV protease: design, synthesis and biological evaluation of picomolar inhibitors containing cyclic P1/P2 scaffolds.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2000Acta crystallographica. Section D, Biological crystallography, Apr, Volume: 56, Issue:Pt 4
An alternate binding site for the P1-P3 group of a class of potent HIV-1 protease inhibitors as a result of concerted structural change in the 80s loop of the protease.
AID1811Experimentally measured binding affinity data derived from PDB2000Acta crystallographica. Section D, Biological crystallography, Apr, Volume: 56, Issue:Pt 4
An alternate binding site for the P1-P3 group of a class of potent HIV-1 protease inhibitors as a result of concerted structural change in the 80s loop of the protease.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2004European journal of biochemistry, Apr, Volume: 271, Issue:8
Crystal structures of HIV protease V82A and L90M mutants reveal changes in the indinavir-binding site.
AID1811Experimentally measured binding affinity data derived from PDB2004European journal of biochemistry, Apr, Volume: 271, Issue:8
Crystal structures of HIV protease V82A and L90M mutants reveal changes in the indinavir-binding site.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2004Biochemistry, Sep-28, Volume: 43, Issue:38
Comparing the accumulation of active- and nonactive-site mutations in the HIV-1 protease.
AID1811Experimentally measured binding affinity data derived from PDB2004Biochemistry, Sep-28, Volume: 43, Issue:38
Comparing the accumulation of active- and nonactive-site mutations in the HIV-1 protease.
AID1811Experimentally measured binding affinity data derived from PDB2005Journal of molecular biology, Dec-09, Volume: 354, Issue:4
Kinetic, stability, and structural changes in high-resolution crystal structures of HIV-1 protease with drug-resistant mutations L24I, I50V, and G73S.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2005Journal of molecular biology, Dec-09, Volume: 354, Issue:4
Kinetic, stability, and structural changes in high-resolution crystal structures of HIV-1 protease with drug-resistant mutations L24I, I50V, and G73S.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB1994The Journal of biological chemistry, Oct-21, Volume: 269, Issue:42
Crystal structure at 1.9-A resolution of human immunodeficiency virus (HIV) II protease complexed with L-735,524, an orally bioavailable inhibitor of the HIV proteases.
AID1811Experimentally measured binding affinity data derived from PDB1994The Journal of biological chemistry, Oct-21, Volume: 269, Issue:42
Crystal structure at 1.9-A resolution of human immunodeficiency virus (HIV) II protease complexed with L-735,524, an orally bioavailable inhibitor of the HIV proteases.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB1998Acta crystallographica. Section D, Biological crystallography, Sep-01, Volume: 54, Issue:Pt 5
Rapid X-ray diffraction analysis of HIV-1 protease-inhibitor complexes: inhibitor exchange in single crystals of the bound enzyme.
AID1811Experimentally measured binding affinity data derived from PDB1998Acta crystallographica. Section D, Biological crystallography, Sep-01, Volume: 54, Issue:Pt 5
Rapid X-ray diffraction analysis of HIV-1 protease-inhibitor complexes: inhibitor exchange in single crystals of the bound enzyme.
AID1805801Various Assay from Article 10.1021/acs.jmedchem.1c00409: \\Perspectives on SARS-CoV-2 Main Protease Inhibitors.\\2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Perspectives on SARS-CoV-2 Main Protease Inhibitors.
AID1811Experimentally measured binding affinity data derived from PDB2002Protein science : a publication of the Protein Society, Feb, Volume: 11, Issue:2
Lack of synergy for inhibitors targeting a multi-drug-resistant HIV-1 protease.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2002Protein science : a publication of the Protein Society, Feb, Volume: 11, Issue:2
Lack of synergy for inhibitors targeting a multi-drug-resistant HIV-1 protease.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,755)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's613 (34.93)18.2507
2000's948 (54.02)29.6817
2010's169 (9.63)24.3611
2020's25 (1.42)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 18.27

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index18.27 (24.57)
Research Supply Index7.68 (2.92)
Research Growth Index4.30 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (18.27)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials328 (17.88%)5.53%
Reviews0 (0.00%)6.00%
Reviews100 (5.45%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies228 (12.43%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other23 (100.00%)84.16%
Other1,178 (64.23%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]